WO1997005131A1 - New carboxamides with antifungal activity - Google Patents

New carboxamides with antifungal activity Download PDF

Info

Publication number
WO1997005131A1
WO1997005131A1 PCT/EP1996/003419 EP9603419W WO9705131A1 WO 1997005131 A1 WO1997005131 A1 WO 1997005131A1 EP 9603419 W EP9603419 W EP 9603419W WO 9705131 A1 WO9705131 A1 WO 9705131A1
Authority
WO
WIPO (PCT)
Prior art keywords
arom
group
methyl
hydroxy
difluorophenyl
Prior art date
Application number
PCT/EP1996/003419
Other languages
French (fr)
Inventor
Javier BARTROLÍ
Enric Turmo
Manuel Anguita
Original Assignee
J. Uriach & Cia. S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES9501564A external-priority patent/ES2107376B1/en
Priority claimed from ES9502042A external-priority patent/ES2112774B1/en
Application filed by J. Uriach & Cia. S.A. filed Critical J. Uriach & Cia. S.A.
Priority to JP9507253A priority Critical patent/JPH10507205A/en
Priority to BR9606546A priority patent/BR9606546A/en
Priority to KR1019970701516A priority patent/KR970705560A/en
Priority to US08/809,815 priority patent/US5888941A/en
Priority to MX9702380A priority patent/MX9702380A/en
Priority to EP96928404A priority patent/EP0783502A1/en
Priority to AU67889/96A priority patent/AU6788996A/en
Publication of WO1997005131A1 publication Critical patent/WO1997005131A1/en
Priority to NO971471A priority patent/NO971471L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/82—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with three ring hetero atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of general formula (I) and their salts and solvates are antifungal agents and as such are useful in the treatment of various fungal infections. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Description

New carboxamides with antifungal activity
Field of the invention
The present invention relates to a new series of carboxamides of general formula I having potent antifungal activity. The invention also relates to a process for their preparation, to pharmaceutical compositions containing them and to their use for the treatment of fungal diseases.
Description of the prior art
The compounds of the present invention are antifungal agents belonging to the azole class, whose mechanism of action is based on the inhibition of the biosynthesis of ergosterol, the main sterol present in fungi membranes.
Other antifungal agents having this mechanism of action have been reported in the literature. Patent applications EP 332387 and EP 617031 describe azole derivatives containing an arylcarboxamide group. The compounds of the present invention are not only more potent antifungal agents than the compounds described in the above two patents but they also have a broader spectrum of antifungal activity since, unlike the compounds described therein, they are also effective against filamentous fungi, including aspergillus.
Description of the invention
The present invention relates to new carboxamides of general formula I
Figure imgf000003_0001
as racemates, diastereomer mixtures or as pure enantiomers, wherein:
X represents N or CH;
Ar represents phenyl or phenyl substituted with one or more halogen and /or trifluoromethyl groups;
R1 is C1-C4 alkyl;
R2 is hydrogen or C1-C4 alkyl;
or R1 together with R2 form a C2-C4 polymethylene chain;
R3 is hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C1-C4 alkyl, C1-C4 haloalkyl, phenyl-C1-C4 alkyl (wherein the phenyl group can be optionally substituted with 1, 2, 3 or 4 groups R5, which can be the same or different), a group -(CH2)n-CH2OH, a group -(CH2)n-CH2OBn, a group -(CH2)n-CH2NR6R7, a group -(CH2)n-CH2COOR6, or a group -(CH2)n- CH2COOBn, in which case R4 is hydrogen;
or R3 together with R4 and the remainder of said compound of formula I form an oxazolidine ring of formula I'
Figure imgf000004_0001
or R3 together with R4 and the remainder of said compound of formula I form a morpholine ring of formula I"
Figure imgf000004_0002
wherein D is O, in which case the dotted line represents a covalent bond, or D is hydroxy or hydrogen, in which case the dotted line is absent;
A represents phenyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 heteroatoms selected from N, O and S and with each ring in the heterocyclic group being formed of 5 or 6 atoms, wherein A can be unsubstituted or have 1, 2, 3 or 4 groups R8;
B represents a phenyl group which can be optionally substituted with 1,
2, 3 or 4 groups R9, or B represents a monocyclic or bicyclic heterocyclic group containing from 1 to 4 heteroatoms selected from N, O and S and with each ring in the heterocyclic group being formed of 5 or 6 atoms, which can be optionally substituted with 1, 2, 3 or 4 groups R9;
R5 represents C1-C4 alkyl, C1-C4 haloalkyl or halogen;
n represents 0, 1, 2 or 3;
R6 and R7 independently represent hydrogen or C1-C4 alkyl;
R8 represents C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, phenyl (optionally substituted with a group halogen, cyano, C1-C4 haloalkyl or C1-C4 haloalkoxy), nitro, cyano, hydroxy, hydroxymethyl, a group -NR6R7, a group -CONR6R7, a group -CORό, a group -COOR6, or a group -SOzR10;
R9 represents C1-C4 alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, 2-carboxy-2-propyl, halogen, nitro, cyano, hydroxy, benzyloxy, hydroxymethyl, a group -CH2-OCO-R6, a group -CO-R6, a group -COO-R6, a group -SOzR10, a group -NR6R7, a group -CONR6R7, a group -C(=NR6)NHR11, a group -C(=NR11)OR6, and additionally one of the groups R9 can also represent 1-pyrrolyl, 1-imidazolyl, 1H-1,2,4-triazol-1-yl, 5-tetrazolyl (optionally substituted with C1-C4 alkyl), 1-pyrrolidinyl, 4-morpholinyl, 4-morpholinyl-N-oxide, phenyl or phenoxy (both optionally substituted with a group C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, nitro or cyano), or a group of formula (i)- (iv)
Figure imgf000005_0001
Figure imgf000005_0002
Figure imgf000005_0004
Figure imgf000005_0003
R10 represents C1-C4 alkyl;
z represents 0, 1 or 2;
R11 represents hydrogen, -CONH2, -COMe, -CN, -SO2NHR6, -SO2R10, -OR6, or -OCOR6;
R12 represents hydrogen or methyl;
R13 represents hydrogen, isopropyl, cyclopentyl, cyclopropyl, 2-butyl, 3-pentyl, 3-hydroxy-2-butyl, or 2-hydroxy-3-pentyl;
p represents 0 or 1;
R14 represents halogen, C1-C4 haloalkyl, C1-C4 haloalkoxy, nitro, amino, cyano, or a group of formula (i);
E represents -CH2- or -C(=O)-; G represents NH or O;
Y represents a single bond, -S-, -SO-, -SO2-, -O- or -NR^-;
m and q independently represent 0, 1 or 2;
and the salts and solvates thereof.
The invention also provides a pharmaceutical composition which comprises an effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable excipients.
The invention further provides the use of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment or prophylaxis of fungal infections in animals, including human beings.
The invention further provides the use of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof for the treatment or prophylaxis of fungal infections in animals, including human beings.
The invention also provides a method of treating or preventing fungal infections in animals, including human beings, which method comprises administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof .
In addition to being useful for the treatment of fungal infections in animals, the compounds of the present invention possess antifungal roperties which can be useful for combatting or preventing plant fungal infections. The invention thus provides the use of a compound of formula I or a salt or solvate thereof for the treatment or prophylaxis of fungal infections in plants.
The invention still further provides an agrochemical composition which comprises an effective amount of a compound of formula I or a salt or solvate thereof in admixture with one or more agrochemically acceptable excipients.
The invention also provides a process for preparing a compound of formula I, which comprises:
(a) reacting a compound of formula II
Figure imgf000006_0001
wherein X, R1, R2, R3, R4 and Ar are as defined above, with an acid of formula III
Figure imgf000007_0001
wherein A, B, Y, m and q are as defined above, in the presence of a condensing agent, or with a reactive derivative of said acid III such as the acid chloride, the anhydride or the mixed anhydride in the presence of a proton scavenger base; or
(b) converting in one or a plurality of steps a compound of formula I into another compound of formula I; and
(c) if desired, after steps (a) or (b), reacting a compound of formula I with an acid to give the corresponding acid addition salt.
In the above definitions, the term C1-C4 alkyl, as a group or part of a group, means a linear or branched alkyl chain containing from 1 to 4 carbon atoms. Therefore, it includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
A C2-C4 alkenyl group means a linear or branched alkyl chain containing from 2 to 4 carbon atoms and additionally containing one or more double bonds. Examples include ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, and 1,3-butadienyl.
A C2-C4 alkynyl group means a linear or branched alkyl chain containing from 2 to 4 carbon atoms and additionally containing one or more triple bonds. Examples include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, and 3-butynyl.
A C2-C4 polymethylene chain means ethylene, propylene or butylene. A C1-C4 haloalkyl group means a group resulting from the substitution of one or more hydrogen atoms of a C1-C4 alkyl group by one or more halogen atoms (i.e. fluorine, chlorine, bromine or iodine), which can be the same or different. Examples include trifluoromethyl, trichloromethyl, fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, dichloromethyl, 2- chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, pentachloroethyl, 2- fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3- chloropropyl, 3,3-dichloropropyl, 3,3,3-trichloropropyl, 2,2,3,3,3-pentachloropropyl, 3-fluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoropropyl, 4-chlorobutyl, 4-fluorobutyl, 4-iodobutyl and 4-bromobutyl.
The term C3-C6 cycloalkyl, as a group or part of a group, represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
The abbreviation Bn represents benzyl.
A C1-C4 alkoxy group means a group derived from the union of a C1-C4 alkyl group to an oxygen atom of an ether functional group. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert- butoxy.
A C1-C4 haloalkoxy group means a group resulting from the substitution of one or more hydrogen atoms of a C1-C4 alkoxy group by one or more halogen atoms, which can be the same or different. Examples include trifluoromethoxy, fluoromethoxy, 2-chloroethoxy, 2-fluoroethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2,2,3,3-tetrafluoropropoxy, 2,2,3,3,3-pentafluoropropoxy, heptafluoropropoxy, 4-fluorobutoxy, and 4-chlorobutoxy.
In the compounds of the present invention Ar represents a phenyl group or a phenyl group substituted with one or more halogen and /or trifluoromethyl groups. The halogen atoms may be fluorine, chlorine, bromine or iodine atoms, of which fluorine and chlorine atoms are preferred. There may be one or more such substituents on the phenyl group, and where there are more than one, these may be the same or different. When the phenyl group is substituted, the substituents can be on any available position of the phenyl ring, but they are preferably on the 2- and/or 4-positions. Examples of substituted phenyl groups include 4-(trifluoromethyl)phenyl, 2-fluorophenyl, 4-fluorophenyl, 2-chloro-4-fluorophenyl, 4-chloro-2-fluorophenyl, 4-bromophenyl, 2-fluoro-4-iodophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-chlorophenyl and 2-fluoro-4-(trifluoromethyl)phenyl, of which 2-fluorophenyl, 4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl and 4- chlorophenyl are preferred, and 2-fluorophenyl, 2,4-dichlorophenyl, 2,4- difluorophenyl, 4-(trifluoromethyl)phenyl and 4-chlorophenyl are more preferred.
In the compounds of the present invention R1 represents a C1-C4 alkyl group, or together with R2 forms a C2-C4 polymethylene chain, but preferably R1 is C1-C4 alkyl, and more preferably R1 is methyl.
In the compounds where R2 is hydrogen or C1-C4 alkyl, or together with R1 forms a C2-C4 polymethylene chain, those wherein R2 is hydrogen or methyl are preferred, and those wherein R2 is hydrogen are more preferred.
From among the compounds wherein R3 and R4 are unconnected or can be bonded together forming an oxazolidine or morpholine ring, those wherein R3 and R4 are unconnected (i.e. R4 represents hydrogen) are preferred, and those wherein both R3 and R4 represent hydrogen are more preferred.
In the compounds of the present invention, the groups A and B represent phenyl or a monocyclic or bicyclic heterocyclic group, wherein each ring in the heterocyclic group is formed of 5 or 6 atoms and wherein from 1 to 4 of the ring atoms forming said heterocyclic group are heteroatoms selected from the group consisting of N, O and S. Both A and B can be unsubstituted or have 1, 2, 3 or 4 substituents Re or R9 respectively, which can be on any available position of any of the rings. When there is more than one substituents on ring A or B, they can be the same or different, provided that, as mentioned above, for certain meanings of R9 there cannot be more than one such group on ring B. Examples of monocyclic heterocyclic groups A or B include thiophene, furan, pyran, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, 1,2,4-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine, furazan, pyrroline, imidazoline and pyrazoline. Examples of bicyclic heterocyclic groups A or B include among others benzimidazole, benzofuran, isobenzofuran, benzofurazan, indole, isoindole, indolizine, indazole, benzothiophene, benzothiazole, quinoline, isoquinoline, phtalazine, quinazoline, quinoxaline, cinnoline, imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, pyrazolopyrazine, pyrazolopyridine and pyrazolopyrimidine.
Among all the possible meanings for A those wherein A represents phenyl or a 5- or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S are preferred; those groups wherein A represents a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S are more preferred; those wherein A represents a thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, 1,2,4-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, or 1,2,4-thiadiazole ring are still more preferred; and those wherein A represents thiophene, thiazole or pyrazole are particularly preferred. All these groups A can be unsubstituted or have 1, 2, 3 or 4, preferably 1 or 2, groups R8. As preferred meanings for Rs we can mention C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, halogen and amino, of which C1-C4 alkyl and C1-C4 haloalkyl are more preferred.
As for B, those groups wherein B represents a phenyl group optionally substituted with 1, 2, 3 or 4 substituents R9 are preferred. As examples of substituted phenyl rings we can mention among others 2-methylphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-(2-carboxy-2-propyl)phenyl, 4-vinylphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-iodophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2,6-difluorophenyl, 2,4- dichlorophenyl, 2,5-dichlorophenyl, 2-chlorophenyl, 2-chloro-4-fluorophenyl, 2,4,6-trifluorophenyl, 2,3,5,6-tetrafluorophenyl, 2-(trifluoromethyl)phenyl, 3- ( tri flu orome th yl) ph en yl, 4- ( tri fluo ro me thyl) ph eny l , 4-(trichloromethyl)phenyl, 2-fluoro-5-(trifluoromethyl)phenyl, 2-fluoro-4- (trifluoromethyl)phenyl, 3-fluoro-4-(trifluoromethyl)phenyl, 4- (difluoromethoxy)phenyl, 4-(trifluoromethoxy)phenyl, 4-(2- fluoroethoxy) phenyl, 4-(2,2-difluoroethoxy)phenyl, 4-(2,2,2- trifluoroethoxy)phenyl, 4-(2,2,3,3-tetrafluoropropoxy)phenyl, 3-nitrophenyl, 4- nitrophenyl, 2-fluoro-4-nitrophenyl, 2-cyanophenyl, 3-cyanophenyl, 4- cyanophenyl, 4-(4-cyanophenyl)phenyl, 4-(4-cyanophenoxy)phenyl, 2-methyl-4-cyanophenyl, 2-chloro-4-cyanophenyl, 2-cyano-4-(trifluoromethyl)phenyl, 4-(methoxycarbonyl)phenyl, 2-methoxy-4-(trifluoromethyl)phenyl, 2-fluoro-4-(ethoxycarbonyl)phenyl, 4-(methylthio)phenyl, 4-(methylsulfinyl)phenyl, 4- (methylsulfonyl)phenyl, 4-aminophenyl, 4-dimethylaminophenyl and 4-carbamoylphenyl. More preferred meanings for B are those wherein B represents phenyl substituted with 1 or 2 groups R9, of which those wherein one of the substituents R9 is in the para position are still more preferred. Preferred meanings for R9 include C1-C4 alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, 2-carboxy-2-propyl, halogen, nitro, cyano, hydroxy, benzyloxy, hydroxymethyl, a group
-CH2-OCO-R6, a group -CO-R6, a group -COO-R6, a group -SOzR10, a group -NR6R7, a group -CONR6R7, a group -C(=NR6) N HR1 1 or a group -C(=NR11)OR6.
In the compounds wherein Y represents a single bond, -S-, -SO-, -SO2-, -O- or -NR6- and m and q independently represent 0, 1 or 2, those wherein Y represents a single bond and m=q=0, that is, those wherein ring B is directly bonded to ring A through a covalent bond are preferred.
Preferred compounds of the present invention include those in which, independently or in any compatible combination:
X represents N;
R1 represents C1-C4 alkyl;
R2 represents hydrogen;
R4 represents hydrogen;
Ar represents 2-fluorophenyl, 4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4- chlorophenyl;
A represents phenyl or a 5- or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S, wherein A can be unsubstituted or have 1, 2, 3 or 4 groups R8;
B represents a phenyl group which can be optionally substituted with 1, 2, 3 or 4 substituents R9;
the stereochemistry of the compounds is (R,R).
Particularly preferred compounds of the present invention include those in which, independently or in any compatible combination:
X represents N;
R1 represents methyl;
R2 represents hydrogen;
R3 represents hydrogen;
R4 represents hydrogen;
Ar represents 2-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4-chlorophenyl;
A represents a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S, and which can be unsubstituted or have 1 or 2 groups R8;
B represents a phenyl group substituted with 1 or 2 groups R9;
Y represents a single bond and m=q=0;
the stereochemistry of the compounds is (R,R).
Accordingly, a preferred class of compounds of formula I is that wherein:
X represents N;
R1 represents C1-C4 alkyl;
R2 represents hydrogen;
R4 represents hydrogen;
Ar represents 2-fluorophenyl, 4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4- chlorophenyl; A represents phenyl or a 5- or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S, wherein A can be unsubstituted or have 1, 2, 3 or 4 groups R8;
B represents a phenyl group which can be optionally substituted with 1, 2, 3 or 4 substituents R9; and
the stereochemistry of the compounds is (R,R).
A more preferred class of compounds of formula I is that wherein:
X represents N;
R1 represents methyl;
R2 represents hydrogen;
R3 represents hydrogen;
R4 represents hydrogen;
Ar represents 2-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4-chlorophenyl;
A represents a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S, and which can be unsubstituted or have 1 or 2 groups R8
B represents a phenyl group substituted with 1 or 2 groups R9;
Y represents a single bond and m=q=0; and
the stereochemistry of the compounds is (R,R).
A particularly preferred class of compounds of formula I is that wherein:
X represents N;
Rl represents methyl;
R2 represents hydrogen;
R3 represents hydrogen;
R4 represents hydrogen;
Ar represents 2-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4-chlorophenyl;
A represents thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, 1,2,4-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, or 1,2,4-thiadiazole, wherein A can be optionally substituted with one or two C1-C4 alkyl or C1-C4 haloalkyl groups;
B represents a phenyl group substituted with 1 or 2 groups R9;
R9 represents C1-C4 alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6 cycloalkyl,
C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, 2-carboxy-2-propyl, halogen, nitro, cyano, hydroxy, benzyloxy, hydroxymethyl, a group -CH2-OCO-R6, a group -CO-R6, a group -COO-R6, a group -SOzR10, a group -NR6R7, a group -CONR6R7, a group -C(=NR6)NHR11 or a group -C(=NR11)OR6.
Y represents a single bond and m=q=0; and
the stereochemistry of the compounds is (R,R).
The compounds of formula I contain one or more basic nitrogen atoms and, consequently, they can form salts with acids, which are also included in the present invention. There is no limitation on the nature of these salts, provided that, when used for therapeutic purposes, they are pharmaceutically acceptable, which, as is well-known in the art, means that they do not have reduced activity (or unacceptable reduced activity) or increased toxicity (or unacceptable increased toxicity) compared with the free compounds. Examples of these salts include: salts with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, perchloric acid, sulfuric acid or phosphoric acid; and salts with an organic acid, such as methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, fumaric acid, oxalic acid, maleic acid; and other mineral and carboxylic acids well known to those skilled in the art. The salts are prepared by reacting the free base with a sufficient amount of the desired acid to produce a salt in the conventional manner. Free bases and their salts differ in certain physical properties, such as solubility, but they are equivalent for the purposes of the invention.
Some compounds of the present invention can exist in solvated form, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for the purposes of the invention.
The compounds of formula I contain one or more asymmetric carbons and, consequently, can exist as different stereoisomers. The present invention covers both each of the individual stereoisomers and their mixtures. When R1 is C1-C4 alkyl and R2 is hydrogen, those compounds of formula I wherein the absolute configuration of the carbon atoms to which the Ar and R1 groups are bonded is (R,R) are preferred, i.e. compounds of formula:
Figure imgf000013_0001
Diastereoisomers can be separated by conventional techniques such as chromatography or fractional crystallization. The optical isomers can be resolved using any of the conventional techniques of optical resolution to give optically pure isomers. Such a resolution can be performed in any chiral synthetic intermediate as well as in the products of general formula I. The optically pure isomers can also be individually obtained using enantiospecific synthesis. We have obtained the optically pure (R,R) isomers starting from optically pure amine II, prepared following the general procedure described in J.Org.Chem, 1995, 60, 3000-3012. As stated above, the present invention covers the individual isomers as well as their mixtures (e.g. racemic mixtures), whether as obtained by synthesis or by physically mixing them up.
Some of the compounds of formula I may present tautomerism. For example, when the compounds of the present invention contain an amidino group of formula -C(=NR6)NHR11, the following tautomeric structures may exist in equilibrium:
Figure imgf000014_0001
all of which are encompassed by the present invention.
The compounds of formula I can be prepared using the procedures described below. The precise method used for the preparation of a given compound may vary depending on its chemical structure.
The compounds of formula I can be prepared by reacting an amine of formula II with an acid of formula III in the presence of an appropriate condensing agent, for example dicyclohexylcarbodiimide, alone or in combination with 1-hydroxybenzotriazole, in a polar solvent, such as a substituted amide (for example N-methylpyrrolidone or dimethylformamide), an ether (for example tetrahydrofuran or dioxane) or diglyme, at a temperature preferably comprised between 0°C and 100°C. Alternatively, compounds of formula I can be prepared by reacting an amine II with a reactive derivative of an acid III, such as the acid chloride, anhydride or mixed anhydride. The reaction is carried out in the presence of a proton scavenger base, such as triethylamine or pyridine, in a suitable solvent such as dichloromethane or chloroform.
Alternatively, compounds of formula I wherein Y represents -O-, -S- or
-NR6- and m is 0 can be prepared from the corresponding compound wherein A is substituted with a halogen atom, for example bromine, instead of a group
-Y(CH2)q-B by treatment with an alkaline metal salt of the corresponding alcohol or thiol of formula HY(CH2)q-B, for example the sodium salt, or by treatment with an amine of formula HNR6(CH2)q-B in a suitable aprotic solvent such as N-methylpyrrolidone at a temperature between room temperature and that of the refluxing solvent.
Moreover, some compounds of formula I can also be prepared by interconversion from another compound of formula I in one or a plurality of steps using reactions well known in organic chemistry, such as the reactions listed below. These reactions are mentioned here only as illustrative examples of the several procedures which can be used to interconvert compounds of the present invention and are not intended to limit the scope of the preparation of compounds of formula I in any way.
Thus, for example, the compounds of formula I wherein R3 together with R4 and the remainder of said compound of formula I form a morpholine ring of formula I", wherein D is hydrogen and the dotted line is absent, can be prepared from the corresponding compound of formula I wherein R3=-(CH2)2OH by treatment with diethylazadicarboxylate and tributylphosphine in a suitable solvent such as tetrahydrofuran. The compounds of formula I wherein R3 together with R4 and the remainder of said compound of formula I form a morpholine ring of formula I", wherein D is hydroxy and the dotted line is absent, can be prepared from the corresponding compound of formula I wherein R3= -(CH2)2OH by oxidation for example by treatment with activated
DMSO and a base, such as triethylamine, in a suitable solvent, such as dichloromethane or chloroform. The compounds of formula I wherein R3 together with R4 and the remainder of said compound of formula I form a morpholine ring of formula I", wherein D is O and the dotted line represents a covalent bond, can be prepared from the corresponding compound of formula I wherein R3= -CH2COOH using a suitable dehydrating agent or alternatively they can be prepared from the corresponding compound of formula I wherein R3= -(CH2)2OH by overoxidation.
Furthermore, it is also possible to convert a group R3 in a compound of formula I into another group R3 using standard methods of organic synthesis .
Thus, a benzyl ether can be converted to the corresponding alcohol by hydrogenation in the presence of a suitable catalyst such as Pd/C in a suitable solvent such as an alcohol at a hydrogen pressure between 1 and 5 atm. An ester group can be hydrolized to the corresponding acid using conventional procedures; in case of benzyl esters, this conversion can be carried out by hydrogenation in the same experimental conditions mentioned above. An ester group can also be reduced by treatment with a suitable metal hydride such as sodium borohydride in a suitable solvent such as ethanol to give the corresponding alcohol.
It is also possible to use a group B in a compound of formula I to generate other groups B thus giving rise to other compounds of formula I. For example, a nitro group can be reduced to an amino group, for example by hydrogenation in the presence of a catalyst such as Pd/C in a suitable solvent such as an alcohol, for example ethanol, at a temperature between room temperature and that of the refluxing solvent and at a pressure preferably between atmospheric pressure and 10 atm. A thioether group can be oxidized to a sulfinyl or sulfonyl group by treatment with a suitable oxidising agent. For example, a thioether group can be oxidized to a sulfonyl group by treatment with m-chloroperbenzoic acid in a suitable solvent such as a halogenated hydrocarbon at a temperature preferably between 0°C and room temperature. Moreover, an amino group can be converted to a group of formula (i) by treatment with phenyl chloroformate, subsequent reaction of the phenyl carbamate thus obtained with hydrazine and finally cyclisation of the resulting semicarbazide with formamidine or acetamidine in a suitable solvent such as dimethylformamide at a temperature between room temperature and that of the refluxing solvent. A nitrile group can be converted to a tetrazole group by treatment with a suitable azide such as sodium azide or ammonium azide (which may be prepared in situ from sodium azide and ammonium chloride) in a suitable solvent such as a polar solvent, for example dimethylformamide or N-methylpyrrolidone, at a temperature preferably between room temperature and that of the refluxing solvent. Another example of interconversion is the N-alkylation of a group of formula (i) or a tetrazole by treatment with the corresponding alkyl halide in the presence of a base such as potassium or cesium carbonate in a suitable aprotic solvent such as dimethylformamide. A nitrile group can be hydrolized to a carbamoyl group by treatment with ammonium hydroxide in a suitable solvent such as tetrahydrofuran-water mixtures under reflux. A nitrile group can also be converted to an alkyl imidate group by bubbling HCl gas in an alcohol, such as methanol. An alkyl imidate group can also be converted to an amino(imino)methyl group by reaction with an amine using the corresponding alkanol as solvent. Moreover, a halogen atom, for example bromo or iodo, can be converted to a phenyl group by a coupling reaction between the corresponding haloderivative and a boronic acid or ester of formula (RO)2B-phenyl (wherein R represents hydrogen or C1-C4 alkyl) in the presence of a palladium catalyst such as Pd(OAc)2 or Pd(PPh3)4 in a suitable solvent such as dimethoxyethane at a temperature preferably between room temperature and that of the refluxing solvent. A halogen atom, for example a fluorine atom, can be converted into a C1-C4 alkoxy, C1-C4 haloalkoxy, phenoxy, -SR10, triazole or imidazole group by treatment with an alkaline metal salt of the corresponding alcohol, thiol, triazole or imidazole, for example the sodium salt, in a suitable aprotic solvent such as N- methylpyrrolidone at a temperature between room temperature and that of the refluxing solvent; moreover, it can also be converted into an amine (-NR6R7, 1-pyrrolidine, morpholine, a group of formula (ii) or a group of formula (iii)) by treatment with the corresponding amine in a suitable aprotic solvent such as N-methylpyrrolidone at a temperature between room temperature and that of the refluxing solvent.
Furthermore, a compound of formula I wherein Y represents -SO- or -SO2- can be prepared from the corresponding compound of formula I wherein Y is -S- by oxidation as described above in connection with group B.
As it will be apparent to those skilled in the art, these interconversion reactions can be carried out both on the final products of formula I or on any synthetic intermediate thereof.
Amines of formula II can be prepared as described in J.Org.Chem, 1995, 60, 3000-3012, EP 332387 or EP 617031.
Acids of formula III or derivatives thereof are commercially available, widely described in the literature or can be prepared by methods analogous to those known in the art. Thus, for example, 5-substituted 1-arylpyrazole-4-carboxylic acids can be prepared by reacting the corresponding arylhydrazine with the product obtained from reacting the corresponding ethyl acylacetate with dimethylformamide dimethylacetal, followed by alkaline hydrolysis
(KOH/ EtOH-H2O), as described in J. Heterocyclic Chem. 1987, 24, 1669. 1-Arylpyrazole-4-carboxylic acids can be prepared by reacting the corresponding arylhydrazine with carbethoxymalonaldehyde, followed by alkaline hydrolysis, as described in Gazz.Chim .ltal ., 1946, 76, 56. 1-Aryl-5-aminopyrazole-4-carboxylic acids can be prepared by reacting ethyl ethoxymethylenecyanoacetate with the corresponding arylhydrazine, followed by hydrolysis under basic conditions, as described in Helv.Chim.Acta, 1959, 349. 2-Aryl-4-alkylthiazole-5-carboxylic acids can be prepared by reacting the corresponding thiobenzamide with methyl acylchloroacetate in ethanol followed by alkaline hydrolysis, as described in Eur.J. Med.Chem. 1976, 11, 567. 2-Arylthiazole-4-carboxylic acids can be prepared by reacting the corrsponding thiobenzamide with ethyl bromopyruvate in ethanol followed by alkaline hydrolysis. 1-Arylpyrrole-3-carboxylic acids are prepared by reacting the correpsonding aniline with 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde in acetic acid under reflux, followed by oxidation with silver nitrate, as described in Org.Prep.Proced.Int., 1995, 27, 236. 5-Arylthiophene-2-carboxylic acids can be prepared by reacting the corresponding acetophenone, dimethylformamide and ethyl thioglycolate in the presence of POCI3, followed by alkaline hydrolysis, as described in Tetrahedron Lett., 1968, 1317. 5-Aryl-3-aminothiophene-2-carboxylic acids can be prepared by reacting the corresponding β-chlorocinnamonitrile with ethyl thioglycolate in the presence of a base, followed by alkaline hydrolysis, as described in Synthesis, 1984, 275. 5-Aryl-1,3,4-oxadiazole-2-carboxylic acids can be prepared by the general procedure described in J. Prakt.Chem. 1985, 327, 109. 3-Aryl-1,2,4- oxadiazole-5-carboxylic acids can be prepared by the general procedure described in J. Med. Chem. 1995, 38, 1355. 5-Aryl-1,2,4-oxadiazole-3-carboxylic acids can be prepared by the general procedure described in Bull . Chem.Soc.Jpn. 1985, 58, 2519. 3-Aryl-1,2,4-thiadiazole-5-carboxylic acids and 5- aryl-1,2,4-thiadiazole-3-carboxylic acids can be prepared by the general procedure described in J. Org.Chem. 1977, 42, 1813.
The present invention further provides compositions that contain a compound of the present invention, together with an excipient and optionally other auxiliary agents, if necessary. The compounds of the present invention can be administered in different pharmaceutical preparations, the precise nature of which will depend, as it is well known, upon the chosen route of administration and the nature of the pathology to be treated.
Thus, solid compositions according to the present invention for oral administration include compressed tablets, dispersible powders, granules and capsules. In tablets, the active component is admixed with at least one inert diluent such as lactose, starch, mannitol, microcrystalline cellulose or calcium phosphate; granulating and disintegrating agents for example corn starch, gelatine, microcrystalline cellulose or polyvinylpyrrolidone; and lubricating agents for example magnesium stearate, stearic acid or talc. The tablets may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and, thereby, provide a sustained action over a longer period. Gastric film-coated or enteric film-coated tablets can be made with sugar, gelatin, hydroxypropylcellulose, or acrylic resins. Tablets with a sustained action may also be obtained using an excipient which provides regressive osmosis, such as the galacturonic acid polymers. Formulations for oral use may also be presented as hard capsules of absorbable material, such as gelatin, wherein the active ingredient is mixed with an inert solid diluent and lubricating agents, or pasty materials, such as ethoxylated saturated glycerides. Soft gelatin capsules are also possible wherein the active ingredient is mixed with water or an oily medium, for example peanut oil, liquid paraffin or olive oil.
Dispersible powders and granules suitable for the preparation of a suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent; a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl- methylcellulose, sodium alginate, polyvinylpirrolidone, gum tragacanth, xantham gum, gum acacia, and one or more preservatives, such as methyl or n-propyl p-hydroxybenzoate. Additional excipients, for example sweetening, flavoring and coloring agents may also be present.
Liquid compositions for oral administration include emulsions, solutions, suspensions, syrups and elixirs containing commonly used inert diluents, such as distilled water, ethanol, sorbitol, glycerol, or propylene glycol. Aqueous solutions can also be prepared using β-cyclodextrins, such as hydroxypropyl-β-cyclodextrin. Such compositions may also comprise adjuvants such as wetting agents, suspending agents, sweetening, flavoring, perfuming, preserving agents and buffers.
Other compositions for oral administration include spray compositions, which may be prepared by known methods. The spray compositions will contain a suitable propellent.
Preparations for injection, according to the present invention, for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions, in a non-toxic parentally-acceptable diluent or solvent. Examples of aqueous solvents or suspending media are distilled water for injection, Ringer's solution, and isotonic sodium chloride solution. Aqueous solutions can also be prepared using β-cyclodextrins, such as hydroxypropyl-β-cyclodextrin. Examples of non-aqueous solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, or alcohols such as ethanol. These Compositions may also include adjuvants such as wetting, preserving, emulsifying and dispersing agents. They may be sterilized by one of the known methods or manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use. When all of the components are sterile, the injectables will maintain the sterility if they are manufactured in sterile environment.
Preparations for vaginal administration according to the present invention include tablets, capsules, softgels, moulded pessaries, creams, foams and vaginal douches. Vaginal tablets provide the active component in admixture with lactose, microcrystalline cellulose, pregelatinized starch, polyvidone and magnesium stearate as typical excipients. Soft gelatin capsules (softgels) can be made dispersing the active ingredient in an oily medium, for example liquid paraffin, dimethylpolysiloxane 1000 or hydrogenated soybean oil. Moulded pessaries provide the active ingredient in admixture with a suitable synthetic or semisynthetic base (such as Suppocire® or Novata® types). Low viscosity saturated C8 to C12 fatty acid glycerides and colloidal silice are also added to improve incorporation and to prevent sedimentation of the active ingredient. Vaginal creams can be prepared as emulsions, with sufficient viscosity to retain their integrity and adhere to the vaginal cavity. Neutral fats, fatty acids, waxes, mineral oils and fatty acid esters can be used as the oily phase. Water, glycerine, sorbitol solution and polyethylene glycol are suitable excipients for the aqueous phase. Non-ionic emulsifying agents like polyethylene glycol ethers may also be used, and such compositions may also contain preserving, buffering and stiffening agents. Foaming systems can be made using a foamer (dispenser) that is able to transform a solution into a foam. Such systems may include cosolvents, buffers, preservatives, foam stabilizers and perfumes in an aqueous vehicle. Vaginal douches may contain cosolvents, preservatives, buffers and perfuming agents in a surfactant rich aqueous solution.
A compound of the invention may also administered in the form of suppositories for rectal administration of the drug, or as creams, ointments, pastes, lotions, gels, sprays, foams, aerosols, solutions, suspensions or powders for topical use. Such compositions are prepared following conventional procedures well known to those skilled in the art.
A compound of the invention may also be administered as a hair or body shampoo. These formulations may be prepared using suitable ionic and/or amphoteric surface-active agents such as sodium laureth sulfate, triethanolamine laureth sulfate, cocoamidopropyl betaine; thickening agents for example cocamide DEA, carbomer, sodium chloride and polyethylene glycol 6000 distearate; and optionally, emolient and superfatting agents, buffers, and preserving and perfuming agents.
The dosage and frequency of dose may vary depending upon the nature and severity of the fungal disease, symptoms, age and body weight of the patient, as well as upon the route of administration. In general, the compounds of the invention will be administered orally or parenterally at a dosage ranging from 0.01 mg/Kg/day to 100 mg/Kg/day, which can be administered as a single dose or as divided doses.
Following are some representative preparations for tablets, capsules, syrups, aerosols and injectables. They can be prepared following standard procedures and they are useful in the treatment of fungal diseases.
Figure imgf000021_0001
Figure imgf000022_0001
The following examples illustrate, but do not limit, the scope of the present invention:
REFERENCE EXAMPLE 1
1-(4-Chlorophenyl)-1H-pyrazole-4-carboxylic acid
(a) A solution of carbethoxymalonaldehyde (0.8 g, 5.55 mmol; obtained according to Panizzi, L. Gazz.Chim.Ital., 1946, 76, 56) in ethanol (25 mL) was treated with 4-chlorophenylhydrazine hydrochloride (1.0 g, 5.55 mmol) at reflux for 5 h. The resulting reddish mixture was concentrated to an oil that was purified by flash chromatography to give ethyl 1-(4-chlorophenyl)-1H- pyrazole-4-carboxylate (0.68 g, 49%) as a white solid: mp 127-128 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.37 (s, 1H, pyrazole), 8.09 (s, 1H, pyrazole), 7.67 (dt, Jt=2, Jd=9, 2H, arom), 7.44 (dt,Jt=2, Jd=9, 2H, arom), 4.35 (q, J=7, 2H, OCH2), 1.38
(t, J=7, 3H, OCH2CH3). Analysis calculated for C12H11CIN2O2: C 57.50; H 4.42; N 11.17. Found: C 57.49; H 4.46; N 11.16.
(b) A solution of the above product (0.44 g, 1.75 mmol) in EtOH (25 mL) and H2O (4 mL) was treated with KOH (85%, 0.81 g, 13 mmol) at reflux for 4 h. Then, the reaction mixture was concentrated, partitioned between H2O and
CHCl3 and the organic phase was discarded. The aqueous phase was acidified to pH 1 with 6N HCl and the precipitate formed was filtered, washed with water and dried to give the title compound as a white solid (0.32 g, 82%): mp 234-235 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.44 (s, 1H, pyrazole), 8.16 (s, 1H, pyrazole), 7.68 (dt,Jt=2,Jd=9, 2H, arom), 7.45 (dt,Jt=2,Jd=9, 2H, arom). Analysis calculated for C10H7CIN2O2: C 53.95; H 3.17; N 12.58. Found: C 53.31; H 3.30; N 12.60.
REFERENCE EXAMPLE 2
1-(4-Chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
The preparation of the following 5-substituted 1-aryl-1H-pyrazole-4- carboxylic acids was carried out according to the general procedure described in Menozzi, G. et al. J. Heterocyclic Chem. 1987, 24, 1669. The following example illustrates this procedure: (a) To a solution of ethyl acetylacetate (6 g, 46 mmol) in benzene (100 mL) was slowly added a solution of dimethylformamide dimethylacetal (8.2 g, 69 mmol) in benzene (100 mL) at 25 °C. After the addition was complete, the reddish mixture was heated at reflux for 1 h and then evaporated to dryness to give ethyl 2-dimethylaminomethylene-3-oxobutanoate (8.66 g) as a reddish oil. This product (3.25 g, 17 mmol) was allowed to react with 4- chlorophenylhydrazine hydrochloride (3.14 g, 17 mmol) in EtOH (50 mL) at reflux for 8 h. The mixture was evaporated to dryness and the product was isolated by flash chromatography to give ethyl 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylate as a white solid (2.07 g, 46%): mp 55-56 °C; !H NMR
(80 MHz, CDCl3) δ (TMS) 8.02 (s, 1H, pyrazole), 7.50 (d, J=9, 2H, arom), 7.34 (d, J=9, 2H, arom), 4.33 (q, J=7, 2H, OCH2), 2.56 (s, 3H, Me-pyrazole), 1.37 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H13CIN2O2: C 58.99; H 4.95; N 10.58. Found: C 59.03; H 5.06; N 10.58.
(b) A solution of the product obtained in section (a) (1.91 g, 7.21 mmol) in EtOH (50 mL) and H2O (10 mL) was treated with KOH (85%, 3.35 g, 50 mmol) at 60 °C for 20 h. Then, the reaction mixture was concentrated and partitioned between H2O and CHCl3. The organic phase was discarded and the aqueous phase was acidified to pH 1 with 3N HCl. The precipitate formed was filtered, washed with water and dried to give the title compound as a white solid (1.42 g, 83%): mp 195-198 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.39 (s, 1H, pyrazole), 7.50 (d, J=9, 2H, arom), 7.34 (d, J=9, 2H, arom), 2.59 (s, 3H, Me-pyrazole). Analysis calculated for C11H9CIN2O2: C 55.83; H 3.83; N 11.84. Found: C 56.10; H 3.82; N 11.54.
REFERENCE EXAMPLE 3
1-(4-Chlorophenyl)-5-isopropyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(4-chlorophenyl)-5-isopropyl-1H-pyrazole-4-carboxylate was obtained as a white solid: mp 86-87 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.01 (s, 1H, pyrazole), 7.48 (dt, Jt=2,Jd=9, 2H, arom), 7.28
(dt, Jt=2,Jd=9, 2H, arom), 4.33 (q, J=7, 2H, OCH2), 3.28 (quint, J=7, 1H, Me2CH), 1.38 (t, J=7, 3H, OCH2CH3), 1.35 (d, J=7, 6H, Me2CH). Analysis calculated for C15H17CIN2O2: C 61.54; H 5.85; N 9.57. Found: C 61.23; H 5.94; N 9.42.
(b) Following a similar procedure to that described in section b of reference example 2 the title compound was obtained as a white solid: mp 211-
212 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.11 (s, 1H, pyrazole), 7.48 (dt,Jt=2,Jd=9, 2H, arom), 7.30 (dt,Jt=2,Jd=9, 2H, arom), 3.29 (quint, J=7, 1H, Me2CH), 1.37 (t, J=7, 6H, Me2CH). Analysis calculated for C13H13CIN2O2: C 58.99; H 4.95; N 10.58. Found: C 59.23; H 4.93; N 10.47.
REFERENCE EXAMPLE 4
5-tertButyl-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 5-tertbutyl-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylate was obtained as a white solid: mp 104-105 °C; 1H NMR (80 MHz, CDCl3 ) δ (TMS) 7.96 (s, 1H, pyrazole), 7.43 (dt,Jt=2,Jd=9, 2H, arom), 7.24 (dt,Jt=2,Jd=9, 2H, arom), 4.31 (q, J=7, 2H, OCH2), 1.37 (t, J=7, 3H, OCH2CH3), 1.31 (s, 9H, Me3C). Analysis calculated for C16H19ClN2O2: C 62.64; H 6.24; N 9.13. Found: C 62.67; H 6.28; N 9.12.
(b) Following the procedure described in section b of reference example 2 the title compound was obtained as a white solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.09 (s, 1H, pyrazole), 7.45 (dt,Jt=2,Jd=9, 2H, arom), 7.26 (dt,Jt=2,Jd=9, 2H, arom), 1.34 (s, 9H, Me3C). Analysis calculated for C14H15ClN2O2: C 60.33; H 5.42; N 10.05. Found: C 60.41; H 5.41; N 10.12.
REFERENCE EXAMPLE 5
1-(4-Chlorophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(4-chlorophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylate was obtained as a white solid: mp 64-65 °C; 1H NMR (80 MHz,
CDCl3) δ (TMS) 8.00 (s, 1H, pyrazole), 7.46 (s, 4H, arom), 4.33 (q, J=7, 2H, OCH2), 2.2-1.8 (m, 1H, c-prop), 1.37 (t, J=7, 3H, OCH2CH3), 1.3-0.8 (m, 2H, c-prop), 0.8-0.5 (m, 2H, c-prop). Analysis calculated for C15H15CIN2O2: C 61.97; H 5.20; N 9.63. Found: C 61.64; H 5.26; N 9.65.
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 186-187 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.09 (s, 1H, pyrazole), 7.46 (s, 4H, arom), 2.2-1.8 (m, 1H, c-prop), 1.3-0.8 (m, 2H, c-prop), 0.8-0.5 (m, 2H, c-prop). Analysis calculated for C13H11CIN2O2: C 59.44; H 4.22; N 10.66. Found: C 59.37; H 4.17; N 10.46.
REFERENCE EXAMPLE 6
5-Methyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 5-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylate was obtained as a white solid: mp 60-61 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.05 (s, 1H, pyrazole), 7.79 (d, J=9, 2H, arom), 7.58 (d, J=9, 2H, arom), 4.33 (q, J=7, 2H, OCH2), 2.62 (s, 3H, Me -pyrazole), 1.38 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H13F3N2O2: C 56.38; H 4.39; N 9.39. Found: C 56.34; H 4.36; N 9.32. (b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 186-187 °C; 1H NMR
(80 MHz, CDCl3) δ (TMS) 8.14 (s, 1H, pyrazole), 7.80 (d, J=9, 2H, arom), 7.60 (d, J=9, 2H, arom), 2.64 (s, 3H, Me-pyrazole). Analysis calculated for C12H9F3N2O2: C 53.34; H 3.36; N 10.37. Found: C 53.68; H 3.38; N 10.22.
REFERENCE EXAMPLE 7
1-(4-Bromophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(4-bromophenyl)-5-methyl-1H-pyrazole-4- carboxylate was obtained as a thick oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.02 (s, 1H, pyrazole), 7.63 (dt,Jt=2, Jd=9, 2H, arom), 7.31 (dt,Jt=2, Jd=9, 2H, arom), 4.33 (q, J=7, 2H, OCH2), 2.56 (s, 3H, Me-pyrazole), 1.37 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H13BrN2O2: C 50.51; H 4.24; N 9.06. Found: C 50.34; H 4.57; N 8.93.
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 213-214 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.10 (s, 1H, pyrazole), 7.65 (dt, Jt=1.5, Jd=9, 2H, arom), 7.31 (dt, Jt=1.5, Jd=9, 2H, arom), 2.59 (s, 3H, Me-pyrazole). Analysis calculated for C11H9BrN2O2: C 47.00; H 3.23; N 9.97. Found: C 47.01; H 3.21; N 9.99.
REFERENCE EXAMPLE 8
5-Trifluoromethyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 5-trifluoromethyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylate was obtained as a white solid: mp 45-46 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.14 (s, 1H, pyrazole), 7.90 (d, J=9, 2H, arom), 7.56 (d, J=9,
2H, arom), 4.38 (q, J=7, 2H, OCH2), 1.39 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H10F6N2O2: C 47.74; H 2.86; N 7.95. Found: C 47.89; H 2.92; N 7.95.
(b) Following the procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 157-158 °C; 1H NMR
(80 MHz, CDCl3) δ (TMS) 8.23 (s, 1H, pyrazole), 7.82 (d, J=9, 2H, arom), 7.58 (d, J=9, 2H, arom). Analysis calculated for C12H6F6N2O2: C 44.46 H 1.87; N 8.64. Found: C 44.76; H 1.82; N 8.50.
REFERENCE EXAMPLE 9
1-(3,5-Dichlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-pyrazole-4- carboxylate was obtained as a pale yellow solid: mp 85-86 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.02 (s, 1H, pyrazole), 7.5-7.3 (m, 3H, arom), 4.34 (q, J=7, 2H, OCH2), 2.61 (s, 3H, Me-pyrazole), 1.37 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H12Cl2N2O2: C 52.19; H 4.04; N 9.36. Found: C 52.20; H 3.99; N 9.97.
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 229-230 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.98 (s, 1H, pyrazole), 7.40 (t, J=1.8, 1H, arom), 7.33 (t, J= 1.8, 2H, arom), 2.54 (s, 3H, Me-pyrazole). Analysis calculated for C11H8Cl2N2O2: C 48.73; H 2.97; N 10.33. Found: C 48.92; H 2.89; N 10.40.
REFERENCE EXAMPLE 10
1-(2,6-Dichlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(2,6-dichlorophenyl)-5-methyl-1H-pyrazole-4-carboxylate was obtained as colourless oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.12 (s, 1H, pyrazole), 7.6-7.4 (m, 3H, arom), 4.34 (q, J=7, 2H, OCH2), 2.36 (s, 3H,
Me-pyrazole), 1.38 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H12Cl2N2O2: C 52.19; H 4.04; N 9.36. Found: C 52.56; H 3.81; N 9.14.
(b) Following the procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 180-182 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.20 (s, 1H, pyrazole), 7.6-7.4 (m, 3H, arom), 2.40 (s,
3H, Me-pyrazole). Analysis calculated for C11H8Cl2N2O2: C 48.73; H 2.97; N 10.33. Found: C 48.82; H 2.90; N 10.20.
REFERENCE EXAMPLE 11
1-(2-Chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(2-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylate was obtained as a colourless oil: 1H NMR (300 MHz, CDCl3) δ (TMS) 8.05 (s, 1H, pyrazole), 7.6-7.4 (m, 4H, arom), 4.32 (q, J=7, 2H, OCH2), 2.39 (s, 3H, Me-pyrazole), 1.37 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H13CIN2O2: C 58.99; H 4.95; N 10.58. Found: C 59.20; H 4.91; N 10.38.
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 150-151 °C; 1H NMR
(300 MHz, CDCl3) δ (TMS) 8.14 (s, 1H, pyrazole), 7.6-7.4 (m, 4H, arom), 2.42 (s,
3H, Me-pyrazole). Analysis calculated for C11H9CIN2O2: C 55.83; H 3.83; N 11.84. Found: C 56.03; H 3.91; N 11.93.
REFERENCE EXAMPLE 12
1-(4-Chlorophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 but reacting ethyl diacetylacetate with 4-chlorophenylhydrazine hydrochloride, ethyl 1-(4-chlorophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate was directly obtained as a white solid: mp 79-80 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.47 (d, J=9, 2H, arom), 7.32 (d, J=9, 2H, arom), 4.32 (q, J=7, 2H, OCH2), 2.51 (s, 3H, Me-pyrazole), 2.49 (s, 3H, Me- pyrazole), 1.38 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H15CIN2O2: C 60.33; H 5.42; N 10.05. Found: C 60.44; H 5.48; N 10.29.
(b) Following the procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 220-223 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.48 (d, J=9, 2H, arom), 7.34 (d, J=9, 2H, arom), 2.55 (s,
3H, Me-pyrazole), 2.52 (s, 3H, Me-pyrazole). Analysis calculated for C12H11CIN2O2: C 57.50; H 4.42; N 11.17. Found: C 57.60; H 4.43; N 11.19.
REFERENCE EXAMPLE 13
5-Amino-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid
(a) A solution of ethyl ethoxymethylenecyanoacetate (3 g, 17.7 mmol) and 4-chlorophenylhydrazine hydrochloride (3.33 g, 18.6 mmol) in ethanol (60 mL) was refluxed for 2 days, following the procedure described in Schmidt, P. et al. Helv.Chim.Acta, 1959, 349. The reaction mixture was then allowed to cool to room temperature, whereupon a precipitate was formed. Cold CHCl3 was added, the precipitate was filtered and washed with more CHCl3. The filtrate and the washings were evaporated to dryness, precipitated with ether, filtered and dried to give ethyl 5-amino-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylate (2.25 g, 48%) as a white solid: mp 150-156 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.77 (s, 1H, pyrazole), 7.48 (s, 4H, arom), 4.30 (q, J=7, 2H, OCH2), 1.36 (t, J=7, 3H, OCH2CH3). Analysis calculated for C12H12CIN3O2: C 54.25; H
4.55; N 15.81. Found: C 54.77; H 4.49; N 15.65.
(b) Following the procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 169-171 °C; 1H NMR (80 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.78 (s, 1H, pyrazole), 7.50 (s, 4H, arom), 4.25 (br s, NH2, OH). Analysis calculated for C10H8ClN3O2: C 50.54; H 3.39; N
17.68. Found: C 50.54; H 3.39; N 17.44.
REFERENCE EXAMPLE 14
5-Amino-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid
(a) Following the procedure described in the reference example 13 ethyl 5-amino-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylate was obtained as an amorphous white solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 7.76 (s, 1H, pyrazole), 7.90 (d, J=9, 2H, arom), 7.56 (d, J=9, 2H, arom), 4.31 (q, J=7, 2H, OCH2),
1.35 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H12F3N3O2): C 52.18; H 4.04; N 14.04. Found: C 52.13; H 4.22; N 14.02
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 169-171 °C; 1H NMR
(80 MHz, CDCl3+MeOH-d4) δ (TMS) 7.78 (s, 1H, pyrazole), 7.90 (d, J=9, 2H, arom), 7.56. (d, J=9, 2H, arom), 4.32 (s, NH2, OH). Analysis calculated for
C11H8F3N3O2: C 48.72; H 2.97; N 15.49. Found: C 48.52; H 3.18; N 15.28.
REFERENCE EXAMPLE 15
5-Methyl-1-(3-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 5-methyl-1-(3-trifluoromethylphenyl)-1H-pyrazole- 4-carboxylate was obtained as a colourless oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.05 (s, 1H, pyrazole), 7.8-7.5 (m, 4H, arom), 4.34 (q, J=7, 2H, OCH2), 2.61 (s, 3H, Me-pyrazole), 1.38 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H13F3N2O2: C 56.38; H 4.39; N 9.39. Found: C 56.42; H 4.67; N 9.13.
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 122-123 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.20 (s, 1H, pyrazole), 7.8-7.7 (m, 4H, arom), 2.69 (s, 3H, Me-pyrazole). Analysis calculated for C12H9F3N2O2: C 53.34; H 3.36; N 10.37. Found: C 53.36; H 3.50; N 10.44.
REFERENCE EXAMPLE 16
5-Methyl-1-(4-trifluoromethoxyphenyl)-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 5-methyl-1-(4-trifluoromethoxyphenyl)-1H-pyrazole-4-carboxylate was obtained as a colourless oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.02 (s, 1H, pyrazole), 7.52 (d, J=9, 2H, arom), 7.32 (d, J=9, 2H, arom), 4.33 (q, J=7, 2H, OCH2), 2.57 (s, 3H, Me-pyrazole), 1.38 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H13F3N2O3: C 53.51; H 4.17; N 8.91. Found: C 53.43; H 4.28; N 8.55.
(b) Following the procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 176-178 °C; 1H NMR
(300 MHz, CDCl3) δ (TMS) 8.46 (s, 1H, pyrazole), 7.55 (dt, Jt=2.8, Jd=8.8, 2H, arom), 7.43 (d, J=8.8, 2H, arom), 2.67 (s, 3H, Me-pyrazole). Analysis calculated for C12H9F3N2O3: C 50.36; H 3.17; N 9.79. Found: C 50.52; H 3.13; N 9.76.
REFERENCE EXAMPLE 17
1-(4-Methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
(a) Following a similar procedure to that described in section a of reference example 2 ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4- carboxylate was obtained as a colourless oil: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.99 (s, 1H, pyrazole), 7.31 (d, J=9, 2H, arom), 6.99 (d, J=9, 2H, arom), 4.31 (q, J=7, 2H, OCH2), 3.85 (s, 3H, OMe), 2.51 (s, 3H, Me-pyrazole), 1.34 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H16N2O3: C 64.60; H 6.20; N 10.76. Found: C 64.89; H 6.41; N 10.51.
(b) Following the procedure described in section b of reference example
2 the title compound was obtained as a white solid: mp 212-213 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.08 (s, 1H, pyrazole), 7.33 (d, J=8.8, 2H, arom), 7.01 (d, J=8.8, 2H, arom), 3.87 (s, 3H, OMe), 2.54 (s, 3H, Me-pyrazole). Analysis calculated for C12H12N2O3: C 62.06; H 5.21; N 12.06. Found: C 62.23; H 2.13; N 12.06.
REFERENCE EXAMPLE 18
2-(4-Chlorophenyl)thiazole-5-carboxylic acid
(a) A solution of ethyl formylchloroacetate (1.45 g, 9.6 mmol; obtained according to Panizzi, L. Gazz . Ch im .Ita l . , 1946 , 76 , 56) and 4-chloro thiobenzamide (1.76 g, 9.6 mmol) in EtOH (50 mL) was refluxed for 48 h.
The reaction mixture was then cooled to -20 °C and the solid formed was filtered and dried to give ethyl 2-(4-chlorophenyl)thiazole-5-carboxylate (0.59 g, 23%): mp 144-145 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.40 (s, 1H, thiazole), 7.92 (dt, Jt=1.8, Jd=8.6, 2H, arom), 7.44 (dt, Jt=1.8, Jd=8.6, 2H, arom), 4.39 (q, J=7, 2H, OCH2), 1.40 (t, J=7, 3H, OCH2CH3). Analysis calculated for
C12H10CINO2S: C 53.84; H 3.76; N 5.23; S 11.97. Found: C 54.22; H 3.52; N 5.25; S 11.46.
(b) Following the hydrolysis procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 233-234 °C; Η NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 8.31 (s, 1H, thiazole),
7.83 (dt, Jt=1.8, Jd=8.8, 2H, arom), 7.37 (dt, Jt=1.8, Jd=8.8, 2H, arom). Analysis calculated for C10H6ClNO2S: C 50.11; H 2.52; N 5.84; S 13.38. Found: C 49.37; H 2.41; N 5.54; S 11.90.
REFERENCE EXAMPLE 19
4-Methyl-2-phenylthiazole-5-carboxylic acid
(a) A solution of methyl 2-chloroacetoacetate (1.86 g, 12.4 mmol) and thiobenzamide (1.7 g, 12.4 mmol) in EtOH (50 mL) was refluxed for 18 h. The mixture was evaporated to dryness and the resulting oil was purified by flash chromatography to give methyl 4-methyl-2-phenylthiazole-5-carboxylate (1.21 g, 42%) as a colourless oil: 1H NMR (300 MHz, CDCl3) δ (TMS) 8.0-7.9 (m, 2H, arom), 7.5-7.4 (m, 3H, arom), 3.87 (s, 3H, OMe), 2.76 (s, 3H, Me-thiazole). Analysis calculated for C12H11NO2S: C 61.78; H 4.75; N 6.00; S 13.74. Found: C 61.56; H 4.71; N 5.82; S 14.61 (b) Following the hydrolysis procedure described in section b of reference example 2 but using MeOH as solvent and heating at 80 °C for 4 h the title compound was obtained as a white solid: mp 215-218 °C; 1H NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.9-7.8 (m, 2H, arom), 7.4-7.3 (m, 3H, arom), 2.66 (s, 3H, Me-thiazole). Analysis calculated for C11H9NO2S: C 60.26 H 4.14; N 6.39; S 14.62. Found: C 60.37; H 4.07; N 6.14; S 14.91.
REFERENCE EXAMPLE 20
2-(4-Chlorophenyl)-4-methylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 methyl 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylate was obtained as a white solid: mp 132-133 °C; Η NMR (80 MHz, CDCl3) δ (TMS) 7.89 (dt, Jt=1.8, Jd=8.8, 2H, arom), 7.40 (dt, Jt=1.8, Jd=8.8, 2H, arom), 3.89 (s, 3H, OMe), 2.77 (s, 3H, Me-thiazole). Analysis calculated for C12H10CINO2S: C 53.84; H 3.76; N 5.23; S 11.97. Found: C 54.09; H 3.78; N 5.10; S 12.27.
(b) Following the hydrolysis procedure described in section b of reference example 19 the title compound was obtained as a white solid: mp 256-263°C; 1H NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.84 (dt, Jt=1.8, Jd=8.8, 2H, arom), 7.40 (dt, Jt=1.8, Jd=8.8, 2H, arom), 2.70 (s, 3H, Me-thiazole). Analysis calculated for C 11H8ClNO2S: C 52.08; H 3.18; N 5.52; S 12.64. Found: C 49.88; H 2.93; N 5.15; S 11.20.
REFERENCE EXAMPLE 21
2-(4-Bromophenyl)-4-methylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 methyl 2-(4-bromophenyl)-4-methylthiazole-5-carboxylate was obtained as a white solid: mp 144-146 °C; Η NMR (80 MHz, CDCl3) δ (TMS) 7.84 (dt, Jt=2, Jd=8.6, 2H, arom), 7.57 (dt, Jt=2, Jd=8.6, 2H, arom), 3.89 (s, 3H, OMe), 2.77 (s, 3H, Me-thiazole). Analysis calculated for C12H10BrNO2S: C 46.17; H 3.23; N 4.49; S 10.27. Found: C 45.95; H 3.27; N 4.52; S 10.34.
(b) Following the hydrolysis procedure described in section b of reference example 19 the title compound was obtained as a white solid: mp
227 °C (dec); 1H NMR (80 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.85 (dt, Jt=1.8, Jd=8.8, 2H, arom), 7.40 (dt, Jt=1.8, Jd=8.8, 2H, arom), 2.79 (s, 3H, Me-thiazole). Analysis calculated for C 11H8BrNO2S: C 44.31; H 2.70; N 4.70; S 10.75. Found: C 44.02; H 3.09; N 4.45; S 10.36.
REFERENCE EXAMPLE 22
4-Methyl-2-(4-trifluoromethoxyphenyl)thiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 methyl 4-methyl-2-(4-trifluoromethoxyphenyl)thiazole-5-carboxylate was obtained as a white solid: mp 76-77 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.00 (dt, Jt=2, Jd=8.8, 2H, arom), 7.30 (dt, Jt=2, Jd=8.8, 2H, arom), 3.90 (s, 3H, OMe), 2.78 (s, 3H, Me-thiazole). Analysis calculated for C13H10F3NO3S: C 49.21; H 3.18; N 4.41; S 10.10. Found: C 49.23; H 3.40; N 4.36; S 10.37.
(b) Following the hydrolysis procedure described in section b of reference example 19 the title compound was obtained as a white solid: mp 179-181 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.00 (dt, Jt=1.8, Jd=8.8, 2H, arom), 7.30 (dt, Jt=1.8, Jd=8.8, 2H, arom), 2.81 (s, 3H, Me-thiazole). Analysis calculated for C12H8F3NO3S: C 47.53; H 2.66; N 4.62; S 10.57. Found: C 47.59; H 2.68; N 4.62; S 10.26.
REFERENCE EXAMPLE 23
4-Methyl-2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]thiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 methyl 4-methyl-2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]thiazole-5-carboxylate was obtained as a white solid: mp 102-103 °C; 1H NMR (80 MHz,
CDCl3) δ (TMS) 7.95 (dt, Jt=2, Jd=8.8, 2H, arom), 7.00 (dt, Jt=2, Jd=8.8, 2H, arom), 6.06 (tt, J=4.6, J= 53, 1H, CHF2), 4.41 (tt, J=1.5, J=11.8, 2H, CH2), 3.89 (s, 3H, OMe), 2.77 (s, 3H, Me-thiazole). Analysis calculated for C15H13F4NO3S: C 49.59; H 3.61; N 3.86; S 8.82. Found: C 49.76; H 3.73; N 3.89; S 8.66.
(b) Following the hydrolysis procedure described in section b of reference example 19 the title compound was obtained as a white solid: mp 167-168 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.95 (dt, Jt=1.8. Jd=8.8, 2H, arom), 7.00 (dt, Jt=1.8, Jd=8.8, 2H, arom), 6.05 (tt, J=4.6, J= 53, 1H, CHF2), 4.41 (tt, J=1.5, J=11.8, 2H, CH2), 2.79 (s, 3H, Me-thiazole). Analysis calculated for C14H 11F4NO3S: C 48.14; H 3.17; N 4.01; S 9.18. Found: C 48.20; H 3.19; N 3.71; S
8.72.
REFERENCE EXAMPLE 24
2-(4-Cyanophenyl)-4-methylthiazole-5-carboxylic acid
(a) A suspension of methyl 2-chloroacetoacetate (30 g, 0.19 mol) and 4-cyanothiobenzamide (21.5 g, 0.13 mol) in MeOH (250 mL) was refluxed for 15 h. The reaction mixture was then cooled to 0°C, filtered after 20 h and washed with cooled (-20 °C) MeOH and with ether. The resulting off-white solid was dried to give methyl 2-(4-cyanophenyl)-4-methylthiazole-5-carboxylate (18.7 g, 55%). If desired, additional product may be recovered by flash chromatography of the washings: mp 186-187 °C; Η NMR (300 MHz, CDCl3) δ (TMS) 8.07 (dt, Jt=1.6, Jd=8.3, 2H, arom), 7.74 (dt, Jt=1.6, Jd=8.3, 2H, arom), 3.91 (s, 3H, OMe), 2.79 (s, 3H, Me-thiazole). Analysis calculated for C13H10N2O2S: C 60.45; H 3.90; N 10.85; S 12.41. Found: C 60.31; H 3.80; N 10.53; S 11.79. (b) The product obtained in section (a) (18.7 g, 72.4 mmol) was dissolved in a mixture of MeOH (0.6 L) and THF (0.3 L). Next, a solution of LiOH.H2O (15.2 g, 0.36 mol) in 60 mL of water was slowly added and the resulting reddish mixture was stirred at 30 °C for 8 h. The mixture was then evaporated to dryness, water was added to the residue, then it was filtered through celite and was acidified with 3N HCl to pH 1.0-1.2, resulting in the appearance of an orange foamy material. This product, which was difficult to filter, was centrifuged, washed with cold water, centrifuged again and then dried to give the title compound as a yellowish solid (18 g, 100%): mp 235-250 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.15 (dt, Jt=1.6, Jd=8.3, 2H, arom), 7.84 (dt, Jt=1.6, 7d=8.3, 2H, arom), 2.74 (s, 3H, Me-thiazole). Analysis calculated for C12H8N2O2S: C 59.01; H 3.30; N 11.47; S 13.12. Found: C 59.31; H 3.18; N 11.68; S 13.01.
REFERENCE EXAMPLE 25
2-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]-4-methylthiazole-5-carboxylic acid
(a) A solution of 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (0.78 g, 3 mmol; obtained in reference example 20) in thionyl chloride (10 mL) was refluxed for 4 h. The reaction mixture was evaporated to dryness, the resulting residue (0.93 g) was taken up in THF (15 mL) and then was slowly added to a cooled (0 °C) 40% ammonium hydroxide solution. Volatiles were removed in υacuo and the resulting aqueous residue was filtered and dried to give 2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (0.63 g, 79%) as a white solid: mp 236-237 °C; 1H NMR (300 MHz, CDCI3 + MeOH-d4) δ (TMS) 7.80 (d, J=8.4, 2H, arom), 7.36 (d, J=8.4, 2H, arom), 2.66 (s, 3H, Me-thiazole).
(b) To a solution of the product obtained in section (a) (0.89 g, 3.52 mmol) in a mixture of toluene (15 mL) and THF (15 mL) was added Lawesson's reagent (0.85 g, 2.11 mmol) and the resulting yellow solution was refluxed for 2 h. The reaction mixture was evaporated to dryness and the resulting product (2-(4-chlorophenyl)-4-methylthiazole-5-carbothioamide, 2.19 g) was then allowed to react with methyl 2-chloroacetoacetate in a similar manner to that described in section a of reference example 19. Methyl 2-[2-(4- chlorophenyl)-4-methylthiazol-5-yl]-4-methylthiazole-5-carboxylate was isolated by flash chromatography as a yellow solid (0.59 g, 46%): mp 174-175 °C; 1H NMR (300 MHz, CDCI3 + MeOH-d4) δ (TMS) 7.90 (d, J=8.4, 2H, arom), 7.42 (d, J=8.4, 2H, arom), 3.91 (s, 3H, OMe)), 2.766 (s, 3H, Me-thiazole), 2.761 (s, 3H, Me-thiazole). Analysis calculated for C16H13CIN2O2S2: C 52.67; H 3.59; N 7.68; S 17.57. Found: C 52.53; H 3.87; N 7.29; S 17.01.
(c) Following the hydrolysis procedure described in section b of reference example 2 the title compound was obtained as a slightly yellowish solid: mp 265-268 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.15 (dt, Jt=1.6, Jd=8.3, 2H, arom), 7.84 (dt, Jt=1.6, Jd=8.3, 2H, arom), 2.74 (s, 6H, Me-thiazole). Analysis calculated for C15H11CIN2O2S2: C 51.35; H 3.16; N 7.98; S 18.28. Found: C 51.32; H 3.12; N 7.78; S 17.43.
REFERENCE EXAMPLE 26
2-(4-Chlorophenyl)-4-trifluoromethylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 but using ethyl 2-chloro-4,4,4-trifluoroacetoacetate and 4- chlorophenylthiobenzamide, ethyl 2-(4-chlorophenyl)-4-trifluoromethyl- thiazole-5-carboxylate was obtained as a white solid, unpurified with a small amount of starting material: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.81 (dt, Jt=2.4, Jd=8.7, 2H, arom), 7.42 (dt, Jt=2.4, Jd=8.7, 2H, arom), 4.3-4.2 (m, 2H, OCH2), 1.32 (t, J=7, 3H, OCH2CH3).
(b) Following the hydrolysis procedure described in section b of reference example 19 the title compound was obtained as a white solid: mp 235-250 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.95 (dt, Jt=2.4, Jd=8.7, 2H, arom), 7.43 (d, J=8.3, 2H, arom). Analysis calculated for C11H5CIF3NO2S: C 42.94; H 1.64; N 4.55; S 10.42. Found: C 43.34; H 1.66; N 4.48; S 9.93.
REFERENCE EXAMPLE 27
4-Trifluoromethyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 but using ethyl 2-chloro-4,4,4-trifluoroacetoacetate and 4-trifluoromethylphenyl thiobenzamide, ethyl 4-trifluoromethyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxylate was obtained as a white solid, which still contained a small amount of starting material: 1H NMR (300 MHz, CDCl3) δ (TMS) 8.01 (d, J=8.1, 2H, arom), 7.71 (d, J=8.1, 2H, arom), 4.3-4.2 (m, 2H, OCH2), 1.34 (t, J=7, 3H, OCH2CH3).
(b) Following the hydrolysis procedure described in section b of reference example 19 the title compound was obtained as a white solid: mp
177-179 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.14 (d, J=8.2, 2H, arom), 7.75 (d, J=8.2, 2H, arom). Analysis calculated for C12H5F6NO2S: C 42.24; H 1.48; N 4.10; S 9.40. Found: C 41.86; H 1.33; N 4.03; S 8.92.
REFERENCE EXAMPLE 28
2-(4-Cyanophenyl)-4-trifluoromethylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 24 but using ethyl 2-chloro-4,4,4-trifluoroacetoacetate, ethyl 2-(4-cyanophenyl)- 4-trifluoromefhylthiazole-5-carboxylate was obtained as a white solid, which still contained a small amount of starting material.
(b) Following the hydrolysis procedure described in section b of reference example 24 the title compound was obtained as a white solid: mp
195-196 °C; 1H NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 8.10 (d, J=8.1, 2H, arom), 7.78 (d, J=8.1, 2H, arom). Analysis calculated for C12H5F3N2O2S: C 48.33;
H 1.69; N 9.39; S 10.75. Found: C 48.36; H 1.88; N 9.08; S 9.97.
REFERENCE EXAMPLE 29
2-[(4-Chlorophenoxy)methyl]-4-methylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 methyl 2-[(4-chlorophenoxy)methyl]-4-methylthiazole-5-carboxylate was obtained as a white solid: mp 88-89 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.25 (dt, Jt=2.1, Jd=8.9, 2H, arom), 6.90 (dt, Jt=2.1, Jd=8.9, 2H, arom), 5.27 (s, 2H, CH2O), 3.86 (s, 3H, OMe), 2.73 (s, 3H, Me-thiazole). Analysis calculated for C13H12CINO3S: C 52.44; H 4.06; N 4.70; S 10.77. Found: C 51.09; H 4.03; N 5.18; S 10.19.
(b) Following the hydrolysis procedure described in section b of reference example 24, but allowing the reaction to proceed overnight, the title compound was obtained as a white solid: mp 233-234 °C; 1H NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.21 (dt, Jt=2.2, Jd=9, 2H, arom), 6.88 (dt, Jt=2.2, Jd=9, 2H, arom), 5.22 (s, 2H, CH2O), 2.66 (s, 3H, Me-thiazole). Analysis calculated for C12H10CINO3S: C 50.80; H 3.55; N 4.94; S 11.30. Found: C 51.13; H 3.57; N 4.97; S 11.12.
REFERENCE EXAMPLE 30
2-[ N-(4-Chlorophenyl)amino]-4-methylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example
19, but using 4-chlorophenylthiourea, methyl 2-[N-(4-chlorophenyl)amino]-4-methylthiazole-5-carboxylate was obtained as a white solid: mp 172-173 °C; 1H NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.43 (dt, Jt=2.3, Jd=8.9, 2H, arom), 7.34 (dt, Jt=2.3, Jd=8-9, 2H, arom), 4.07 (br s, 1H, NH), 3.83 (s, 3H, OMe), 2.64 (s, 3H, Me-thiazole). Analysis calculated for C12H11ClN2O2S: C 50.98; H 3.92; N
9.91; S 11.34. Found: C 51.21; H 3.80; N 9.81; S 10.11.
(b) Following the hydrolysis procedure described in section b of reference example 2 but heating the reaction at reflux overnight the title compound was obtained as a white solid: mp >250 °C; 1H NMR (300 MHz, CDCl3 + MeOH-d4) δ (TMS) 7.40 (dt, Jt=2.1, Jd=9, 2H, arom), 7.30 (dt, Jt=2.1, Jd=9, 2H, arom), 2.58 (s, 3H, Me-thiazole). Analysis calculated for C11H9ClN2O2S: C 49.17; H 3.38; N 10.42; S 11.93. Found: C 49.29; H 3.31; N 10.32; S 11.32.
REFERENCE EXAMPLE 31 2-(4-Chlorophenyl)thiazole-4-carboxylic acid
(a) A solution of ethyl bromopyruvate (354 mg, 1.8 mmol) and 4-chlorothiobenzamide (283 g, 1.65 mmol) in EtOH (40 mL) was refluxed for 3 h. The mixture was evaporated to dryness and the resulting oil was purified by flash chromatography to give ethyl 2-(4-chlorophenyl)thiazole-4-carboxylate as a colourless oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.15 (s, 1H, thiazole), 7.95 (dt, Jt=2, Jd=8.5, 2H, arom), 7.42 (dt, Jt=2, Jd=8.5, 2H, arom), 4.45 (q, J=7, 2H, OCH2), 1.43 (t, J=7, 3H, OCH2CH3). Analysis calculated for C12H10ClNO2S: C 53.84; H 3.76; N 5.23; S 11.97. Found: C 53.65; H 3.77; N 5.23; S 11.51.
(b) Following the hydrolysis procedure described in section b of reference example 2 but heating the solution overnight, the title compound was obtained as a white solid: mp 189-190 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.29 (s, 1H, thiazole), 7.93 (dt, Jt=2, Jd=8.5, 2H, arom), 7.45 (dt, Jt=2, Jd=8.5, 2H, arom). Analysis calculated for C10H6ClNO2S: C 50.11 H 2.52; N 5.84; S 13.35. Found: C 50.21; H 2.45; N 5.79; S 13.21.
REFERENCE EXAMPLE 32
2-(4-Trifluoromethylphenyl)thiazole-4-carboxylic acid
(a) Following the procedure described in section a of reference example 31 ethyl 2-(4-trifluoromethylphenyl)thiazole-4-carboxylate was obtained as a white solid: mp 102-103 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.21 (s, 1H, thiazole), 8.15 (d, J=8.3, 2H, arom), 7.71 (d, J=8.3, 2H, arom), 4.47 (q, J=7, 2H, OCH2), 1.44 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H10F3NO2S: C 51.83; H 3.35; N 4.65; S 10.64. Found: C 51.91; H 3.34; N 4.61; S 10.29.
(b) Following the hydrolysis procedure described in section b of reference example 31 the title compound was obtained as a white solid: mp
188-189 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.37 (s, 1H, thiazole), 8.13 (d, J=8.5, 2H, arom), 7.73 (d, J=8.5, 2H, arom). Analysis calculated for C11H6F3NO2S: C 48.36 H 2.21; N 5.13; S 11.73. Found: C 48.46; H 2.22; N 5.17; S 11.75.
REFERENCE EXAMPLE 33
2-Phenylthiazole-4-carboxylic acid
(a) Following the procedure described in section a of reference example 31 ethyl 2-phenylthiazole-4-carboxylate was obtained as a colourless oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.14 (s, 1H, thiazole), 8.1-7.8 (m, 2H, arom), 7.6- 7.2 (m, 3H, arom), 4.45 (q, J=7, 2H, OCH2), 1.42 (t, J=7, 3H, OCH2CH3).
(b) Following the hydrolysis procedure described in section b of reference example 31 the title compound was obtained as an amorphous white solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.27 (s, 1H, thiazole), 8.2-7.8 (m, 2H, arom), 7.6-7.4 (m, 3H, arom).
REFERENCE EXAMPLE 34
2-[4-(2,2,3,3-Tetrafluoropropoxy)phenyl]thiazole-4-carboxylic acid
(a) Following the procedure described in section a of reference example 31 ethyl 2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]thiazole-4-carboxylate was obtained as a colourless oil: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.11 (s, 1H, thiazole), 7.98 (dt, Jt=2, Jd=8.8, 2H, arom), 6.98 (dt, Jt=2, Jd=8.8, 2H, arom), 6.06 (tt, J=4-6,J=53, 1H, CHF2), 4.41 (tt, J=1.5, J=11.8, 2H, CH2), 4.35 (q, J=7, 2H, OCH2), 1.42 (t, J=7, 3H, OCH2CH3).
(b) Following the hydrolysis procedure described in section b of reference example 31 the title compound was obtained as a white solid: mp 170-173 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.95 (s, 1H, thiazole), 8.70 (dt, Jt=2, Jd=8.8, 2H, arom), 7.75 (dt, Jt=2, Jd=8.8, 2H, arom), 6.79 (tt, J=4.6, J=53, 1H, CHF2), 5.16 (tt, J=1.5, J=11.8, 2H, CH2).
REFERENCE EXAMPLE 35
5-(4-Cyanophenyl)thiophene-2-carboxylic acid
(a) Following the procedure described in Hauptmann et al, Tetrahedron Lett. 1968, 1317, ethyl 5-(4-cyanophenyl)thiophene-2-carboxylate was obtained as a white solid: mp 133-134 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 7.83 (d, J=4, 1H, thiophene), 7.81 (dt, Jt=1.6, Jd=8.3, 2H, arom), 7.70 (dt, Jt=1.6, Jd=8.3, 2H, arom), 7.43 (d, J=4, 1H, thiophene), 4.44 (q, J=7, 2H, OCH2), 1.45 (t, J=7, 3H, OCH2CH3). Analysis calculated for C14H 11NO2S: C 65.35; H 4.31; N 5.44; S 12.46. Found: C 64.92; H 4.19; N 5.34; S 12.19.
(b) Following the hydrolysis procedure described in section b of reference example 24 the title compound was obtained as a white solid: mp
>300 °C; 1H NMR (300 MHz, DMSO-d6) δ (TMS) 7.99 (d, J=8.3, 2H, arom), 7.87 (d, J=8.3, 2H, arom), 7.74 (s, 2H, thiophene).
REFERENCE EXAMPLE 36
5-(4-Chlorophenyl)-3-methylthiophene-2-carboxylic acid
(a) To a cooled (-78 °C) solution of 3-(4-chlorophenyl)-3-chloroacrolein
(2.0 g, 10.4 mmol, obtained according to Hauptmann et al, Tetrahedron Lett. 1968, 1317) in dry THF (30 mL) was added dropwise a 3M solution of methylmagnesium bromide in THF (3.47 mL, 10.4 mmol). After the addition was complete, the reaction mixture was stirred at -78 °C for 0.5 h. Next, saturated aqueous NH4CI solution was added and the mixture was concentrated. The resulting aqueous residue was extracted with CHCl3, dried, filtered, concentrated and purified by flash chromatography to give 4-(4-chlorophenyl)-4-chloro-3-buten-2-ol (1.54 g, 71%) as a colourless oil: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.51 (dt, Jt=2.6, Jd=8.6, 2H, arom), 7.33 (dt, Jt=2.6, Jd=8.6, 2H, arom), 6.18 (d, J=7.5, 1H, =CH), 4.93 (quint, J=6.4, 1H, CHOH), 1.39 (d, J=6.4, 3H, CHCH3).
(b) CH2Cl2 (160 mL), pyridine (14 mL, 0.175mol) and CrO3 (8.76 g, 87 mmol) were placed in a flask. The resulting reddish solution was cooled to 0
°C, stirred for 0.5 h, and a solution of 4-(4-chlorophenyl)-4-chloro-3-buten-2-ol (2.8 g, 14.6 mmol, obtained in the preceding section) in CH2Cl2 (20 mL) was added dropwise. The reaction mixture was then stirred at room temperature for 4 h, filtered through celite, washed, concentrated and purified by flash chromatography to afford 4-(4-chlorophenyl)-4-chloro-3-buten-2-one as a colourless oil (1.3 g, 45%): 1H NMR (300 MHz, CDCl3) δ (TMS) 7.61 (dt, Jt=2.6, Jd=8.6, 2H, arom), 7.39 (dt, Jt=2.6, Jd=8.6, 2H, arom), 6.75 (s, 1H, =CH), 2.47 (s, 3H, Me).
(c) Following the procedure described in the literature (see reference example 35), the compound obtained in section (b) was allowed to react with the sodium salt of ethyl mercaptoacetate to give ethyl 5-(4-chlorophenyl)-3-methylthiophene-2-carboxylate as an amorphous solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.54 (dt, Jt=2.5, Jd=9, 2H, arom), 7.37 (dt, Jt=2.5, Jd=9, 2H, arom), 7.11 (s, 1H, thiophene), 4.35 (q, J=7, 2H, OCH2), 2.57 (s, 3H, Me-thiophene), 1.40 (t, J=7, 3H, OCH2CH3).
(d) Following the hydrolysis procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 245-246 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH) 7.63 (dt, Jt=2, Jd=8.6, 2H, arom), 7.39 (dt, Jt=2, Jd=8.6, 2H, arom), 7.25 (s, 1H, thiophene), 2.52 (s, 3H, Me-thiophene). Analysis calculated for C12H9CIO2S: C 57.03; H 3.59; S 12.69.
Found: C 56.94; H 3.20; S 12.39.
REFERENCE EXAMPLE 37
5-(4-Cyanophenyl)-3-methylthiophene-2-carboxylic acid
(a) Following the procedure described in reference example 36a 4-(4- cyanophenyl)-4-chloro-3-buten-2-ol was obtained as a colourless oil: 1H NMR
(300 MHz, CDCl3) δ (TMS) 7.70 (dt, Jt=2.1, Jd=8.7, 2H, arom), 7.64 (dt, Jt=2.1, Jd=8.7, 2H, arom), 6.33 (d, J=7.5, 1H, =CH), 4.95 (quint, J=6.5, 1H, CHOH), 1.41 (d, J=6.5, 3H, CHCH3).
(b) Following the procedure described in reference example 36b 4-(4- cyanophenyl)-4-chloro-3-buten-2-one was obtained as a colourless oil: 1H
NMR (300 MHz, CDCl3) δ (TMS) 7.79 (dt, Jt=2.2, Jd=8.7, 2H, arom), 7.71 (dt, Jt=2.2, Jd=8.7, 2H, arom), 6.79 (s, 1H, =CH), 2.49 (s, 3H, Me).
(c) Following the procedure described in reference example 36c ethyl 5- (4-cyanophenyl)-3-methylthiophene-2-carboxylate was obtained as a white solid: mp 129-130 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.68 (s, 4H, arom), 7.19 (s, 1H, thiophene), 4.35 (q, J=7, 2H, OCH2), 2.57 (s, 3H, Me-thiophene), 1.39
(tJ=7, 3H, OCH2CH3).
(d) Following the hydrolysis procedure described in section b of reference example 24 the title compound was obtained as a white solid: mp 248-253 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.68 (d, J=9, 2H, arom), 7.66 (d, J=9, 2H, arom), 7.20 (s, 1H, thiophene), 2.53 (s, 3H, Me-thiophene). Analysis calculated for C13H9NO2S: C 64.18; H 3.73; N 5.76; S 13.18. Found: C 64.18; H 3.71; N 5.60; S 13.00.
REFERENCE EXAMPLE 38
2-(4-Chlorophenyl)-5-methyl-3H-imidazole-4-carboxylic acid
(a) A solution of ethyl 2-oximinoacetoacetate (6 g, 38 mmol; obtained according to Org.Synth. 1941, 21, 67) in MeCN (75 mL) was treated with 4- chlorobenzylamine (5.6 g, 40 mmol) at reflux for 18 h. Next, the reaction mixture was allowed to cool and the yellow solid formed was collected by filtration to give ethyl 2-(4-chlorophenyl)-5-methyl-3H-imidazole-4- carboxylate as a white solid (4.1 g, 40%): mp 237-238 °C; αH NMR (300 MHz, DMSO-d6) δ (DMSO) 7.96 (d, J=8, 2H, arom), 7.57 (d, J=8, 2H, arom), 4.27 (q, J=7, 2H, OCH2), 2.54 (s, 3H, Me-imidazole), 1.33 (t, J=7, 3H, OCH2CH3). Analysis calculated for C13H13ClN2O2: C 58.99; H 4.95; N 10.58. Found: C 59.20; H 4.95; N 10.59.
(b) Following the hydrolysis procedure described in section b of reference example 2 the title compound was obtained as a white solid: 1H NMR (300 MHz, DMSO-d6) δ (DMSO) 7.98 (br), 7.50 (d, J=8.5, 2H, arom), 2.49 (s,
3H, Me-imidazole).
REFERENCE EXAMPLE 39
Mixture of 2-(4-chlorophenyl)-3,5-dimethyl-3H-imidazole-4-carboxylic acid and 2-(4-chlorophenyl)-1,5-dimethyl-lFf-imidazole-4-carboxylic acid
A solution of ethyl 2-(4-chlorophenyl)-5-methyl-3H-imidazole-4-carboxylate (2.7 g, 10 mmol, obtained in reference example 38) in DMF (50 mL) was treated with K2CO3 (1.4 g, 10 mmol) and Mel (0.95 mL, 15.3 mmol) at 60 °C for 2 h. The mixture was then evaporated to dryness and the resulting residue partitioned between EtOAc and water. The organic phase was separated, dried over Na2SO4, filtered and concentrated to afford a ca. 1:1 mixture of N-methylimidazole derivatives. This mixture was then hydrolyzed as described above to give a mixture of acids N-methylated on the imidazole ring. This mixture was directly used in the next step as obtained. REFERENCE EXAMPLE 40
5-(4-Chlorophenyl)-1,3,4-oxadiazole-2-carboxylic acid
(a) This product was prepared by a modification of the general procedure described in Dost, J. et al. J .Prakt.Chem.1985, 327, 109. To a cooled (0°C) solution of 4-chlorobenzhydrazide (5 g, 29 mmol) and triethylamine (7.4 mL, 51 mmol) in CH2Cl2 (100 mL) was added drop wise ethyl oxalyl chloride (4 g, 29 mmol) and the mixture was stirred for 3 h. Next, saturated NaHCO3 solution (50 mL) and CHCl3 were added. The organic phase was dried over anhydrous Na2S O 4, filtered and concentrated to give ethyl 4- chlorobenzoylhydrazinooxalate as a colourless oil which was purified by flash chromatography to yield 1.1 g of a white solid. This product was then dissolved in POCl3 (30 mL) and heated at 100 °C for 15 h. The reaction mixture was evaporated to dryness and partitioned between 10% aqueous NaHCO3 and CHCl3. The organic phase was separated, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to afford ethyl 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-carboxylate as a white solid (450 mg): mp 117-118 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.11 (dt, Jt=2.3, Jd=8.6, 2H, arom), 7.54 (dt, Jt=2.3, Jd=8.6, 2H, arom), 4.56 (q, J=7.1, 2H, OCH2), 1.49 (t, J=7.1, 3H, OCH2CH3). Analysis calculated for C11H9CIN2O3: C 52.29; H 3.59; N 11.09. Found: C 52.70; H 3.42; N 10.89.
(b) Following the hydrolysis procedure described in section b of reference example 2, the title compound was obtained as a white solid: mp 277-284 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH) 7.87 (d, J=8.5, 2H, arom), 7.51 (d, J=8.5, 2H, arom).
REFERENCE EXAMPLE 41
3-(4-Chlorophenyl)-1,2,4-oxadiazole-5-carboxylic acid
(a) This product was prepared by a modification of the general procedure described in Diana et al. J.Med.Chem. 1995, 38, 1355. A mixture of 4- chlorobenzonitrile (5 g, 36.34 mmol), EtOH (90 mL), hydroxylamine hydrochloride (2.52 g, 36.34 mmol) and K2CO3 (2.51 g, 18.17 mmol) was refluxed for 20 h. The reaction mixture was concentrated, cold water was added, and it was filtered and dried to give 4-chlorobenzoamidoxime as a white solid (3.5 g, 56%). Next, this product (1.7 g, 10 mmol) was taken up in pyridine (34 mL) and treated with ethyl oxalyl chloride (2.22 mL, 20 mmol) at 0 °C. The reaction mixture was stirred for 1 h, then poured into pH 7 phosphate buffer, concentrated and partitioned between CHCl3 and water. The organic phase was washed with 10% aqueous NaHCO3 solution, dried over Na2SO4, filtered, concentrated and purified by flash chromatography to give ethyl 3-(4-chlorophenyl)-1,2,4-oxadiazole-5-carboxylate as an amorphous solid (2.14 g, 85%): 1H NMR (300 MHz, CDCl3) δ (TMS) 8.18 (dt, Jt=2.2, Jd=8.6, 2H, arom), 7.56 (dt, Jt=2.2, Jd=8.6, 2H, arom), 4.66 (q, J=7.1, 2H, OCH2), 1.57 (t, J=7.1, 3H, OCH2CH3).
(b) This product was subjected to the hydrolysis procedure described in reference example 24 for 1 h to give the title compound as a white solid, which contained a small amount of the decarboxylated product: mp 43-44 °C; 1H NMR (300 MHz, CDCI3 + MeOH-d4) δ (TMS) 7.63 (d, J=9, 2H, arom), 7.50 (d, J=9, 2H, arom).
REFERENCE EXAMPLE 42
5-(4-Chlorophenyl)-1,2,4-oxadiazole-3-carboxylic acid
(a) This product was prepared by a modification of the general procedure described in Shimizu, T. et al. Bull.Chem.Soc.Jpn. 1985, 58, 2519. A mixture of 4-chlorobenzonitrile (1.7 g, 12.2 mmol), and diethyl nitromalonate (2.5 g, 12.2 mmol) in dodecane (20 mL) was heated at 150°C for 15 h. After the reaction was complete, the mixture was allowed to cool to room temperature and was then concentrated in vacuo. The residue was purified by flash chromatography to yield ethyl 5-(4-chlorophenyl)-1,2,4-oxadiazole-3-carboxylate as a light brown solid: mp 88-89 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.15 (dt, Jt=2.3, Jd=8.7, 2H, arom), 7.54 (dt, Jt=2.3, Jd=8.7, 2H, arom), 4.55
(q, J=7.1, 2H, OCH2), 1.47 (t, J=7.1, 3H, OCH2CH3).
(b) Following the hydrolysis procedure described in section b of reference example 2 the title compound was obtained as a white solid, contaminated with a small amount of the decarboxylated product: 1H NMR (300 MHz, CDCI3 + MeOH-d4) δ (TMS) 8.11 (d, J=9, 2H, arom), 7.51 (d, J=9, 2H, arom).
REFERENCE EXAMPLE 43
2-(4-tert-Butylphenyl)-4-methylthiazole-5-carboxylic acid
(a) Following the procedure described in section a of reference example 19 methyl 2-(4-tert-butylphenyl)-4-methylthiazole-5-carboxylate was obtained as a colourless oil: 1H NMR (300 MHz, CDCI3) δ (TMS) 7.89 (dt, Jt=2.2, Jd=8.6, 2H, arom), 7.46 (dt, Jt=2.2, Jd=8.6, 2H, arom), 3.89 (s, 3H, OMe), 2.78 (s, 3H, Me- thiazole), 1.35 (s, 9H, CMe3).
(b) Following the hydrolysis procedure described in section b of reference example 2 the title compound was obtained as a white solid: mp 190- 193 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH) 7.89 (dt, Jt=2.2, Jd=8.6, 2H, arom), 7.53 (dt, Jt=2.2, Jd=8.6, 2H, arom), 2.72 (s, 3H, Me-thiazole), 1.36 (s, 9H, CMe3). Analysis calculated for C15H17NO2S: C 65.43; H 6.22; N 5.09; S 11.64. Found: C 65.41; H 6.22; N 4.92; S 10.84.
EXAMPLE 1
(1R,2R)-1-(4-Chlorophenyl)- N-[2-{2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-1H-pyrazole-4-carboxamide
To a solution of (2R,3R)-3-amino-2-(2,4-difluorophenyl)-1-(1H-1,2,4- triazol-1-yl)-2-butanol (340 mg, 1.26 mmol, prepared as described in J. Org. Chem., 1995, 60, 3000-3012) in DMF (6 mL) was added 1-hydroxybenzotriazole (207 mg, 1.32 mmol). Next, 1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid (280 mg, 1.26 mmol, obtained in reference example 1) and DCC (272 mg, 1.32 mmol) were added and the mixture was stirred at room temperature for 18 h.
The reaction mixture was then cooled to 0 °C and the dicyclohexylurea formed was filtered, washed with CHCl3 and the remaining solution was evaporated to dryness and partitioned between 10% aqueous NaHCO3 solution and CHCl3. The layers were separated and the organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (hex: EtOAc 1:1 then 1:3) to afford the title product, which was recrystallized from EtOAc: ether: hexane to yield a white solid (560 mg, 94%): mp 212-213 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.39 (s, 1H, pyrazole), 8.02 (s, 1H, pyrazole), 7.9-7.2 (m, 7H, arom), 7.0-6.6 (m, 2H, arom), 6.43 (br d, J=9, 1H, NH), 5.35 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m,
1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.02 (d, J=7, 3H, MeCH); [α]D= -106.3° (c 1, CHCl3). Analysis calculated for C22H19CIF2N6O2: C 55.88; H 4.05; N 17.77. Found: C 55.96; H 4.06; N 17.55.
EXAMPLE 2
(1R,2R)-1-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (reference example 2) the title compound was obtained as a white solid: mp 154-155°C; 1H NMR (80 MHz, CDCI3) δ (TMS) 7.90 (s, 1H, triazole), 7.79 (s, 2H, triazole, pyrazole),
7.6-7.2 (m, 5H, arom), 7.0-6.6 (m, 2H, arom), 6.37 (br d, J=9, 1H, NH), 5.35 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.61 (s, 3H, Me-pyrazole), 1.02 (d, J=7, 3H, MeCH); [α]D= -91.4° (c 1, CHCl3). Analysis calculated for C23H21ClF2N6O2: C 56.74; H 4.35; N 17.26. Found: C 56.79; H 4.62; N 17.15.
EXAMPLE 3
(1R,2R)-1-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-5-trifluoromethyl-1H-pyrazole-4-carboxamide Following a similar procedure to that described in example 1 but using 1-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid the title compound was obtained as a white solid: mp 138-139 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 7.98 (s, 1H, triazole), 7.79 (s, 2H, triazole, pyrazole), 7.6-7.2 (m, 5H, arom), 7.0-6.6 (m, 2H, arom), 6.48 (br d, J=9, 1H, NH), 5.31 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.02 (d, J=7, 3H, MeCH); [α]D= -103.6° (c 1, CHCl3). Analysis calculated for C23H18ClF5N6O2: C 51.07; H 3.35; N 15.54. Found: C 50.66; H 3.41; N 15.39.
EXAMPLE 4
(1R,2R)-1-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-propyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(4-chlorophenyl)-5-propyl-1H-pyrazole-4-carboxylic acid the title compound was obtained as an amorphous solid: 1H NMR (80 MHz, CDCI3) δ (TMS) 7.88
(s, 1H, triazole), 7.79 (s, 2H, triazole, pyrazole), 7.6-7.2 (m, 5H, arom), 7.0-6.6 (m, 2H, arom), 6.38 (br d, J=9, 1H, NH), 5.35 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 3.2-2.8 (m, 2H, Pr), 1.7-1.5 (m, 2H, Pr), 1.02 (d, J=7, 3H, MeCH), 0.87 (t, 3H, Pr); [α]D= -79.5° (c 1, CHCl3). Analysis calculated for C25H25ClF2N6O2: C 58.31; H 4.89; N 16.32.
Found: C 58.14; H 5.14; N 16.36.
EXAMPLE 5
(1R,2 R)-1-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-isopropyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using
1-(4-chlorophenyl)-5-isopropyl-1H-pyrazole-4-carboxylic acid (reference example 3) the title compound was obtained as an amorphous solid: mp 85-92 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 7.83 (s, 1H, pyrazole), 7.79 (s, 2H, triazole), 7.6-7.2 (m, 5H, arom), 7.0-6.6 (m, 2H, arom), 6.41 (br d, J=10, 1H, NH), 5.32 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50
(d, J=14.5, 1H, TrCH(H)), 3.4-3.1 (m, 1H, CHMe2), 1.38 (d, J=7, 6H, CHMe2), 1.02 (d, J=7, 3H, MeCH); [α]D= -82.5° (c 1, CHCl3). Analysis calculated for C25H25ClF2N6O2.1 /2H2O: C 57.30; H 5.00; N 16.04. Found: C 57.04; H 5.27; N 15.73.
EXAMPLE 6
(1R,2R)-5-tertButyl-1-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 5-tertbutyl-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid (reference example 4) the title compound was obtained as a white solid: mp 191-192 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.80 (s, 2H, triazole), 7.68 (s, 1H, pyrazole), 7.6-7.2 (m, 5H, arom), 7.0-6.6 (m, 2H, arom), 6.45 (br d, J=10, 1H, NH), 5.31 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.31 (s, 9H, t-Bu), 1.02 (d, J=7, 3H, MeCH); [α]D= -92.0° (c 1, CHCl3). Analysis calculated for C26H27CIF2N6O2: C 59.03; H 5.14; N 15.89. Found: C 59.36; H 5.66; N 15.87.
EXAMPLE 7
(1R,2R)-1-(4-Chlorophenyl)-5-cyclopropyl- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(4-chlorophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylic acid (reference example 5) the title compound was obtained as a white solid: mp 181-182 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.06 (s, 1H, pyrazole), 7.79 (s, 2H, triazole),
7.49 (s, 4H, arom), 7.6-7.2 (m, 1H, arom), 7.0-6.6 (m, 3H, arom, NH), 5.33 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.2-1.8 (m, 1H, c-prop), 1.3-1.0 (m, 2H, c-Pr), 1.04 (d, J=7, 3H, MeCH), 0.8-0.5 (m, 2H, c-pr); [α]D= -112.6° (c 1, CHCl3). Analysis calculated for C25H23ClF2N6O2: C 58.54; H 4.52; N 16.38. Found: C 58.90; H 4.87; N 16.27.
EXAMPLE 8
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1- yl)propyl]-5-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 5-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid (reference example 6) the title compound was obtained as a white solid: mp 180-181 °C; ϊH NMR (80 MHz, CDCl3) δ (TMS) 8.02 (s, 1H), 7.9-7.2 (m, arom), 7.0-6.6 (m, 2H, arom), 6.37 (br d, J=10, 1H, NH), 5.37 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.69 (s, 3H, Me-pyrazole), 1.04 (d, J=7, 3H, MeCH); [α]D= -90.8° (c 1, CHCl3). Analysis calculated for C24H21F5N6O2: C 55.39; H 4.07; N 16.15. Found: C 55.57; H 4.27; N 16.01.
EXAMPLE 9
(1R,2R)-1-(4-Bromophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using
1-(4-bromophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (reference example 7) the title compound was obtained as a white solid: mp 153-154 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.91 (s, 1H, pyrazole), 7.81 (s, 1H, triazole), 7.80 (s, 1H, triazole), 7.66 (d, J=8.7, 2H, arom), 7.4 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.32 (d, J=8.7, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.35 (br d, J=9.5, 1H, NH), 5.36 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.53 (d, J=14.5, 1H, TrCH(H)), 2.63 (s, 3H, Me-pyrazole), 1.03 (d, J=6.8, 3H, MeCH); MS 306 and 308 (ethylaminoacyl group, Ci3Hi3BrN3O), 263 and 265 (acyl group, CnH8BrN2O), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -86.8° (c 1, CHCl3). Analysis calculated for C23H21BrF2N6O2: C 51.99; H 3.98; N 15.82. Found: C 52.10; H 4.01; N 15.76.
EXAMPLE 10
(1R,2R)- N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-trifluoromethyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 5-trifluoromethyl-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid (reference example 8) the title compound was obtained as a white solid: mp
141-143 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.02 (s, 1H), 7.9-7.2 (m, arom), 7.0-6.4 (m, 3H, arom, NH), 5.31 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.02 (d, J=7, 3H, MeCH); [α]D= -86.3° (c 1, CHCl3). Analysis calculated for C24H18F8N6O2: C 50.18; H 3.16; N 14.63. Found: C 49.75; H 3.20; N 14.45.
EXAMPLE 11
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1-(2,4-difluorophenyl)-5-methyl-1 H-pyrazole-4-carboxaιnide
Following a similar procedure to that described in example 1 but using 1-(2,4-difluorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid the title compound was obtained as a white solid: mp 208-209 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.93 (s, 1H, triazole), 7.78 (s, 2H, triazole, pyrazole), 7.6-7.0 (m, 3H, arom), 7.0-6.6 (m, 3H, arom), 6.35 (br d, J=9, 1H, NH), 5.34 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.49 (s, 3H, Me-pyrazole), 1.02 (d, J=7, 3H, MeCH); [α]D= -89.6° (c 1,
CHCl3). Analysis calculated for C23H20F4N6O2: C 56.56; H 4.13; N 17.21. Found: C 56.88; H 4.36; N 16.83.
EXAMPLE 12
(1R,2R)-1-(3,5-Dichlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl- 3-(1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(3,5-dichlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (reference example 9) the title compound was obtained as a white solid: mp 220-221 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.92 (s, 1H, pyrazole), 7.81 (s, 1H, triazole), 7.80 (s, 1H, triazole), 7.5-7.3 (m, 4H, arom), 6.8-6.6 (m, 2H, arom), 6.36 (br d, J=9.5, 1H, NH), 5.36 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 4.96 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.5, 1H, TrCH(H)), 2.68 (s, 3H, Me-pyrazole), 1.03 (d, J=6.8, 3H, MeCH); MS 296 and 298 (ethylaminoacyl group, C13H12Cl2N3O), 253 and 255 (acyl group, C11H7Cl2N2O), 224 (Tr-CH2COHAr, C 10H 8F2N 3O); [α ]D = -83.1° (c 1, CHCl3). Analysis calculated for C23H20Cl2F2N6O2: C 52.99; H 3.87; N 16.12. Found: C 53.58; H 4.08; N 15.90.
EXAMPLE 13
(1R,2R)-1-(2,6-Dichlorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(2,6-dichlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (reference example 10) the title compound was obtained: mp 226-227 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.03 (s, 1H, pyrazole), 7.81 (s, 2H, triazole), 7.6-7.3 (m, 4H, arom), 6.8-6.6 (m, 2H, arom), 6.42 (br d, J=9.5, 1H, NH), 5.38 (d, J=1.3, 1H, OH), 5.07 (d, J=14.5, 1H, TrCH(H)), 4.97 (br quint, J=7, 1H, CHMe), 4.57 (d, J=14.5, 1H, TrCH(H)), 2.44 (s, 3H, Me-pyrazole), 1.04 (d, J=6.8, 3H, MeCH); MS 296 and 298 (ethylaminoacyl group, C13H 12Cl2N 3O), 253 and 255 (acyl group, C11H7Cl2N2O), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -80.3° (c 1, CHCl3).
Analysis calculated for C23H20Cl2F2N6O2: C 52.99; H 3.87; N 16.12. Found: C 53.29; H 3.91; N 15.93.
EXAMPLE 14
(1R,2R)-1-(2-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(2-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (reference example 11) the title compound was obtained as a white solid: mp 232-233 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.97 (s, 1H, pyrazole), 7.81 (s, 2H, triazole), 7.6-7.3 (m, 5H, arom), 6.8-6.6 (m, 2H, arom), 6.39 (br d, J=9.5, 1H, NH), 5.38 (d, J=1.5, 1H,
OH), 5.07 (d, J=14.4, 1H, TrCH(H)), 4.97 (br quint, J=7, 1H, CHMe), 4.57 (d, J=14.4, 1H, TrCH(H)), 2.48 (s, 3H, Me-pyrazole), 1.05 (d, J=6.8, 3H, MeCH); [α]D= -85.2° (c 1, CHCl3). Analysis calculated for C23H21ClF2N6O2: C 56.74; H 4.35; N 17.26. Found: C 56.87; H 4.56; N 17.03.
EXAMPLE 15
(1R,2R)-1-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-3,5-dimethyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(4-chlorophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid (reference example 12) the title compound was obtained : mp 144-145 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.978 (s, 2H, triazole), 7.6-7.2 (m, 5H, arom), 7.0-6.6 (m, 2H, arom), 6.28 (br d, J=10, 1H, NH), 5.35 (d, J=1.3, 1H, OH), 5.07 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.56 (s, 3H, Me- pyrazole), 2.54 (s, 3H, Me-pyrazole), 1.02 (d, J=7, 3H, MeCH); [α]D= -93.9° (c 1, CHCl3). Analysis calculated for C24H23ClF2N6O2: C 57.55; H 4.63; N 16.78. Found: C 57.91; H 4.80; N 16.53.
EXAMPLE 16
(1R,2R)-5-Amino-1-(4-chlorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 5-amino-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid (reference example 13) the title compound was obtained as a white solid: mp 181-182 °C; !H NMR (80 MHz, CDCl3) δ (TMS) 7.78 (s, 2H, triazole), 7.69 (s, 1H, pyrazole), 7.50 (br s,
4H, arom), 7.6-7.2 (m, 1H, arom), 7.0-6.6 (m, 2H, arom), 6.15 (br d, J=9, 1H, NH), 5.55 (br s, 2H, NH2), 5.36 (s, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.02 (d, J=7, 3H, MeCH); [α]D= -86.7° (c 1, CHCl3). Analysis calculated for C22H20ClF2N7O2: C 54.16; H 4.13; N 20.10. Found: C 54.28; H 4.35; N 19.76.
EXAMPLE 17
(1R,2R)-5-Amino- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 5-amino-1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid (reference example 14) the title compound was obtained as a white solid: mp 208-210 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 7.76 (m, 7H, triazole, arom, pyrazole), 7.6-7.3 (m, 1H, arom), 7.0-6.6 (m, 2H, arom), 6.18 (br d, J=9, 1H, NH), 5.6 (br s, 2H, NH2), 5.37 (s, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.02 (d, J=7, 3H, MeCH); [α]D= -69.6° (c 1, CHCl3).
Analysis calculated for C23H20F5N7O2.2H2O: C 49.55; H 4.34; N 17.59. Found: C 49.33; H 3.99; N 17.58.
EXAMPLE 18
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1-(3-trifluoromethylphenyl)-1H-pyrazole-4-carboxa mide
Following a similar procedure to that described in example 1 but using 5-methyl-1-(3-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid (reference example 15) the title compound was obtained as a white solid: mp 146-147 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.95 (s, 1H, pyrazole), 7.82 (s, 2H, triazole), 7.6-7.5 (m, 4H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.41 (br d, J=9.5, 1H, NH), 5.37 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)),
4.96 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.5, 1H, TrCH(H)), 2.67 (s, 3H, Me-pyrazole), 1.03 (d, J=6.8, 3H, MeCH); MS 296 (ethylaminoacyl group,
C 14H 13F3N 3O), 253 (acyl group, C12H8F3N2O), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -90.5° (c 1, CHCl3). Analysis calculated for C24H21F5N6O2: C 55.39; H 4.07; N 16.15. Found: C 55.33; H 3.97; N 16.12.
EXAMPLE 19
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1-(4-trifluoromethoxyphenyl)-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using
5-methyl-1-(4-trifluoromethoxyphenyl)-1H-pyrazole-4-carboxylic acid
(reference example 16) the title compound was obtained as a white solid: mp 134-135 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.93 (s, 1H, pyrazole), 7.815 (s,
1H, triazole), 7.810 (s, 1H, triazole), 7.6-7.3 (m, 5H, arom), 6.8-6.6 (m, 2H, arom), 6.38 (br d, J=9.5, 1H, NH), 5.37 (d, J=1.3, 1H, OH), 5.07 (d, J=14.5, 1H, TrCH(H)),
4.97 (br quint, J=7, 1H, CHMe), 4.54 (d, J=14.5, 1H, TrCH(H)), 2.65 (s, 3H, Me-pyrazole), 1.04 (d, J=6.8, 3H, MeCH); MS 312 (ethylaminoacyl group, C 14H13F3N3O2), 269 (acyl group, C12H8F3N2O2), 224 (Tr-CH2COHAr,
C10H8F2N3O); [α]D= -83.1° (c 1, CHCl3). Analysis calculated for C24H21F5N6O3: C 53.73; H 3.95; N 15.67. Found: C 53.99; H 3.94; N 15.46.
EXAMPLE 20
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (reference example 17) the title compound was obtained: mp 176-177 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.89 (s, 1H, pyrazole), 7.81 (s, 2H, triazole), 7.41 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.33 (dt, Jt=2.5, Jd=6.6, 2H, arom), 7.02 (dt, Jt=2.5, Jd=6.6,
2H, arom), 6.8-6.6 (m, 2H, arom), 6.35 (br d, J=9.5, 1H, NH), 5.37 (d, J=1.3, 1H, OH), 5.07 (d, J=14.5, 1H, TrCH(H)), 4.97 (br quint, J=7, 1H, CHMe), 4.55 (d, J=14.5, 1H, TrCH(H)), 3.88 (s, 3H, OMe), 2.59 (s, 3H, Me-pyrazole), 1.04 (d, J=6.8, 3H, MeCH); MS 258 (ethylaminoacyl group, C14H16N3O2), 215 (acyl group, C12H11N2O2), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -90.3° (c 1, CHCl3). Analysis calculated for C24H24F2N6O3: C 59.75; H 5.01; N 17.42. Found: C 59.88; H 4.91; N 17.30.
EXAMPLE 21 (1R,2R)-1-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]pyrrole-3-carboxamide
Following a similar procedure to that described in example 1 but using 1-(4-chlorophenyl)pyrrole-3-carboxylic acid (prepared as described in Fabis et al, Org.Prep.Proced.Int. 1995, 27, 236) the title compound was obtained as an amorphous solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 7.79 (s, 2H, triazole), 7.63 (t, J=2, 1H, pyrrole), 7.6-7.3 (m, 5H, arom), 7.02 (t, J=2, 1H, pyrrole), 7.0-6.6 (m, 2H, arom), 6.63 (t, J=2, 1H, pyrrole), 6.35 (br d, 1H, NH), 5.36 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.03 (d, J=7, 3H, MeCH); [α]D = -95.2° (c 1, CHCl3). Analysis calculated for C23H20ClF2N5O2: C 58.54; H 4.27; N 14.84. Found: C 58.42; H 4.26; N 14.65.
EXAMPLE 22
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using
2-(4-chlorophenyl)thiazole-5-carboxylic acid (reference example 18) the title compound was obtained as a white solid: mp 194-195 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.25 (s, 1H, thiazole), 7.93 (dt, Jt=2, Jd=9, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.45 (dt, Jt=2, Jd=9, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.55 (br d, J=9.3, 1H, NH), 5.40 (d, J=1.6,
1H, OH), 5.03 (d, J=14.5, 1H, TrCH(H)), 4.95 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.5, 1H, TrCH(H)), 1.04 (d, J=6.8, 3H, MeCH); HPLC-MS 265 and 267 (ethylaminoacyl group, C12H10ClN2OS), 222 (acyl group, C10H5CINOS), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -105.6° (c 1, CHCl3). Analysis calculated for C22H18ClF2N5O2S: C 53.94; H 3.70; N 14.29; S 6.54. Found: C 54.04; H 3.78; N
14.16; S 6.12.
EXAMPLE 23
(1R,2R)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)p ropyl]-4-methyl-2-phenylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using
4-methyl-2-phenylthiazole-5-carboxylic acid (reference example 19) the title compound was obtained as an amorphous solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 8.0-7.9 (m, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.5-7.4 (m, 3H, arom), 7.38 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.9-6.7 (m, 2H, arom), 6.40 (br d, J=9.5, 1H, NH), 5.38 (d, J=1.3, 1H, OH), 5.05 (d, J=14.2, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.2, 1H, TrCH(H)), 2.82 (s, 3H, Me-thiazole), 1.03 (d, J=6.8, 3H, MeCH); [α]D= -114.2° (c 1, CHCl3). Analysis calculated for C23H21F2N5O2S: C 58.84; H 4.51; N 14.92; S 6.83. Found: C 58.59; H 4.78; N 15.02; S 6.50.
EXAMPLE 24
(1R,2R)- N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using
4-methyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxylic acid and recrystallizing the product obtained from DMF-H2O, the title compound was obtained as a white solid: mp 79-82 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.1 (s, 1H, triazole), 8.03 (s, 1H, triazole), 7.78 (br s, arom), 7.66 (s, arom), 7.6-7.2 (1H, arom), 7.0-6.6 (m, 2H, arom), 6.4 (br d, J=9, 1H, NH), 5.38 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.82 (s, 3H, Me-thiazole), 1.02 (d, J=7, 3H, MeCH); [α]D= -103.2° (c 1, CHCl3). Analysis calculated for C24H20F5N5O2S: C 53.63; H 3.75; N 13.03; S 5.96. Found: C 53.77; H 3.97; N 13.51; S 5.51.
EXAMPLE 25
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid (reference example 20) the title compound was obtained as a white solid: mp 159-160 °C; 1H NMR (80
MHz, CDCl3) δ (TMS) 8.0-7.8 (m, 4H, arom, triazole), 7.6-7.2 (m, 3H, arom), 7.0-6.6 (m, 2H, arom), 6.4 (br d, J=10, 1H, NH), 5.37 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.80 (s, 3H, Me-thiazole), 1.02 (d, J=7, 3H, MeCH); MS 281 and 283 (ethylaminoacyl group, C13H14CIN2OS), 236 and 238 (acyl group, C11H7CINOS), 224 (Tr-CH2COHAr,
C 10H 8F2N 3O); [α]D = -117.1° (c 1, CHCl3). Analysis calculated for C23H20ClF2N5O2S: C 54.82; H 4.00; N 13.90; S 6.36. Found: C 55.13; H 3.93; N 13.86; S 6.09.
EXAMPLE 26
(1R,2R)-2-(4-Bromophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-bromophenyl)-4-methylthiazole-5-carboxylic acid (reference example 21) the title compound was obtained as a white solid: mp 165-166 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 7.71 (d, J=7.5, 2H, arom), 7.79 (s, 2H, triazole), 7.57 (d, J=7.5, 2H, arom), 7.6-7.2 (m, 1H, arom), 7.0-6.6 (m, 2H, arom), 6.43 (br d, J=10, 1H, NH), 5.39 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.80 (s, 3H, Me-thiazole), 1.02 (d, J=7, 3H, MeCH); MS 323 and 325 (ethylaminoacyl group, C13H12BrN2OS), 280 and 282 (acyl group, C 11H7BrNOS), 224 (Tr-CH2COHAr, Cι0H8F2N3O); [α]D= -108.7° (c 1, CHCl3). Analysis calculated for C23H2θBrF2N5O2S: C 50.37; H 3.68; N 12.77; S 5.85. Found: C 50.61; H 3.66; N 12.81; S 5.62.
EXAMPLE 27
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methyl-2-(4-trifluoromethoxyphenyl)thiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 4-methyl-2-(4-trifluoromethoxyphenyl)thiazole-5-carboxylic acid (reference example 22) the title compound was obtained as an amorphous solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 8.01 (dt, Jt=2, Jd=9, 2H, arom), 7.83 (s, 1H, triazole), 7.81 (s, 1H, triazole), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.32 (d, J=9, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.44 (br d, J=9.5, 1H, NH), 5.40 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 4.95 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.5, 1H, TrCH(H)), 2.83 (s, 3H, Me-thiazole), 1.04 (d, J=6.8, 3H, MeCH); MS 329
(ethylaminoacyl group, C14H12F3N2O2S), 286 (acyl group, C12H7F3NO2S), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -105.4° (c 1, CHCl3). Analysis calculated for C24H20F5N5O3S: C 52.08; H 3.64; N 12.65; S 5.79. Found: C 52.27; H 3.88; N 12.26; S 5.40.
EXAMPLE 28
(1R,2R)- N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methyl-2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]thiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 4-methyl-2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]thiazole-5-carboxylic acid
(reference example 23) the title compound was obtained as an amorphous solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.95 (dt, Jt=2, Jd=9, 2H, arom), 7.82 (s, 1H, triazole), 7.80 (s, 1H, triazole), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.02 (dt, Jt=2, Jd=9, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.41 (br d, J=9.5, 1H, NH), 6.08 (tt, J=4.7, J=53, 1H, CF2H), 5.39 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 4.95
(br quint, J=7, 1H, CHMe), 4.53 (d, J=14.5, 1H, TrCH(H)), 4.35 (tt, J=1.3, J=12, 2H, OCH2), 2.81 (s, 3H, Me-thiazole), 1.03 (d, J=6.8, 3H, MeCH); MS 375 (ethylaminoacyl group, C16H15F4N2O2S), 332 (acyl group, C14H10F4NO2S), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -85.7° (c 1, CHCl3). Analysis calculated for C26H23F6N5O3S: C 52.09; H 3.87; N 11.68; S 5.35. Found: C 52.23; H 3.60; N 11.62: S 5.24.
EXAMPLE 29
(1R,2R)-2-(4-Cyanophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-cyanophenyl)-4-methylthiazole-5-carboxylic acid (reference example 24) the title compound was obtained as a white solid: mp 109-111 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.07 (d, J=8.3, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.75 (d, J=8.3, 2H, arom), 7.37 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.46 (br d, J=9.5, 1H, NH), 5.40 (s, 1H, OH), 5.03 (d, J=14.5, 1H, TrCH(H)), 4.94 (br quint, J=7, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 2.83 (s, 3H, Me-thiazole), 1.02 (d, J=6.8, 3H, MeCH); MS 270 (ethylaminoacyl group, C14H12N3OS), 227 (acyl group, C12H7N2OS), 224 (Tr-CH2COHAr, C10H8F2N3O); [αp= -120.8° (c 1, CHCl3). Analysis calculated for C24H20F2N6O2S: C 58.29; H 4.08; N 16.99; S 6.48 Found: C 57.83; H 3.96; N 16.70; S 6.16.
EXAMPLE 30
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide, oxalate
To a solution of (1R,2R)-2-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2- hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide (obtained in example 29) in EtOH was added 2 equivalents of oxalic acid and some diethyl ether. The solution was cooled to -20°C and the precipitate formed was collected by filtration and dried to give the title compound as a white solid: mp 104-108 °C; 1H NMR (300 MHz, MeOH-d4) δ (TMS) 8.28 (s, 1H, triazole), 8.14 (d, J=8.3, 2H, arom), 8.1-7.9 (m, 1H), 7.84 (d, J=8.3, 2H, arom), 7.73 (s, 1H, triazole), 7.37 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.0-6.9 (m, 1H, arom), (6.9-6.8 (m, 1H, arom), 5.1-4.9 (m, 2H, TrCH(H), CHMe), 4.59 (d, J=14.5, 1H, TrCH(H)), 2.73 (s, 3H, Me-thiazole), 1.05 (d, J=6.8, 3H, MeCH); [α]D= -72° (c 1, MeOH). Analysis calculated for C24H20F2N6O2S.C2H4O2.1 /2H2O: C 52.61; H 3.90; N 14.16; S 5.39. Found: C 52.74; H 3.80; N 13.88; S 5.01.
EXAMPLE 31
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide, methane-sulfonate
To a solution of (1R,2R)-2-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide (obtained in example 29) in MeOH was added 2 equivalents of methanesulfonic acid diluted in MeOH. The solution was cooled to 0°C and the precipitate formed was collected by filtration and dried to give the title compound as white needles: mp 126-138 °C; 1H NMR (300 MHz, DMSO-d6) δ (DMSO) 8.55 (s, 1H, triazole), 8.15 (d, J=9.2, 1H, NH), 8.13 (d, J=8.3, 2H, arom), 7.98 (d, J=8.3, 2H, arom), 7.87 (s, 1H, triazole), 7.30 (br q, J- 8.5, 1H, arom), 7.20 (ddd, J=2.4, J=9.2, J=11.8, 1H, arom), 6.92 (dt, Jd= 2.4, Jt=8.5, 1H, arom), 4.9-4.8 (m, 2H, TrCH(H), CHMe), 4.54 (d, J=14.5, 1H, TrCH(H)), 2.68 (s, 3H, Me-thiazole), 2.38 (s, 3H, MeSO3H), 0.93 (d, J=6.8, 3H, MeCH); [α]D= -71° (c 1, DMF). Analysis calculated for C24H20F2N6O2S.CH4O3S.H2O: C 49.34; H 4.31; N 13.81; S 10.53. Found: C 49.35; H 4.11; N 13.72; S 10.30.
EXAMPLE 32
(1R,2R)-2-(4-Carbamoylphenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl- 3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
To a solution of NH4OH in a H2O-THF mixture was added (1R,2R)-2-(4- cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4- triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide methanesulfonate (0.5 g, 0.84 mmol, obtained in example 31). The mixture was refluxed for 2 days, then was concentrated and the aqueous residue was extracted with CHCl3. The organic layer was separated, dried over Na2SO4, filtered and the filtrate was concentrated to a solid (0.53 g). This was purified by flash chromatography to give the title compound as a white solid: 133-135 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.98 (d, J=8.3, 2H, arom), 7.87 (d, J=8.3, 2H, arom), 7.81 (s, 1H, triazole), 7.71 (s, 1H, triazole), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.57 (br d, J=9.5, 1H, NH), 6.27 (br s, 2H, NH2), 5.63 (s, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 4.98 (br quint, J=7, 1H, CHMe), 4.57 (d, J=14.5, 1H, TrCH(H)), 2.81 (s, 3H, Me-thiazole), 1.05 (d, J=6.8, 3H, MeCH); MS 288 and 289 (ethylaminoacyl group, C14H15N3O2S), 245 (acyl group, C12H9N2O2S), 224 (Tr- CH2COHAr, C10H8F2N3O); [α]D= -74.5° (c 1, MeOH). Analysis calculated for C24H22F2N6O3S: C 56.24; H 4.33; N 16.40; S 6.26. Found: C 55.90; H 4.64; N 15.29;
S 5.62.
EXAMPLE 33
(1R,2R)-2-[2-(4-Chlorophenyl)-4-methylthiazol-5-yl]-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl]-4-methylthiazole-5-carboxylic acid (reference example 25) the title compound was obtained as a yellow solid: mp 110-114°C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.92 (dt, Jt=2, Jd=9, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.32 (dt, Jt=2, Jd=9, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.42 (br d, J=9.5, 1H, NH), 5.40 (d, J=1.1, 1H, OH), 5.05 (d, J=14.3, 1H, TrCH(H)), 4.95 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.3, 1H, TrCH(H)), 2.80 (s, 3H, Me-thiazole), 2.78 (s, 3H, Me-thiazole), 1.03 (d, J=6.8, 3H, MeCH); HPLC-MS 376 and 378 (ethylaminoacyl group, C17H15ClN3OS2), 333 and 335 (acyl group, C15H 10ClN2OS2), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -98° (c 1, CHCl3). Analysis calculated for C27H23CIF2N6O2S2: C 53.95; H 3.86; N 13.98; S 10.67. Found: C 54.21; H 4.02; N 13.60; S 9.78.
EXAMPLE 34
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-trifluoromethylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-chlorophenyl)-4-trifluoromethylthiazole-5-carboxylic acid (reference example 26), the title compound was obtained as a white solid: mp 78-79 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.91 (dt, Jt=2.5, Jd=8.5, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.48 (dt, Jd= 2.5, Jt=8.5, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.87 (br d, J=9.0, 1H, NH), 6.8-6.6 (m, 2H, arom), 5.38 (br s, 1H, OH), 5.01 (d, J=14.2, 1H, TrCH(H)), 4.91 (br quint, J=7, 1H, CHMe), 4.51 (d, J=14.2, 1H, TrCH(H)), 1.02 (d, J=6.8, 3H, MeCH); [α]D= -88.8° (c 1, CHCl3). Analysis calculated for C23H17CIF5N5O2S: C 49.51; H 3.07; N 12.55; S 5.75. Found: C 49.86; H 3.08; N 12.36; S 5.38.
EXAMPLE 35
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-trifluoromethyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 4-trifluoromethyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxylic acid (reference example 27), the title compound was obtained as a white solid: mp
83-86 °C; Η NMR (300 MHz, CDCl3) δ (TMS) 8.12 (d, J=8.1, 2H, arom), 7.84 (s, 1H, triazole), 7.80 (s, 1H, triazole), 7.77 (d, J=8.1, 2H, arom), 7.38 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.95 (br d, J=9.0, 1H, NH), 6.8-6.6 (m, 2H, arom), 5.42 (d, J=1.6, 1H, OH), 5.03 (d, J=14.2, 1H, TrCH(H)), 4.96 (br quint, J=7, 1H, CHMe), 4.51 (d, J=14.2, 1H, TrCH(H)), 1.04 (d, J=6.8, 3H, MeCH); [αp= -79° (c 1, CHCl3).
Analysis calculated for C24H17F8N5O2S: C 48.74; H 2.90; N 11.84; S 5.42. Found: C 49.16; H 3.19; N 11.47; S 5.03.
EXAMPLE 36
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-4-trifluoromethylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-cyanophenyl)-4-trifluoromethylthiazole-5-carboxylic acid (reference example 28), the title compound was obtained as a white solid: mp 101-108 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.13 (d, J=8.1, 2H, arom), 7.86 (s, 1H, triazole), 7.83 (d, J=8.1, 2H, arom), 7.83 (s, 1H, triazole), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.98 (br d, J=9.0, 1H, NH), 6.8-6.6 (m, 2H, arom), 5.44 (d, J=1.6, 1H, OH), 5.05 (d, J=14.2, 1H, TrCH(H)), 4.96 (br quint, J=7, 1H, CHMe), 4.55 (d, J=14.2, 1H, TrCH(H)), 1.07 (d, J=6.8, 3H, MeCH); [α]D= -79.9° (c 1, CHCl3). Analysis calculated for C24H17F5N6O2S: C 52.56; H 3.12; N 15.32; S 5.85. Found: C 51.98; H 3.51; N 11.29; S 5.16.
EXAMPLE 37
(1R,2R)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-[4-(1H-tetrazol-5-yl)phenyl]-4-trifluoromethylthiazole-5-carboxamide, hydrochloride
The compound obtained in the previous example (400 mg, 0.73 mmol) was treated with sodium azide (143 mg, 2.18 mmol) and triethylammonium hydrochloride (151 mg, 1.09 mmol) in NMP (5 mL) at 150 °C for 2 h. The mixture was cooled to room temperature, H2O was added and it was made acidic with 6N HCl. A creamy solid (350 mg) was obtained, which was recrystallized from isopropanol to give the title compound as a creamy solid: mp >250 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH-d4) 9.32 (s, 1H, triazole), 8.39 (s, 1H, triazole), 8.28 (d, J=8.8, 2H, arom), 8.24 (d, J=8.8, 2H, arom), 7.36 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.06 (ddd, J=2.4, J=8.7, J=11.5, 1H, arom), 6.90 (dt, Jd=
2.1, Jt=8.0, 1H, arom), 5.13 (d, J=14.3, 1H, TrCH(H)), 5.01 (q, J=7, 1H, CHMe), 4.77 (d, J=14.3, 1H, TrCH(H)), 1.10 (d, J=7, 3H, MeCH); DIP/MS 367 (ethylaminoacyl group, C14H10F3N6OS), 324 (acyl group, C12H5F3N5OS), 224 (Tr-CH2COHAr, C10H8F2N3O). Analysis calculated for C24H18F5N9O2S.HCl.H2O: C 44.62; H 3.28; N 19.51; S 4.96. Found: C 44.12; H 2.89; N 19.01; S 4.71.
EXAMPLE 38
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]-4-trifluoromethylthiazole-5-carboxamide
The compound obtained in the preceding example (162 mg, 0.27 mmol) was treated with methyl iodide (48 mg, 0.34 mmol) and K2CO3 (38 mg, 0.28 mmmol) in DMF (2 mL) at 25 °C for 2 h. The reaction mixture was then evaporated to dryness, and the residue partitioned between H2O and CHCl3. The organic phase was separated, dried and concentrated. The residue was flash chromatographed to afford mainly the title compound (38 mg) as a white solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 8.29 (d, 7=8.3, 2H, arom), 8.13 (d, J=8.3, 2H, arom), 7.84 (s, 1H, triazole), 7.81 (s, 1H, triazole), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.91 (br d, 7=9.0, 1H, NH), 6.8-6.6 (m, 2Η, arom), 5.41 (d, 7=1.6, 1H, OH), 5.05 (d, 7=14.2, 1H, TrCH(H)), 4.94 (br quint, J=7, 1H, CHMe), 4.55 (d, 7=14.2, 1Η, TrCΗ(H)), 4.45 (s, 3Η, Me-tetrazol), 1.05 (d, 7=6.8, 3H, MeCH); DIP/MS 381 (ethylaminoacyl group, C15H12F3N6OS), 338 (acyl group, C13H7F3N5OS), 224 (Tr-CH2COHAr, C10H8F2N3O).
EXAMPLE 39
(1R,2R)-2-[(4-Chlorophenoxy)methyl]-N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-[ (4-chlorophenoxy )methyl]-4-methy lthiazole-5-carboxylic acid (reference example 29) the title compound was obtained as a white solid: mp 134-135 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.80 (s, 1H, triazole), 7.77 (s, 1H, triazole), 7.36 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.28 (dt, Jt=2, Jd=9, 2H, arom), 6.93 (dt, Jt=2, Jd=9, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.35 (br d, J=9.5, 1H, NH), 5.34 (d, J=1.3, 1H, OH), 5.30 (s, 2H, CH2O), 5.02 (d, J=14.3, 1H, TrCH(H)), 4.91 (br quint, J=7, 1H, CHMe), 4.48 (d, J=14.3, 1H, TrCH(H)), 2.76 (s, 3H, Me-thiazole), 0.99 (d, J=6.8,
3H, MeCH); GC/MS 309 and 310 (ethylaminoacyl group, C14H14ClN2O2S), 266 and 268 (acyl group, C12H9ClNO2S), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -94° (c 1, CHCl3). Analysis calculated for C24H22ClF2N5O3S: C 53.98; H 4.15; N 13.12; S 6.00 Found: C 54.04; H 4.48; N 12.35; S 5.27.
EXAMPLE 40
(1R,2R)-2-[ N-(4-Chlorophenyl)amino]-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-[N-(4-chlorophenyl)amino]-4-methylthiazole-5-carboxylic acid (reference example 30) the title compound was obtained as a white amorphous solid:
HPLC-MS 295 and 267 (ethylaminoacyl group, C13H14CIN3OS), 251 and 253 (acyl group, C 11H8ClN2OS), 224 (Tr-CH2COHAr, C10H8F2N3O).
EXAMPLE 41
(1R,2R)-2-(4-Chlorophenoxy)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
(a) Following a similar procedure to that described in example 1 but using 2-bromo-4-methylthiazole-5-carboxylic acid (obtained as described in Singh, J.M. J.Med.Chem . 1969, 12, 1553), (lR ,2R )-2-bromo-N-[2-(2,4- difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide was obtained as a white solid: mp 155-163 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.81 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.35 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.36 (br d, J=9.5, 1H, NH), 5.4 (br s, 1H, OH), 5.00 (d, J=14.2, 1H, TrCH(H)), 4.90 (br quint, J=7, 1H, CHMe), 4.46 (d, J=14.2, 1H, TrCH(H)), 2.74 (s, 3H, Me-thiazole), 0.99 (d, J=6.8, 3H, MeCH); [α]D= -97.8° (c 1, CHCl3). Analysis calculated for C17H16BrF2N5O2S: C 43.23; H 3.41; N 14.83: S 6.79. Found: C 43.23; H 3.64; N 14.58; S 6.29.
(b) To a solution of the product obtained in section (a) (375 mg, 0.79 mmol) in N-methylpyrrolidone (5 mL) was added 4-chlorophenol (117 mg, 0.91 mmol) and anhydrous K2CO3 (109 mg, 0.79 mmol). The mixture was stirred at 130°C for 18 h and then water and EtOAc were added. The organic phase was separated and the aqueous residue was extracted with EtOAc. The combined organic extracts were dried over Na2SO4, concentrated and purified by flash chromatography to give the title compound as an amorphous solid (159 mg): 1H NMR (300 MHz, CDCI3) δ (TMS) 7.80 (s, 1H, triazole), 7.77 (s, 1H, triazole), 7.41 (d, J=9, 2H, arom), 7.36 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.25 (d, J=9, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.20 (br d, J=9.5, 1H, NH), 5.33 (d, J=1.5, 1H, OH), 5.00 (d, J=14.2, 1H, TrCH(H)), 4.91 (br quint, J=7, 1H, CHMe), 4.46 (d, J=14.2, 1H, TrCH(H)), 2.62 (s, 3H, Me-thiazole), 0.98 (d, J=6.8, 3H, MeCH); GC-MS 295 and 297 (ethylaminoacyl group, C13H12CIN2O2S), 252 and 254 (acyl group, C11H7ClNO2S), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -93° (c 1, CHCl3).
EXAMPLE 42
(1R,2R)-2-(4-Chlorobenzenesulfonyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following the procedure described in example 41 but using the sodium salt of 4-chlorobenzenesulfinic acid (obtained as described in Org.Synth.Coll.Vol IV, 674, from 4-chlorobenzenesulfonyl chloride and sodium sulfite) instead of the mixture of 4-chlorophenol and K2CO3, the title compound was obtained as a white amorphous solid: 1H NMR (300 MHz,
CDCI3) δ (TMS) 8.04 (dt, Jt= 1.9, Jd=8.7, 2H, arom), 7.81 (s, 1H, triazole), 7.76 (s, 1H, triazole), 7.56 (dt, Jt= 1.9, Jd=8.7, 2H, arom), 7.34 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.20 (br d, J=9.5, 1H, NH), 5.41 (d, J=1.5, 1H, OH), 4.97 (d, J=14.2, 1H, TrCH(H)), 4.86 (br quint, J=7, 1H, CHMe), 4.42 (d, J=14.2, 1H, TrCH(H)), 2.74 (s, 3H, Me-thiazole), 0.99 (d, J=6.8, 3H, MeCH); GC-MS 343 and
345 (ethylaminoacyl group, C13H12ClN2O3S2), 300 and 302 (acyl group, C11H7ClNO3S2), 224 (Tr-CH2COHAr, C10H8F2N3O).
EXAMPLE 43
(1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-methylfuran-3-carboxamide
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)-2-methylfuran-3-carboxylic acid the title compound was obtained as a white solid: mp 189-190 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 7.80 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.59 (dt, Jt=2, Jd=8.4, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.37 (dt, Jt=2, Jd=8.4, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.27 (s, 1H, furan), 6.29 (br d, J=9.5, 1H, NH), 5.35 (s, 1H, OH), 5.04 (d, J=14.2, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.51 (d, J=14.2, 1H, TrCH(H)), 2.71 (s, 3H, Me-furan), 1.01 (d, J=6.8, 3H, MeCH); HPLC-MS 262 and 264 (ethylaminoacyl group, C14H13ClNO2), 219 and 221 (acyl group, Cι2H8C1O2), 224 (Tr-CH2COHAr, CιoH8F2N3O); [αp= -131.2° (c 1, CHCl3). Analysis calculated for C24H21ClF2N4O3: C 59.20; H 4.35; N 11.51. Found: C 59.22; H 4.34; N 11.58.
EXAMPLE 44
(1R,2R)-5-(4-Chlorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-trifluoromethylfuran-3-carboxamide
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)-2-trifluoromethylfuran-3-carboxylic acid the title compound was obtained as a white amorphous solid: 1H NMR (300 MHz,
CDCl3) δ (TMS) 7.81 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.66 (dt, Jt=2, Jd=8.4, 2H, arom), 7.43 (dt, Jt=2, Jd=8.4, 2H, arom), 7.36 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.98 (s, 1H, furan), 6.8-6.6 (m, 2H, arom), 6.60 (br d, J=9.3, 1H, NH), 5.34 (s, 1H, OH), 5.03 (d, J=14.2, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.50 (d, J=14.2, 1H, TrCH(H)), 1.00 (d, J=6.8, 3H, MeCH); GC/MS 316 and 318 (ethylaminoacyl group, C14H10ClF3NO2), 273 and 275 (acyl group, C12H5CIF3O2), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -84.6° (c 1, CHCl3). Analysis calculated for C24H18ClF5N4O3: C 53.30; H 3.35; N 10.36. Found: C 53.12; H 3.82; N 10.36.
EXAMPLE 45
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1 H-1,2,4-triazol-1-yl)propyl]-4-methyloxazole-5-carboxamide
A solution of N-(4-chlorobenzoyl)-L-alanine (1.46 g, 6.41 mmol) in benzene (35 mL) was treated with oxalyl chloride (0.55 mL, 6.41 mmol) at 45 °C for 3 h. Next, a solution of (2R,3R)-3-amino-2-(2,4-difluorophenyl)-1-(1H-1,2,4- triazol-1-yl)-2-butanol (1.72 g, 6.41 mmol) and triethylamine (2.2 mL) in CHCl2
(20 mL) was slowly added and the reaction mixture was stirred at 0 °C for 0.5 h. The crude product was then poured into cold water and extracted with CHCl3. The organic solution was dried over Na2SO4, filtered and the filtrate was concentrated in vacuo to give a mixture of several products (TLC) from which the title compound was isolated by flash chromatography as a white solid (140 mg): mp 89-93 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.04 (d, J=8.5, 2H, arom), 7.79 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.49 (d, J=8.5, 2H, arom), 7.37 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 3H, arom, NH), 5.38 (d, J=1.1, 1H, OH), 5.04 (d, J=14.3, 1H, TrCH(H)), 4.96 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.3, 1H, TrCH(H)), 2.60 (s, 3H, Me-oxazole), 1.04 (d, J=6.8, 3H, MeCH); HPLC-MS 263 and 265 (ethylaminoacyl group, C13H12CIN2O2), 220 and 222 (acyl group, C11H7CINO2), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -141° (c 0.5, CHCl3). Analysis calculated for C23H20CIF2N5O3: C 56.62; H 4.13; N 14.35. Found: C 56.41; H 4.19; N 14.50.
EXAMPLE 46
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiazole-4-carboxamide
Following a similar procedure to that described in example 1 but using
2-(4-chlorophenyl)thiazole-4-carboxylic acid (reference example 31) the title compound was obtained as a white solid: mp 201-204 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.15 (s, 1H, thiazole), 8.0-7.7 (m, 4H, triazole, arom), 7.6-7.2 (3H, arom), 7.0-6.6 (m, 2H, arom), 5.33 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.5 (d, J=14.5, 1H, TrCH(H)), 1.07 (d, J=7, 3H,
MeCH); [α]D= -130.7° (c 1, CHCl3). Analysis calculated for C22H18CIF2N5O2S: C 53.94; H 3.70; N 14.29; S 6.54. Found: C 54.03; H 4.05; N 13.85; S 6.51.
EXAMPLE 47
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-(4-trifluoromethylphenyl)thiazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-trifluoromethylphenyl)thiazole-4-carboxylic acid (reference example 32) the title compound was obtained as a white solid: mp 167-168 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.21 (s), 8.16 (s), 8.07 (s), 8.1-7.6 (m, arom), 7.6-7.3 (1H, arom), 7.0-6.6 (m, 2H, arom), 5.34 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H,
TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.5 (d, J=14.5, 1H, TrCH(H)), 1.08 (d, J=7, 3H, MeCH); [αp= -136.7° (c 1, CHCl3). Analysis calculated for C23H18F5N5O2S: C 52.77; H 3.47; N 13.38; S 6.12. Found: C 52.92; H 3.47; N 13.42; S 6.08.
EXAMPLE 48
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-phenylthiazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 2-phenylthiazole-4-carboxylic acid (reference example 33) the title compound was obtained as a white solid: mp 174-175 °C; 1H NMR (80 MHz, CDCl3) δ (TMS) 8.15 (s), 8.1-7.9 (m, arom), 7.81 (s), 7.75 (s), 7.6-7.3 (m, 4H, arom), 7.0-6.6 (m, 2H, arom), 5.35 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.5 (d, J=14.5, 1H, TrCH(H)), 1.08 (d, J=7, 3H, MeCH); [α]D= -145.5° (c 1, CHCl3). Analysis calculated for C22H19F2N5O2S: C 58.01; H 4.20; N 15.38; S 7.04. Found: C 58.11; H 4.59; N 15.34; S 6.85.
EXAMPLE 49
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(_H-1,2,4-triazol-1-yl)propyl]-2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]thiazole-4-carboxamide
Following a similar procedure to that described in example 1 but using
2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl] thiazole-4-carboxylic acid (reference example 34) the title compound was obtained as an amorphous solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.10 (s), 8.1-7.8 (m, arom), 7.6-7.4 (m, 1H, arom), 7.2-6.7 (m, 2 + 1 /4 H, arom, CHF2), 6.07 (t, J=4.3, 1 /2H, CHF2), 5.41 (t, J=4.3, 1 /4H, CHF2), 5.34 (d, J=1.3, 1H, OH), 5.06 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.5 (d, J=14.5, 1H, TrCH(H)), 4.44 (tt, J=0.8, J=12, 2H, OCH2), 1.07 (d, J=7, 3H, MeCH); [α]D= -123.8° (c 1, CHCl3). Analysis calculated for C25H21F6N5O3S: C 51.28; H 3.62; N 11.96; S 5.48. Found: C 50.89; H 3.90; N 11.34; S 5.34.
EXAMPLE 50
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-(3-pyridyl)thiazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 2-(3-pyridyl)thiazole-4-carboxylic acid the title compound was obtained as a white solid: mp 182-183 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 9.23 (br s, 1H, pyridine), 8.7 (br s, 1H, pyridine), 8.34 (br s, 1 J2H, pyridine), 8.21 (s, 1.5H, thiazole, pyridine), 8.1-7.7 (m, triazole), 7.6-7.3 (m, 2H, arom, pyridine), 7.0-6.6 (m, 2H, arom), 5.34 (d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.08 (d, J=7, 3H, MeCH); [αp= -151.3° (c 1, CHCl3). Analysis calculated for C21H18F2N6O2S: C 55.26; H 3.97; N 18.41; S
7.02 Found: C 55.14; H 3.93; N 18.41; S 6.81.
EXAMPLE 51
(1R,2R)-5-(4-Chlorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using
5-(4-chlorophenyl)thiophene-2-carboxylic acid (prepared as described in Hauptmann et al, Tetrahedron Lett. 1968, 1317) the title compound was obtained as a white solid: mp 169-170 °C; Η NMR (300 MHz, CDCI3) δ (TMS) 7.79 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.55 (dt, Jt=2.5, Jd=6.6, 2H, arom), 7.54 (d, J=3.5, 1H, thiophene), 7.38 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.38 (dt, Jt=2.5, Jd=6.6, 2H, arom), 7.25 (d, J=3.5, 1H, thiophene), 6.8-6.6 (m, 2H, arom), 6.53 (br d, J=9.5, 1H, NH), 5.35 (d, J=1.5, 1H, OH), 5.04 (d, J=14.3, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.51 (d, J=14.3, 1H, TrCH(H)), 1.02 (d, J=6.8, 3H, MeCH); MS 264 and 266 (ethylaminoacyl group, C13H11CINOS), 221 and 223 (acyl group, C11H6C1OS), 224 (Tr-CH2COHAr, C10H8F2N3O); [αp= -101.0° (c 1, CHCl3). Analysis calculated for C23H19CIF2N4O2S: C 56.50 H 3.92; N 11.46; S 6.56. Found: C 56.52; H 3.93; N 11.39; S 6.11.
EXAMPLE 52
(1R,2R)-5-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 5-(4-cyanophenyl)thiophene-2-carboxylic acid (reference example 35) the title compound was obtained as a white solid: mp 210-211 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.80 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.71 (d, J=8, 2H, arom), 7.70 (d, J=8, 2H, arom), 7.58 (d, J=3.9, 1H, thiophene), 7.41 (d, J=3.9, 1H, thiophene), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.57 (br d, J=9.4, 1H, NH), 5.37 (d, J=1.5, 1H, OH), 5.05 (d, J=14.3, 1H, TrCH(H)), 4.94 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.3, 1H, TrCH(H)), 1.03 (d, J=6.8, 3H, MeCH);
HPLC-MS 212 (acyl group, C12H6NOS), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -105.6° (c 1, CHCl3). Analysis calculated for C24H19F2N5O2S: C 60.12 H 3.99; N 14.61; S 6.69. Found: C 58.98; H 3.90; N 14.26; S 6.28.
EXAMPLE 53
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-(2-pyridyl)thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 5-(2-pyridyl)thiophene-2-carboxylic acid the title compound was obtained as a white solid: mp 212-213 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.60 (dt, Jt=1, Jt=5, 1H, arom), 7.9-7.5 (m, arom), 7.5-7.2 (m, arom), 6.9-6.5 (m, arom, NH), 5.34
(d, J=1.3, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.02 (d, J=7, 3H, MeCH); [α]D= -116.8° (c 1, CHCl3). Analysis calculated for C22H19F2N5O2S: C 58.01; H 4.20; N 15.38; S 7.04. Found: C 58.20; H 4.55; N 15.82; S 6.85.
EXAMPLE 54
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(lH-1,2,4-triazol-1-yl)propyl]-5-[1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl]thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 5-[1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl]thiophene-2-carboxylic acid the title compound was obtained as a white solid: mp 106-110 ºC:1H NMR (300
MHz, CDCI3) δ (TMS) 7.79 (s, 1H, triazole), 7.77 (s, 1H, triazole), 7.54 (d, J=3.8,
1H, thiophene), 7.38 (dt, Jd= 6.5, Jt=8-8, 1H, arom), 7.30 (d, J=3.8, 1H, thiophene), 6.84 (s, 1H, pyrazole), 6.8-6.6 (m, 2H, arom), 6.52 (br d, J=9.3, 1H, NH), 5.34 (d, J=1.5, 1H, OH), 5.03 (d, J=14.3, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.3, 1H, TrCH(H)), 4.03 (s, 3H, Me-pyrazole), 1.01 (d, J=6.8, 3H, MeCH); MS 302 (ethylaminoacyl group, C12H 11F3N 3OS), 259 (acyl group, C10H6F3N2OS), 224 (Tr-CH2COHAr, C10H8F2N3O); [αp= -90.1° (c 1, CHCl3). Analysis calculated for C22Hi9F5N6O2S: C 50.19; H 3.64; N 15.96; S 6.09. Found: C 50.27; H 3.77; N 15.71; S 5.58.
EXAMPLE 55
(1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-3-methylthiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)-3-methylthiophene-2-carboxylic acid (reference example 36) the title compound was obtained as an amorphous solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.84 (s, 1H, triazole), 7.82 (s, 1H, triazole), 7.56 (dt, Jt=2.5, Jd=6.6, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.39 (d, J=7, 2H, arom), 7.14
(s, 1H, thiophene), 6.8-6.6 (m, 2H, arom), 6.42 (br d, J=9.3, 1H, NH), 5.38 (br s, 1H, OH), 5.08 (d, J=14.5, 1H, TrCH(H)), 4.95 (br quint, J=7, 1H, CHMe), 4.55 (d, J=14.5, 1H, TrCH(H)), 2.82 (s, 3H, Me-thiophene), 1.04 (d, J=6.8, 3H, MeCH); MS 278 and 280 (ethylaminoacyl group, C14H13CINOS), 235 and 237 (acyl group, Cι2H8ClOS), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -114.9° (c 1, CHCl3).
Analysis calculated for C24H21CIF2N4O2S: C 57.31 H 4.21; N 11.14; S 6.37. Found: C 57.39; H 4.21; N 11.21; S 6.59.
EXAMPLE 56
(1R,2R)- N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-methyl-5-(4-trifluoromethylphenyl)thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 3-methyl-5-(4-trifluoromethylphenyl)thiophene-2-carboxylic acid (obtained by a similar procedure to that described in reference example 36) the title compound was obtained as an amorphous solid: MS 312 (ethylaminoacyl group, C15H13F3NOS), 269 (acyl group, C13H8F3OS), 224 (Tr-CH2COHAr,
C 10H 8F2N 3O); [α]D = -104.2° (c 1, CHCl3). Analysis calculated for C25H21F5N4O2S: C 55.97 H 3.95; N 10.44; S 5.98. Found: C 56.27; H 4.00; N 10.58; S 5.77.
EXAMPLE 57
(1R,2R)-5-(4-Cyanophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-3-methylthiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 5-(4-cyanophenyl)-3-methylthiophene-2-carboxylic acid (reference example 37) the title compound was obtained as a white solid: mp 176-177 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.79 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.69 (s, 4H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.23 (s, 1H, thiophene), 6.9-6.6 (m, 2H, arom), 6.43 (br d, J=9.4, 1H, NH), 5.35 (d, J=1.3, 1H, OH), 5.04 (d, J=14.2, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.2, 1H, TrCH(H)), 2.60 (s, 3H, Me-thiophene), 1.02 (d, J=6.8, 3H, MeCH); GC/MS 269 (ethylaminoacyl group, C15H13N2OS), 226 (acyl group, C13H8NOS), 224 (Tr-CH2COHAr, C 10H 8F2N 3O); [α]D = -116.3° (c 1, CHCl3). Analysis calculated for C25H21F2N5O2S: C 60.84 H 4.29; N 14.19; S 6.50. Found: C 60.54; H 4.25; N 13.81; S 5.90.
EXAMPLE 58
(1R,2R)-3-A mino-5-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylic acid (obtained as described in Hartmann, Synthesis 1984, 275) the title compound was obtained as a yellow solid: mp 107-111 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.79 (s, 2H, triazole), 7.61 (dt, Jt=2, Jd=9, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.37 (dt, Jt=2, Jd=9, 2H, arom), 6.9-6.6 (m, 2H, arom), 6.78 (s, 1H, thiophene), 5.93 (br d, J=9.3, 1H, NH), 5.69 (br s, 2H, NH2), 5.35 (d, J=1.3, 1H, OH), 5.02 (d, J=14.3, 1H, TrCH(H)), 4.88 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.3, 1H, TrCH(H)), 1.01 (d, J=6.8, 3H, MeCH); HPLC-MS 279 and 281 (ethylaminoacyl group, C13H12CIN2OS), 236 (acyl group, C11H7CINOS); [α]D= -137.8° (c 1, CHCl3). Analysis calculated for C23H20CIF2N5O2S: C 54.82; H 4.00; N 13.90; S 6.36. Found: C 55.42; H 4.19; N 13.34; S 5.35.
EXAMPLE 59
(1R,2R)-3-Amino-4-[(4-chlorophenyl)sulfonyl]-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 3-amino-4-[(4-chlorophenyl)sulfonyl]thiophene-2-carboxylic acid the title compound was obtained as a hygroscopic amorphous solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.1-7.7 (m, arom), 7.9-7.5 (m, arom), 7.6-7.3 (m, arom), 6.9-6.5 (m, arom, NH2), 6.00 (br d, J=9.5, 1H, NH), 5.31 (d, J=1.5, 1H, OH), 4.95 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.44 (d, J=14.5, 1H, TrCH(H)), 0.96 (d, J=7, 3H, MeCH); [αP= -59.2° (c 1, CHCl3). Analysis calculated for C23H20CIF2N5O4S2: C 48.64 H 3.55; N 12.33; S 11.29. Found: C 48.27; H 3.91; N 12.60; S 10.65.
EXAMPLE 60 (1R,2R)-4-[(4-Chlorophenyl)sulfonyl]-N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-methylthiophene-2-carboxamide
Following a similar procedure to that described in example 1 but using 4-[(4-chlorophenyl)sulfonyl]-3-methylthiophene-2-carboxylic acid the title compound was obtained as a white amorphous solid: 1H NMR (80 MHz, CDCl3) δ (TMS) 8.33 (s, 1H, thiophene), 7.85 (d, J=8.8, 2H, arom), 7.78 (s, 1H, triazole), 7.75 (s, 1H, triazole), 7.50 (d, J=8.8, 2H, arom), 7.41 (dt, Jd= 6.5, Jt=9, 1H, arom), 6.9-6.6 (m, 2H, arom), 6.42 (br d, J=9.5, 1H, NH), 5.32 (d, J=1.5, 1H, OH), 4.99 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.41 (d, J=14.5, 1H, TrCH(H)), 2.54 (s, 3H, Me-thiophene), 0.98 (d, J=7, 3H, MeCH); [αp= -73.8° (c 1,
CHCl3). Analysis calculated for C24H21CIF2N4O4S2: C 50.84 H 3.73; N 9.88; S 11.31. Found: C 51.23; H 4.12; N 9.67; S 10.62.
EXAMPLE 61
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-5-methyl-3H-imidazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-chlorophenyl)-5-methyl-3H-imidazole-4-carboxylic acid (reference example 38) the title compound was obtained as a white solid: mp 165-166 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 9.48 (br s, 1H, NH-imidazole), 7.81 (s, 1H, triazole), 7.78 (d, J=8.8, 2H, arom), 7.75 (s, 1H, triazole), 7.71 (d, J=9.6, 1H, NH),
7.43 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.42 (d, J=8.8, 2H, arom), 6.8-6.6 (m, 2H, arom), 5.38 (s, 1H, OH), 5.03 (d, J=14.3, 1H, TrCH(H)), 4.85 (br quint, J=7, 1H, CHMe), 4.60 (d, J=14.3, 1H, TrCH(H)), 2.68 (s, 3H, Me-imidazole), 1.07 (d, J=6.8, 3H, MeCH); HPLC-MS 262 and 264 (ethylaminoacyl group, C13H13CIN3O), 219 (acyl group, CnH8ClN2O); [α]D= -105.9° (c 1, MeOH). Analysis calculated for
C23H21ClF2N6O2: C 56.74; H 4.35; N 17.26. Found: C 54.48; H 4.05; N 16.09.
EXAMPLE 62
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-3,5-dimethyl-3H-imidazole-4-carboxamide
Following a similar procedure to that described in example 1 but using the mixture of acids obtained in reference example 39 (2-(4-chlorophenyl)-3,5- dimethyl-3H-imidazole-4-carboxylic acid and 2-(4-chlorophenyl)-1,5-dimethyl- 1H-imidazole-4-carboxylic acid) two products were obtained, which were easily separated by flash chromatography. The less polar product (TLC in EtOAc) was identified by NOE as the title compound and was isolated as a white amorphous solid: 1H NMR (300 MHz, CDCl3) δ (TMS) 7.81 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.55 (d, J=8.5, 2H, arom), 7.45 (d, J=8.5, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.39 (d, J=9.5, 1H, NH), 5.37 (d, J=1.5, 1H, OH), 5.05 (d, J=14.3, 1H, TrCH(H)), 4.96 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.3, 1H, TrCH(H)), 3.87 (s, 3H, N-Me), 2.61 (s, 3H, Me-imidazol), 1.03 (d, J=6.8, 3H, MeCH); GC/MS 276 and 278 (ethylaminoacyl group, C14H15CIN3O), 198 and 200 (acyl group, C12H10N2O), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -71.4° (c 1, CHCl3). Analysis calculated for C24H23ClF2N6O2.H2O: C 55.55; H 4.86; N 16.19. Found: C 55.11; H 4.75; N 15.93.
EXAMPLE 63
(1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-1,5-dimethyl-1H-iιnidazole-4-carboxamide
In the flash chromatography of the preceding example a second more polar product also eluted, which was identified by NOE as the title compound and which was also obtained as a white amorphous solid: 1H NMR (300 MHz, CDCI3) δ (TMS) 7.81 (s, 1H, triazole), 7.73 (s, 1H, triazole), 7.68 (br d, J=9.4, 1H, NH), 7.57 (d, J=8.5, 2H, arom), 7.48 (d, J=8.5, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 5.36 (d, J=1.5, 1H, OH), 5.03 (d, J=14.3, 1H,
TrCH(H)), 4.83 (br quint, J=7, 1H, CHMe), 4.56 (d, J=14.3, 1H, TrCH(H)), 3.59 (s, 3H, N-Me), 2.68 (s, 3H, Me-imidazol), 1.04 (d, J=6.8, 3H, MeCH); GC/MS 276 and 278 (ethylaminoacyl group, C14H15CIN3O), 198 and 200 (acyl group, C12H10N2O), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -108.7° (c 1, CHCl3). Analysis calculated for C24H23CIF2N6O2.H2O: C 55.55; H 4.86; N 16.19. Found:
C 55.68; H 4.94; N 15.75.
EXAMPLE 64
(1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3,4-oxadiazole-2-carboxamide, chloroform solvate
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-carboxylic acid (reference example 40) and recrystallizing the final product from CHCl3 the title compound was obtained as a white solid: mp 188-190°C; Η NMR (300 MHz, MeOH-d4) δ (MeOH-d4) 8.24 (s, 1H, triazole), 7.9-7.8 (m, 2H, arom), 7.68 (s, 1H, triazole), 7.52
(dt, Jt=2, Jd=8.7, 2H, arom), 7.35 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.95 (ddd, J=2.4, J=8.7, J=11.5, 1H, arom), 6.81 (dt, Jd= 2.0, Jt=8.0, 1H, arom), 4.88 (d, J=14.4, 1H, TrCH(H)), 4.82 (m, 1H, CHMe), 4.54 (d, J=14.4, 1H, TrCH(H)), 0.99 (d, J=6.8, 3H, MeCH); HPLC-MS 250 and 252 (ethylaminoacyl group, C11H9CIN3O2), 207 and 209 (acyl group, C9H4ClN2O2), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -66.5° (c 1, MeOH).
EXAMPLE 65
(1R,2R)-3-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 3-(4-chlorophenyl)-1,2,4-oxadiazole-5-carboxylic acid (reference example 41) the title compound was obtained as a white solid: mp 170-172 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.10 (dt, Jt=2, Jd=9, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.69 (br d, J=9.3, 1H, NH), 7.52 (dt, Jt=2, Jd=9, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 5.46 (d, J=1.5, 1H, OH), 5.02 (d, J=14.2, 1H, TrCH(H)), 4.95 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.2, 1H, TrCH(H)), 1.07 (d, J=6.8, 3H, MeCH); HPLC-MS 250 and 252 (ethylaminoacyl group, C11H9CIN3O2), 207 and 209 (acyl group, C9H4CIN2O2), 224 (Tr-CH2COHAr, CιoHsF2N3O); [α]D= -81.8° (c 1, MeOH).
EXAMPLE 66
(1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,2,4-oxadiazole-3-carboxamide
Following a similar procedure to that described in example 1 but using
5-(4-chlorophenyl)-1,2,4-oxadiazole-3-carboxylic acid (reference example 42) the title compound was obtained as a white solid: mp 79-83°C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.16 (dt, Jt=1.8, Jd=8.6, 2H, arom), 7.79 (br s, 2H, triazole), 7.60 (br d, J=9.3, 1H, NH), 7.56 (dt, Jt=1.8, Jd=8.6, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 5.38 (d, J=1.5, 1H, OH), 5.04 (d, J=14.4,
1H, TrCH(H)), 4.95 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.4, 1H, TrCH(H)), 1.06 (d, J=6.8, 3H, MeCH); HPLC-MS 250 and 252 (ethylaminoacyl group, C11H9CIN3O2), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -67.4° (c 1, MeOH).
EXAMPLE 67
(1R,2R)-3-(4-Chlorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-1,2,4-thiadiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 3-(4-chlorophenyl)-1,2,4-thiadiazole-5-carboxylic acid (prepared as described in Howe et al, J.Org.Chem. 1977, 42, 1813) the title compound was obtained as a white solid: mp 215-220 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH-d4) 8.45
(dt, Jt=2, Jd=7, 2H, arom), 8.32 (s, 1H, triazole), 7.75 (s, 1H, triazole), 7.65 (dt, Jt=2, Jd=7, 2H, arom), 7.50 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.08 (ddd, J=2.4, J=8.7, J=11.5, 1H, arom), 6.94 (dt, Jd= 2.0, Jt=8.0, 1H, arom), 5.12 (q, J=6.8, 1H, CHMe), 5.05 (d, J=14.6, 1H, TrCH(H)), 4.70 (d, J=14.6, 1H, TrCH(H)), 1.18 (d, J=6.8, 3H, MeCH); HPLC-MS 266 and 268 (ethylaminoacyl group, C 11H9ClN3OS), 223 and 225 (acyl group, C9H4CIN2OS), 224 (Tr-CH2COHAr, C10H8F2N3O); [αp= -106.3° (c 1, CHCl3).
EXAMPLE 68 (1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,2,4-thiadiazole-3-carboxamide
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)-1,2,4-thiadiazole-3-carboxylic acid (prepared as described in Howe et al, J.Org.Chem. 1977, 42, 1813) the title compound was obtained as a white solid: mp 186-187 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH) 8.32 (s, 1H, triazole), 8.22 (dt, Jt=2, Jd=8.4, 2H, arom), 7.76 (s, 1H, triazole), 7.70 (dt, Jt=2, Jd=8.4, 2H, arom), 7.49 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.08 (ddd, J=2.4, J=8.7, J=11.5, 1H, arom), 6.94 (dt, Jd= 2.0, Jt=8.0, 1H, arom), 5.15 (q, J=6.8, 1H, CHMe), 5.05 (d, J=14.6, 1H, TrCH(H)), 4.70 (d, J=14.6, 1H, TrCH(H)), 1.17 (d, J=6.8, 3H,
MeCH); HPLC-MS 266 and 268 (ethylaminoacyl group, C11H9CIN3OS), 223 and 225 (acyl group, C9H4ClN2OS), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -80.8° (c 1, CHCl3).
EXAMPLE 69
(1R,2R)-3-(2-Chloro-6-fluorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-methylisoxazole-4-carboxamide
Following a similar procedure to that described in example 1 but using 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid the title compound was obtained as an amorphous solid: 1H NMR (80 MHz, CDCI3) δ (TMS) 7.77 (s, 1H, triazole), 7.70 (s, 1H, triazole), 7.6-7.0 (m, 4H, arom), 6.9-6.5 (m, 2H, arom), 5.88 (br d, J=9, 1H, NH), 4.83 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.17 (d, J=14.5, 1H, TrCH(H)), 2.83 (s, 3H, Me-isoxazole), 0.74 (d, J=6.6, 3H, MeCH); [α]D= -98.2° (c 1, CHCl3). Analysis calculated for C23H19CIF3N5O3: C 54.61; H 3.79; N 13.84. Found: C 55.38; H 4.02; N 13.76.
EXAMPLE 70
(1R,2R)- N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-(1,2,3-thiadiazol-4-yl)benzamide
Following a similar procedure to that described in example 1 but using 4-(1,2,3-thiadiazol-4-yl)benzoic acid the title compound was obtained as a yellow solid: mp 196-198 °C; 1H NMR (80 MHz, CDCI3) δ (TMS) 8.76 (s, 1H, thiadiazole), 8.29 (d, J=8, 2H, arom), 7.98 (d, J=8, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.5, 1H, arom), 7.79 (s, 2H, triazole), 6.9-6.5 (m, 3H, arom, NH), 5.37 (br s, 1H, OH), 5.08 (d, J=14.5, 1H, TrCH(H)), 5.1-4.8 (m, 1H, CHMe), 4.50 (d, J=14.5, 1H, TrCH(H)), 1.06 (d, J=7, 3H, MeCH); [α]D= -121.2° (c 1, CHCl3). Analysis calculated for C21H18F2N6O2S: C 55.26; H 3.97; N 18.41; S 7.02. Found: C 55.65; H 4.11; N 19.05; S 7.39.
EXAMPLE 71
(1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]nicotinamide
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)nicotinic acid the title compound was obtained: mp 93-101 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 9.02 (d, J=2.1, 1H, pyr), 8.96 (d, J=2.2, 1H, pyr), 8.33 (t, J=2.2, 1H, pyr), 7.8 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.58 (dt, Jt=2, Jd=8.7, 2H, arom), 7.49 (dt, Jt=2, Jd=8.7, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 3H, arom, NH), 5.41 (d, J=1.4, 1H, OH), 5.06 (d, J=14.2, 1H, TrCH(H)), 5.03 (br quint, J=7, 1H, CHMe), 4.50 (d, J=14.2, 1H, TrCH(H)), 1.06 (d, J=6.8, 3H, MeCH); GCJMS 259 and 261 (ethylaminoacyl group, C14H12ClN2O), 216 and 218 (acyl group, C12H7ClNO), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -96.6° (c 1, CHCl3).
EXAMPLE 72
(1R,2R)-3-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]benzamide
Following a similar procedure to that described in example 1 but using
3-(4-chlorophenyl)benzoic acid the title compound was obtained as a white solid: mp 90-91 °C; Η NMR (300 MHz, CDCI3) δ (TMS) 8.05 (t, J=1.7, 1H, arom), 7.80 (dt, Jt=1.2, Jd=8.3, 1H, arom), 7.79 (s, 2H, triazole), 7.72 (dt, Jt=1.2, Jd=8.3, 1H, arom), 7.56 (dt, Jt=2, Jd=8.7, 2H, arom), 7.5-7.6 (m, 1H, arom), 7.44 (dt, Jt=2, Jd=8.7, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 3H, arom, NH),
5.36 (d, J=1.2, 1H, OH), 5.08 (d, J=14.2, 1H, TrCH(H)), 5.01 (br quint, J=7, 1H, CHMe), 4.50 (d, J=14.2, 1H, TrCH(H)), 1.05 (d, J=6.8, 3H, MeCH); GC/MS 258 and 260 (ethylaminoacyl group, C15H13CINO), 224 (Tr-CH2COHAr, C10H8F2N3O), 215 and 217 (acyl group, C13H8CIO); [α]D= -97.7° (c 1, CHCl3).
EXAMPLE 73
(1R,2R)-4-(4-Chlorophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]benzamide
Following a similar procedure to that described in example 1 but using 4-(4-chlorophenyl)benzoic acid the title compound was obtained as a white solid: mp 173-174 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 7.93 (dt, Jt=1.7, Jd=8.4,
2H, arom), 7.79 (s, 2H, triazole), 7.66 (dt, Jt=1.7- Jd=8.4, 2H, arom), 7.55 (dt, Jt=2, Jd=8.6, 2H, arom), 7.44 (dt, Jt=2, Jd=8.6, 2H, arom), 7.40 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 3H, arom, NH), 5.37 (br s, 1H, OH), 5.08 (d, J=14.3, 1H, TrCH(H)), 5.00 (br quint, J=7, 1H, CHMe), 4.50 (d, J=14.3, 1H, TrCH(H)), 1.04 (d, J=6.8, 3H, MeCH); GC/MS 258 and 260 (ethylaminoacyl group, C15H13CINO), 224 (Tr-CH2COHAr, C10H8F2N3O), 215 and 217 (acyl group, Cι3H8ClO); [α]D= -110.2° (c 1, CHCl3).
EXAMPLE 74 (1R,2R)-2-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-7-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-chlorophenyl)-7-methylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid the title compound was obtained as a white solid: mp 227-228 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.61 (s, 1H, arom), 7.99 (dt, Jt=2.0, Jd=8.6, 2H, arom), 7.83 (s, 2H, triazole), 7.47 (dt, Jt=2.0, Jd=8.6, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.03 (s, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.62 (br d, J=9.4, 1H, NH), 5.42 (s, 1H, OH), 5.13 (d, J=14.2, 1H, TrCH(H)), 5.02 (br quint, J=7, 1H, CHMe), 4.55 (d, J=14.2, 1H, TrCH(H)), 3.13 (s, 3H, Me-heterocycle), 1.09 (d, J=6.8, 3H, MeCH); MS 313 and 315 (ethylaminoacyl group, C16H14ClN4O), 270 and 272 (acyl group, C14H9CIN3O), 224 (Tr-CH2COHAr, C10H8F2N3O); [αp= -93.8° (c 1, CHCl3). Analysis calculated for C26H22ClF2N7O2S: C 58.05 H 4.12; N 18.23. Found: C 58.37; H 4.19; N 18.04.
EXAMPLE 75
(1R,2R)-5-(4-Chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]furan-2-carboxaιnide
Following a similar procedure to that described in example 1 but using 5-(4-chlorophenyl)furan-2-carboxylic acid the title compound was obtained as a white solid: mp 218-219 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 7.79 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.69 (dt, Jt=2, Jd=8-4, 2H, arom), 7.42 (dt, Jt=2- Jd=8.4, 2H, arom), 7.39 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.25 (d, J=3.6, 1H, furan), 6.88 (br d, J=9.5, 1H, NH), 6.8-6.6 (m, 2H, arom), 6.76 (d, J=3.6, 1H, furan), 5.39 (br s, 1H, OH), 5.04 (d, J=14.2, 1H, TrCH(H)), 4.96 (br quint, J=7, 1H, CHMe), 4.53
(d, J=14.2, 1H, TrCH(H)), 1.05 (d, J=6.8, 3H, MeCH); GC-MS 248 and 250 (ethylaminoacyl group, C13H 11ClNO2), 224 (Tr-CH2COHAr, C10H8F2N3O), 205 and 207 (acyl group, C11H6C;O2); [α]D= -173° (c 1, CHCl3). Analysis calculated for C23H19ClF2N4O3: C 58.42; H 4.05; N 11.85. Found: C 57.15; H 3.85; N 10.74.
EXAMPLE 76
(1R*,2R*)-2-(4-Cyanophenyl)-N-[2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)-2-(4-trifluoromethylphenyl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 29 but using (2R*,3R*)-3-amino-1-(1H-1,2,4-triazol-1-yl)-2-(4-trifluoromethylphenyl)-2-butanol (obtained as described in EP 617031) the title compound was obtained as a white solid: mp 105-111 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.08 (d, J=8.2, 2H, arom), 7.84 (s, 1H, triazole), 7.76 (d, J=8.2, 2H, arom), 7.64 (s, 1H, triazole), 7.57 (d, J=8.4, 2H, arom), 7.47 (d, J=8.4, 2H, arom), 6.45 (br d, J=9.2, 1H, NH), 5.46 (d, J=1.0, 1H, OH), 4.75 (d, J=14.2, 1H, TrCH(H)), 4.74 (br quint, J=7, 1H, CHMe), 4.55 (d, J=14.2, 1H, TrCH(H)),2.83 (s, 3H, Me-thiazole), 1.03 (d, J=6.8, 3H, MeCH); GC-MS 270 (ethylaminoacyl group, C14H12N3OS), 256 (Tr- CH2COHAr, C11H9F3N3O), 227 (acyl group, C12H7N2OS).
EXAMPLE 77
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N-methyl-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 29 but using (2R,3R)-3-(N-methylamino)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (obtained as described in EP 332,387) the title compound was obtained as a white amorphous solid: 1H NMR (300 MHz, CDCI3) δ (TMS) 8.04 (d, J=8.4, 2H, arom), 7.9-7.7 (m, 4H, triazole, arom), 7.5-7.3 (m, 1H, arom), 6.9-6.7 (m. 2H, arom), 5.5-5.3 (m, 3H, OH, TrCH(H), CHMe), 4.37 (d, J=14.2, 1H, TrCH(H)), 3.28 (s, 3H, NMe), 2.55 (s, 3H, Me-thiazole), 1.2-1.1 (m, 3H, MeCH); GC-MS 284 (ethylmethylaminoacyl group, C15H14N3OS), 227 (acyl group, C12H7N2OS),
224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -115.2° (c 1, CHCl3). Analysis calculated for C25H22F2N6O2S: C 59.05; H 4.36; N 16.53; S 6.30. Found: C 58.81; H 4.53; N 16.42; S 5.69.
EXAMPLE 78
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N-(2-benzyloxyethyl)-4-methylthiazole-5- carboxamide
Following a similar procedure to that described in example 29 but using (2R,3R)-3-[[2- (benzyloxy)ethyl]amino]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (obtained as described in EP 617031) the title compound was obtained as a white amorphous solid: 1H NMR (300 MHz, CDCI3) δ (TMS) 8.1-7.9 (m, arom), 7.76 (s), 7.74 (s), 7.7-7.5 (m, arom), 7.4-7.2 (m, arom), 6.9-6.7 (m, 2H, arom), 5.5 (br m, 1H), 5.04 (d, J=14.2, 1H, TrCH(H)), 4.7-4.5 (m, 4H, CH2OCH2), 4.40 (d, J=14.2, 1H, TrCH(H)), 4.0-3.5 (m), 2.47 (s, 3H, Me-thiazole), 1.2-1.0 (m, 3H, MeCH); MS (DIP) 284 (ethylbenzyloxyethylaminoacyl,
C23H22N 3O2S), 227 (acyl group, C12H7N 2OS), 224 (Tr-CH2C OH Ar, C10H8F2N3O); [αP= -69.7° (c 1, CHCl3).
EXAMPLE 79
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-N-(ethoxycarbonylmethyl)-4-methylthiazole-5- carboxamide
Following a similar procedure to that described in example 29 but using (2R,3R)-3-[(ethoxycarbonylmethyl)amino]-2-(2,4-difuorophenyl)-1-(1H-1,2,4- triazol-1-yl)-2-butanol (obtained as described in EP 617031) the title compound was obtained as a white amorphous solid: 1H NMR (300 MHz, CDCI3) δ (TMS) 8.08 (m, 2H, arom), 7.8 (m, 4H, triazole, arom), 7.4-7.1 (m, 1H, arom), 6.9-6.7 (m, 2H, arom), 5.5 (m, 1H, OH), 5.2-5.1 (m, 2H, CH2CO2Et), 5.0-4.1 (m, 5H, TrCH2, CHMe, CH3CH2O), 2.61 and 2.53 (br s, 3H, Me-thiazole), 1.2-1.0 (m, 6H, MeCH, CH3CH2O); [α]D= -142.5° (c 1, CHCl3). Analysis calculated for C28H26F2N6O4S.1H2O: C 56.18; H 4.71; N 14.04; S 5.36. Found: C 56.19; H 4.50; N 14.00; S 5.17.
EXAMPLE 80
(1R,2R)-2-(4-Cyanophenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N-(benzyloxycarbonylmethyl)-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 29 but using (2R,3R)-3-[(benzyloxycarbonylmethyl)amino]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (obtained as described in EP 617031) the title compound was obtained as a white amorphous solid: 1H NMR (300 MHz, CDCI3) δ (TMS) 8.0 (m, 2H, arom), 7.8-7.7 (m, 4H, triazole, arom), 7.4-7.1 (m, 6H, arom), 6.8-6.6 (m, 2H, arom), 5.5 (m, 1H, OH), 5.4-4.4 (m, 7H, CH2Ph, CH2CO2Bn, TrCH2, CHMe), 2.5 (br s, 3H, Me-thiazole), 1.2-1.0 (m, 3H, MeCH); [α]D= -114.2° (c 0.2, CHCl3).
EXAMPLE 81
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N-(carboxymethyl)-4-methylthiazole-5-carboxamide, trihydrate
A mixture of the product obtained in the preceding example (600 mg, 1 mmol), 5% Pd/C (25 mg) and ethanol (25 mL) was hydrogenated (1 atm) at room temperature for 6 h. The resulting crude product was filtered through celite and the filtrate was evaporated to dryness to afford the title compound as a white solid (450 mg, 88 %): mp 153-159 °C; [α]D= -73.8° (c 0.2, MeOH). Analysis calculated for C26H22F2N6O4S.3H2O: C 51.48; H 4.65; N 13.85; S 5.29.
Found: C 51.85; H 4.40; N 13.60; S 4.61.
EXAMPLE 82
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-N-(2-hydroxyethyl)-4-methylthiazole-5-carboxamide
To a solution of the product obtained in example 79 (2.46 g, 4.23 mmol) in ethanol (25 mL) was slowly added NaBH4 in 3 portions (0.48 mg, 12.7 mmol). The mixture was stirred at room temperature for 20 h, and the reaction was then quenched by the addition of saturated aqueous NH4CI solution. The resulting mixture was concentrated and the residue partitioned between water and CHCl3. The organic phase was separated, dried over anhydrous Na2SO4, filtered and concentrated to a residue. This was purified by flash chromatography to give the title compound as a white solid: mp 113- 119 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.27 (br s), 8.05 (br m, 2H, arom), 7.75 ( br m, 4H, triazole, arom), 7.36 (m, 1H, arom), 6.9-6.5 (m, 2H, arom), 5.71 (br s, 1H, OH), 4.9-4.6 (m, 2H, TrCH(H), CHMe), 4.2-3.5 (m, 5H, NCH2CH2, TrCH(H)), 2.54 and 2.46 (s, 3H, Me-thiazole), 1.3-1.1 (m, 3H, MeCH); GC-MS 314 (ethylhydroxyethylaminoacyl group, C16H16N3O2S), 271 (ethylaminoacyl group + 1, C14H12N3OS), 227 (acyl group, C12H7N2OS), 224 (Tr-CH2COHAr, C10H8F2N3O); α]D= -76.5° (c 1, CHCl3).
EXAMPLE 83
(4R,5R)-4-[5-[5-(2,4-Difluorophenyl)-4-methyl-5-[(1H-1,2,4-triazol-1-yl)methyl]-oxazolidine-3-carbonyl]-4-methylthiazol-2-yl]benzonitrile
Following a similar procedure to that described in example 29 but using (4R,5R)-5-(2,4-difluorophenyl)-4-methyl-5-[(1H-1,2,4-triazol-1-yl)methyl]oxazolidine (obtained as described in EP 332,387) the title compound was obtained as a white solid: mp 200-201 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.08 (d, J=8.1, 2H, arom), 7.77 (d, J=8.1, 2H, arom), 7.77 (s, 1H, triazole), 7.72 (s, 1H, triazole),
7.31 (dt, Jd=6.6, Jt=8.7, 1H, arom), 7.0-6.8 (m, 2H, arom), 5.43 (br s, 1H, OCH(H)N), 5.31 (d, J=4.5, 1H, OCH(H)N), 5.1-4.9 (br s, 1H, CHMe), 4.58 (AB q, Δv=0.059, J=14.7, 2H, TrCH2), 2.65 (s, 3H, Me-thiazole), 1.04 (d, J=6.6, 3H, MeCH); GC-MS 227 (acyl group, C12H7N2OS); [α]D= +17.5° (c 1, CHCl3). Analysis calculated for C25H20F2N6O2S: C 59.28; H 3.98; N 16.59; S 6.33. Found:
C 59.29; H 3.83; N 16.16; S 6.06.
EXAMPLE 84
(2R,3R)-4-[5-[2-(2,4-Difluorophenyl)-3-methyl-2-[(1H-1,2,4-triazol-1-yl)methyl]morpholine-4-carbonyl]-4-methylthiazol-2-yl]benzonitrile
A cooled (0 °C) solution of (1R,2R)-2-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N-(2-hydroxyethyl)-4-methylthiazole-5-carboxamide (0.45 g, 0.83 mmol, obtained in example 82) in THF (10 mL) was treated with diethylazadicarboxylate (0.20 mL, 1.25 mmol) and tributylphosphine (0.31 mL, 1.25 mmol) for 20 h at room temperature. The mixture was evaporated to dryness and the residue was purified by flash chromatography to give the title compound as a white solid: mp 150-160 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.06 (d, J=8.4, 2H, arom), 7.76 (s, 1H, triazole), 7.76 (d, J=8.4, 2H, arom), 7.30 (s, 1H, triazole), 7.4-7.2 (m, 1H, arom), 7-6.7 (m, 2H, arom), 5.53 (br), 5.17 (d, J=15.1, 1H, TrCH(H)), 4.7 (br d, 1H), 4.6-4.4 (m, 1H), 4.0 (br d), 3.6 (br s), 2.57 (s, 3H, Me-thiazole), 1.13 (d, J=6.8, 3H, MeCH); GC-MS 293 (M+-acyl, C14H15N4F2O), 227 (acyl group, C 12H7N2OS);α]D= -80.5° (c 1, CHCl3).
EXAMPLE 85
(2R,3R)-4-[5-[2-(2,4-Difluorophenyl)-6-hydroxy-3-methyl-2-[(1H-1,2,4-triazol-1-yl)methyl]morpholine-4-carbonyl]-4-methylthiazol-2-yl]benzonitrile
To a cooled (-78 °C) solution of DMSO (0.29 mL, 4.17 mmol) in CH2Cl2 (10 mL) was added a solution of trifluoroacetic anhydride (0.30 mL, 2.09 mmol) in CH2Cl2 (1 mL) dropwise. After ten minutes, a solution of (1R,2R)-2-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N-(2-hydroxyethyl)-4-methylthiazole-5-carboxamide (0.9 g, 1.67 mmol, obtained in example 82) in CH2Cl2 (3 mL) was added. The mixture was stirred for 1 h, and then triethylamine (1.1 mL, 8.3 mmol) was added. The reaction mixture was allowed to warm up to -40 °C and was stirred at this temperature for 1.5 h and then at -10 °C for 30 min. 10% aqueous NaHCO3 solution was added, the organic phase was separated and the aqueous phase was extracted with chloroform. The combined organic extracts were washed with water, dried over anhydrous Na2SO4, filtered and concentrated to a crude product. Purification by flash chromatography afforded the title compound as a white solid: mp 225-228 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.06 and 8.05 (d, J=8.4, 2H, arom), 7.77 (s, 1H, triazole), 7.76 (d, J=8.4, 2H, arom), 7.35 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.30 (s, 1H, triazole), 7.0-6.7 (m, 2H, arom), 5.83 (m, 1H, OCHOH), 5.8-3.2 (several broad signals), 2.57 and 2.55 (s, 3H, Me-thiazole), 1.14 (d, J=6.8, 3H, MeCH); [α]D= -79.8° (c 1, CHCl3). Analysis calculated for
C26H22F2N6O3S.1/2H2O: C 57.24; H 4.21; N 15.40; S 5.86. Found: C 57.49; H 4.03; N 15.08; S 5.69.
EXAMPLE 86
(2R,3R)-4-[5-[2-(2,4-Difluorophenyl)-3-methyl-6-oxo-2-[(1H-1,2,4-triazol-1-yl)methyl]morpholine-4-carbonyl]-4-methylthiazol-2-yl]benzonitrile
From the first fractions of the above chromatography the title compound was isolated as a white amorphous solid: GC-MS 227 (acyl group, C12H7N2OS).
EXAMPLE 87
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-dichlorophenyl)-2-hydroxy-1-methyl-3- (1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 29 but using (2R,3R)-3-amino-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (obtained following the general procedure described in J. Org. Chem., 1995, 60, 3000-3012) the title compound was obtained as a white solid: mp 109-113 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.07 (dt, Jt=1.8, Jd=6.9, 2H, arom), 7.83 (s, 1H, triazole), 7.81 (s, 1H, triazole), 7.76 (dt, Jt=1.8, Jd=6.9, 2H, arom), 7.51 (d, J=8.4, 1H, arom), 7.35 (d, J=2.1, 1H, arom), 7.12 (dd, J=2.1, J=8.7, 1H, arom), 6.50 (br d, J=9.2, 1H, NH), 5.63 (d, J=14.4, 1H, TrCH(H)), 5.51 (br s, 1H, OH), 5.45 (m, 1H, CHMe), 4.45 (d, J=14.4, 1H, TrCH(H)), 2.83 (s, 3H, Me-thiazole), 0.99 (d, J=6.6, 3H, MeCH); GC-MS 270 (ethylaminoacyl group, C14H12N3OS), 256 and 258 (Tr-CH2COHAr, CιoH8Cl2N3O), 227 (acyl group, C12H7N2OS); [α]D= -106.3° (c 1, CHCl3). Analysis calculated for C24H20Cl2N6O2S: C 54.75; H 3.83; N 15.97; S
6.08. Found: C 54.28; H 3.89; N 16.02; S 5.69.
EXAMPLE 88
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-[4-[hydroxyamino(imino)methyl]phenyl]-4-methylthiazole-5-carboxamide
To a solution of Na2CO3 (0.72 g, 6.77 mmol) in a mixture of H2O (5 mL) and THF (5 mL) was added (1 R ,2R)-2-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide methanesulfonate (0.5 g, 0.84 mmol, obtained in example 31) and hydroxylamine hydrochloride (0.29 g, 4.23 mmol). The reaction mixture was stirred at room temperature overnight, and was then concentrated and the aqueous residue extracted with CHCl3. The organic phase was separated, dried over Na2SO4, filtered and the filtrate was concentrated to a solid. Purification by flash chromatography afforded the title compound as a pale yellow solid: mp 135-148 °C; 1H NMR (300 MHz, MeOH-d4) δ (MeOH-d4) 8.24 (s, 1H, triazole), 8.03 (dt, Jt=1.6, Jd=8.5, 2H, arom), 7.78 (dt, Jt=1.6, Jd=8.5, 2H, arom), 7.71 (s, 1H, triazole), 7.38 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.97 (ddd, J=2.4, J=8.7, J=11-5, 1H, arom), 6.84 (dt, Jd= 2.1, Jt=8.0, 1H, arom), 5.00 (q, J=7, 1H, CHMe), 4.99 (d, J=14.3, 1H, TrCH(H)), 4.58 (d, J=14.3, 1H, TrCH(H)), 2.74 (s, 3H, thiazole-Me), 1.05 (d, J=7, 3H, MeCH); MS 496 (M+-NH2); [α]D= - 77.2° (c 1, MeOH). Analysis calculated for C24H23F2N7O3S.H2O: C 52.84; H 4.62; N 17.97; S 5.88 Found: C 53.48; H 4.61; N 17.19; S 5.34.
EXAMPLE 89
(1R,2R)-2-[4-[Acetoxyamino(imino)methyl]phenyl]- N-[2-(2,4-difluorophenyl)- 2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5- carboxamide
A solution of the product obtained in example 88 (150 mg, 0.28 mmol) in CHCl3 (10 mL) was treated with triethylamine (33 μL, 0.33 mmol) and acetyl chloride (25 μL, 0.32 mmol) at 25 °C for 18 h. Next, 10% aqueous NaHCO3 was added and the layers were separated. The organic phase was washed with water, dried over Na2SO4, filtered, concentrated and purified by flash chromatography to give the title compound as a white solid: mp 146-147 °C; 1H NMR (300 MHz, CDCl3) δ (TMS) 8.01 (dt, Jt= 1.9, Jd=8.7, 2H, arom), 7.81 (s, 1H, triazole), 7.80 (dt, Jt= 1.9, Jd=8.7, 2H, arom), 7.79 (s, 1H, triazole), 7.38 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.43 (br d, J=9.5, 1H, NH), 5.38 (s, 1H, OH), 5.13 (br s, 2H, NH2), 5.05 (d, J=14.5, 1H, TrCH(H)), 4.94 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.5, 1H, TrCH(H)), 2.82 (s, 3H, Me-thiazole), 2.27 (s, 3H, COM.), 1.02 (d, J=6.8, 3H, MeCH); MS 327 (N-ethylheterocycle - H2O, C16H16N4O2S), 284 (acyl group - H2O, C14H10N3O2S), 224 (Tr-CH2COHAr, C 10H 8F2N 3O); [α]D = -103.9° (c 1, MeOH). Analysis calculated for C26H25F2N7O4S: C 54.83; H 4.42; N 16.76; S 5.63 Found: C 53.97; H 4.38; N 16.90; S 5.23.
EXAMPLE 90
(1R,2R)-2-(4-Tert-butylphenyl)- N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-tert-butylphenyl)-4-methylthiazole-5-carboxylic acid (reference example 43) the title compound was obtained as a white solid: mp 85-91 °C; 1H NMR
(300 MHz, CDCI3) δ (TMS) 7.88 (dt, Jt=2, Jd=8.5, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.47 (dt, Jt=2, Jd=8.5, 2H, arom), 7.38 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 6.8-6.6 (m, 2H, arom), 6.38 (br d, J=9.5, 1H, NH), 5.37 (s, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 4.93 (br quint, J=7, 1H, CHMe), 4.53 (d, J=14.5, 1H, TrCH(H)), 2.81 (s, 3H, Me-thiazole), 1.35 (s, 9H, CMe3), 1.02 (d, J=6.8, 3H,
MeCH); GC-MS 301 (ethylaminoacyl group, C17H22N2OS), 258 (acyl group, C15H16NOS), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -105.9° (c 1, CHCl3). Analysis calculated for C27H29F2N5O2S: C 61.70; H 5.56; N 13.32; S 6.10. Found: C 61.70; H 6.20; N 12.64; S 5.24.
EXAMPLE 91
(1R,2R)-2-(4-Cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-imidazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-cyanophenyl)-4-methylthiazole-5-carboxylic acid (reference example 24) and (2R,3R)-3-amino-2-(2,4-difluorophenyl)-1-(1H-imidazol-1-yl)-2-butanol (75 mg, 0.28 mmol, obtained following the general procedure described in J. Org. Chem., 1995, 60, 3000-3012) in DMF (5 mL) the title compound was obtained as a white solid: mp 126-128 °C; 1H NMR (300 MHz, CDCI3) δ (TMS) 8.05 (dt, Jt=2, Jd=8.4, 2H, arom), 7.50 (dt, Jt=2, Jd=8-4, 2H, arom), 7.47 (dt, Jd= 6.5, Jt=8.8, 1H, arom), 7.24 (s, 1H, imidazole), 6.8-6.6 (m, 2H, arom), 6.52 (br d, J=9.5, 1H, NH), 6.51 (s, 1H, imidazole), 6.32 (s, 1H, imidazole), 4.85 ( br quint, J=7, 1H, CHMe), 4.68 (d, J=14.5, 1H, ImCH(H)), 4.29 (d, J=14-5, 1H, ImCH(H)), 2.80 (s, 3H, Me-thiazole), 1.06 (d, J=6.8, 3H, MeCH); MS 227 (acyl group, C12H7N2OS), 223 (Im-CH2COHAr, C11H9F2N2O); [α]D= -20.4° (c 1, CHCl3). Analysis calculated for C25H21F2N5O2S: C 60.84; H 4.29; N 14.19; S 6.50 Found: C 60.85; H 4.31; N 13.75; S 6.18.
EXAMPLE 92
(1R,2R)-2-{4-Cyanophenyl)-N-[2-(2-fluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2, 4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 29 but using (2R,3 R)-3-amino-2-(2-fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (obtained as described in J. Org. Chem., 1995, 60, 3000-3012) the title compound was obtained as a white solid: mp 107-114 ºC; 1H NMR (300 MHz, CDCl3) δ (TMS)
8.07 (dt, Jt=1.8, Jd=8.6, 2H, arom), 7.79 (s, 1H, triazole), 7.76 (dt, Jt=1.8, Jd=8.6, 2H, arom), 7.75 (s, 1H, triazole), 7.36 (dt, Jd=1.6, Jt=7.8, 1H, arom), 7.3-7.3 (m, 1H, arom), 7.1-7.0 (m, 2H, arom), 6.50 (br d, J=9.3, 1H, NH), 5.29 (d, J=1.6, 1H, OH),
5.08 (d, J=14.2, 1H, TiCH(H)), 4.99 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.2, 1H, TrCH(H)), 2.83 (s, 3H, Me-thiazole), 1.03 (d, J=6.8, 3H, MeCH); GC/MS 270
(ethylaminoacyl group, C14H12N3OS), 227 (acyl group, C12H7N2OS), 206 (Tr- CH2COHAr, C10H9FN3O); [α]D= -115.6° (c 1, CHCl3). Analysis calculated for C24H21FN6O2S.1/2H2O: C 59.36; H 4.53; N 1730; S 6.59. Found: C 59.63; H 4.73; N 16.68; S 6.15.
EXAMPLE 93
(1R,2R)-N-[2-(2,4-Difluorophenyl)-2-hydxoxy-1-methyl-3-(1H-lΛ4-triazol-1- yl)propyl]-2-(4-fluorophenyl)-4-methylthiazole-5-carboxamide
Following a similar procedure to that described in example 1 but using 2-(4-fluorophenyl)-4-methylthiazole-5-carboxylic acid the title compound was obtained as a white amorphous solid: 1H NλlR (300 MHz, CDCl3) δ (TMS) 7.96
(m, 2H, arom), 7.81 (s, 1H, triazole), 7.79 (s, 1H, triazole), 7.37 (dt, Jd= 65, Jt=8.8, 1H, arom), 7.16 (tt, J=2, J=8.5, 2H, arom), 6.8-6.6 (m, 2H, arom), 6.40 (br d, J=9.5, 1H, NH), 5.41 (s, 1H, OH), 5.05 (d, J=14.5, 1H, TrCH(H)), 4.94 (br quint, J=7, 1H, CHMe), 4.52 (d, J=14.5, 1H, TrCH(H)), 2.80 (s, 3H, Me-thiazole), 1.02 (d, J=6.8, 3H, MeCH); MS 263 (ethylaminoacyl group, C13H12FN2OS), 220 (acyl group, C11H7FNOS), 224 (Tr-CH2COHAr, C10H8F2N3O); [α]D= -113.5° (c 0.5, CHCl3). Analysis calculated for C23H20F3N5O2S: C 56.67; H 4.14; N 14.37; S 6.58 Found: C 56.87; H 4.19; N 14.00; S 6.29. EXAMPLE 94
In vitro activity
In vitro activity was evaluated against C. albicans, C. krusei, and Aspergillus fumigaius by the agar dilution method. Test strains were either clinical isolates or were obtained from ATCC. Stock solutions containing 800 μgJmL were prepared by solving the test products in 50% ethanol. The culture medium used was Kimmig's agar (K.A., E. Merck) suplemented with 0.5% glycerol. Plates containing serial dilutions (80 to 0.025 μgJmL) of the test products were inoculated with 10 μL of the fungal inocula, containing 105 colony forming units (cfu)JmL. Plates were incubated at 25 °C during 48 h for Candida sp. and during 5 days for Apergillus fumigatus. Following incubation MICs (minimal inhibitory concentrations) were determined. Results are shown in the following table:
Figure imgf000076_0001
Figure imgf000077_0001
EXAMPLE 95
In vivo activity (systemic candidaasis)
Groups of 10 male mice were inoculated i.v. with 0.2 mL of a suspension containing (2-8) × 107 cfuJmL of Candida albicans. Compounds were administered orally at 1 mgJkg at times 1, 4 and 24 h after infection. Following this protocol, animals treated with the products of examples 2, 3, 4, 7, 8, 9, 10, 15, 16, 18, 19, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 34, 36, 43, 44, 51, 52, 55, 56, 57, 62, 66, 73, 74, 77, 82, 83, 84, 85, 87 and 92 showed 100% protection on the day where all the animals in the control group had died (days 2-4).
EXAMPLE 96
In vivo activity (systemic aspergillosis)
According to a similar in vivo model of systemic aspergillosis in mice, animals treated with the products of examples 3, 25, 26, 29, 51, and 57 (p.o. 20 mgJkgJday, 5 days) showed 60-100% protection on day 25 postinfection. Mortality in the control group on day 25 was 90%.

Claims

1.- A compound of formula I:
Figure imgf000078_0001
as a racemate, a diastereomer mixture or as a pure enantiomer, wherein:
X represents N or CH;
Ar represents phenyl or phenyl substituted with one or more halogen andJor trifluoromethyl groups;
R1 is C1-C4 alkyl;
R2 is hydrogen or C1-C4 alkyl;
or R1 together with R2 form a C2-C4 polymethylene chain;
R3 is hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C1-C4 alkyl, C1-C4 haloalkyl, phenyl-C1-C4 alkyl (wherein the phenyl group can be optionally substituted with 1, 2, 3 or 4 groups R5, which can be the same or different), a group -(CH2)n-CH2OH, a group -(CH2)n-CH2OBn, a group -(CH2)n-CH2NR6R7, a group -(CH2)n-CH2COOR6, or a group -(CH2)n- CH2COOBn, in which case R4 is hydrogen;
or R3 together with R4 and the remainder of said compound of formula I form an oxazolidine ring of formula I'
Figure imgf000078_0002
or R3 together with R4 and the remainder of said compound of formula I form a morpholine ring of formula I"
Figure imgf000079_0001
wherein D is O, in which case the dotted line represents a covalent bond, or D is hydroxy or hydrogen, in which case the dotted line is absent;
A represents phenyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 heteroatoms selected from N, O and S and with each ring in the heterocyclic group being formed of 5 or 6 atoms, wherein A can be unsubstituted or have 1, 2, 3 or 4 groups R8;
B represents a phenyl group which can be optionally substituted with 1, 2, 3 or 4 groups R9, or B represents a monocyclic or bicyclic heterocyclic group containing from 1 to 4 heteroatoms selected from N, O and S and with each ring in the heterocyclic group being formed of 5 or 6 atoms, which can be optionally substituted with 1, 2, 3 or 4 groups R9;
R5 represents C1-C4 alkyl, C1-C4 haloalkyl or halogen;
n represents 0, 1, 2 or 3;
R6 and R7 independently represent hydrogen or C1-C4 alkyl;
R8 represents C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, phenyl (optionally substituted with a group halogen, cyano, C1-C4 haloalkyl or C1-C4 haloalkoxy), nitro, cyano, hydroxy, hydroxymethyl, a group -NR6R7, a group -CONR6R7, a group -COR6, a group
-COOR6, or a group -SOzR10;
R9 represents C1-C4 alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, 2-carboxy-2-propyl, halogen, nitro, cyano, hydroxy, benzyloxy, hydroxymethyl, a group -CH2-OCO-R6, a group -CO-R6, a group -COO-R6, a group -SOzR10, a group -NR6R7, a group -CONR6R7, a group -C(=NR6)NHR 11, a group -C(=NRπ)OR6, and additionally one of the groups R9 can also represent 1-pyrrolyl, 1-imidazolyl, 1H-1,2,4- triazol-1-yl, 5-tetrazolyl (optionally substituted with C1-C4 alkyl), 1- pyrrolidinyl, 4-morpholinyl, 4-morpholinyl-N-oxide, phenyl or phenoxy (both optionally substituted with a group C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, nitro or cyano), or a group of formula (i)- (iv)
Figure imgf000080_0001
Figure imgf000080_0002
Figure imgf000080_0004
Figure imgf000080_0003
R10 represents C1-C4 alkyl;
z represents 0, 1 or 2;
R11 represents hydrogen, -CONH2, -COMe, -CN, -SO2NHR6, -SO2R10, -OR6, or -OCOR6;
R12 represents hydrogen or methyl;
R13 represents hydrogen, isopropyl, cyclopentyl, cyclopropyl, 2-butyl, 3- pentyl, 3-hydroxy-2-butyl, or 2-hydroxy-3-pentyl;
p represents 0 or 1;
R14 represents halogen, C1-C4 haloalkyl, C1-C4 haloalkoxy, nitro, amino, cyano, or a group of formula (i);
E represents -CH2- or -C(=O)-;
G represents NH or O;
Y represents a single bond, -S-, -SO-, -SO2-, -O- or -NR6-;
m and q independently represent 0, 1 or 2;
and the salts and solvates thereof.
2.- A compound as claimed in claim 1 wherein X represents N.
3.- A compound as claimed in claims 1 or 2 wherein Ri represents C1-C4 alkyl and R2 represents hydrogen.
4.- A compound as claimed in claim 3 wherein Ri represents methyl.
5.- A compound as claimed in any one of claims 1 to 4 wherein R4 represents hydrogen.
6.- A compound as claimed in claim 5 wherein R3 represents hydrogen.
7.- A compound as claimed in any one of claims 1 to 6 wherein Ar represents 2-fluorophenyl, 4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-dichlorophenyl,
2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4-chlorophenyl.
8.- A compound as claimed in any one of claims 1 to 7 wherein A represents phenyl or a 5- or 6-membered heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S, wherein A can be unsubstituted or have 1, 2, 3 or 4 groups R8.
9.- A compound as claimed in claim 8 wherein A represents a 5- or 6- membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms selected from N, O and S, and which can be unsubstituted or have 1 or 2 groups R8.
10.- A compound as claimed in any one of claims 1 to 9 wherein B represents a phenyl group which can be optionally substituted with 1, 2, 3 or 4 substituents R9.
11.- A compound as claimed in any one of claims 2 to 10 wherein the stereochemistry of the compounds is (R,R).
12.- A compound as claimed in claim 1 wherein:
X represents N;
R1 represents methyl;
R2 represents hydrogen;
R3 represents hydrogen;
R4 represents hydrogen;
Ar represents 2-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-(trifluoromethyl)phenyl or 4-chlorophenyl;
A represents thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, 1,2,4- triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, or 1,2,4-thiadiazole, wherein A can be optionally substituted with one or two C1-C4 alkyl or C1-C4 haloalkyl groups;
B represents a phenyl group substituted with 1 or 2 groups R9;
R9 represents C1-C4 alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6 cycloalkyl,
C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, 2-carboxy-2-propyl, halogen, nitro, cyano, hydroxy, benzyloxy, hydroxymethyl, a group -CH2-OCO-R6, a group -CO-R6, a group -COO-R6, a group -SOzR10, a group -NR6R7, a group -CONR6R7, a group -C (=NR6)NHR11 or a group -C(=NR11)OR6;
Y represents a single bond and m=q=0; and
the stereochemistry of the compounds is (R,R).
13.- A compound as claimed in claim 1 selected from:
(a) (1R,2R)-1-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-methyl-1H-pyrazole-4-carboxamide;
(b) (1R,2R)-1-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-trifluoromethyl-1H-pyrazole-4-carboxamide; (c) (1R,2R) -1-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3,5-dimethyI-1H-pyrazole-4-carboxamide;
(d) (1R,2R) -N-[2-(2,4-difluorophenyl)-2-hydτoxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methyl-2-(4-trifluoromethylphenyl)thiazole-5-carboxamide;
(e) (1R,2R)-2-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4 -methyIthiazole-5-carboxaιnide;
(f) (1R,2R)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methyl-2-(4-trifluoromethoxyphenyl)thiazole-5-carboxamide;
(g) (1R,2R)-2-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxamide;
(h) (1R,2R)-5-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thiophene-2-carboxamide;
(i) (1R,2R)-5-(4-chlorophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-methylthiophene-2-carboxaιnide;
(j) (1R,2R) -5-(4-cyanophenyl)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1- methyI-3-(1H-1,2,4-triazol-1-yl)propyl]-3-methylthiophene-2-carboxamide;
(k) (1R,2R) -2-(4-cyanophenyl)-N-[2-(2-fluorophenyl)-2-hydroxy-1- methyI-3-(1H-1,2,4-triazol-1-yl)propyl]-4-methylthiazole-5-carboxa_nide;
(l) (1R,2R) -N-[2-α,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2-(4-fluorophenyl)-4-methylthiazole-5-carboxamide;
or a salt or solvate thereof.
14.- A process for preparing a compound of formula I as defined in claim 1, which comprises:
(a) reacting a compound of formula II
Figure imgf000082_0001
wherein X, R1, R2, R3, R4 and Ar are as defined in claim 1, with an acid of formula III
Figure imgf000083_0001
wherein A, B, Y, m and q are as defined in claim 1, in the presence of a condensing agent, or with a reactive derivative of said acid III such as the acid chloride, the anhydride or the mixed anhydride in the presence of a proton scavenger base; or
(b) converting in one or a plurality of steps a compound of formula I into another compound of formula I; and
(c) if desired, after steps (a) or (b), reacting a compound of formula I with an acid to give the corresponding acid addition salt.
15.-A pharmaceutical composition which comprises an effective amount of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable excipients.
16.- The use of a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment or prophylaxis of fungal infections in animals, including human beings.
17.- An agrochemical composition which comprises an effective amount of a compound of formula I as claimed in claim 1 or a salt or solvate thereof in admixture with one or more agrochemically acceptable excipients.
18.- The use of a compound of formula I as claimed in claim 1 or a salt or solvate thereof for the treatment or prophylaxis of fungal infections in plants.
PCT/EP1996/003419 1995-08-02 1996-08-02 New carboxamides with antifungal activity WO1997005131A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP9507253A JPH10507205A (en) 1995-08-02 1996-08-02 Novel carbonamide with antifungal activity
BR9606546A BR9606546A (en) 1995-08-02 1996-08-02 New carboxamides with fungicidal activity
KR1019970701516A KR970705560A (en) 1995-08-02 1996-08-02 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY WITH ANTIFUNGAL ACTIVITY
US08/809,815 US5888941A (en) 1995-08-02 1996-08-02 Carbozamides with antifungal activity
MX9702380A MX9702380A (en) 1995-08-02 1996-08-02 New carboxamides with antifungal activity.
EP96928404A EP0783502A1 (en) 1995-08-02 1996-08-02 New carboxamides with antifungal activity
AU67889/96A AU6788996A (en) 1995-08-02 1996-08-02 New carboxamides with antifungal activity
NO971471A NO971471L (en) 1995-08-02 1997-04-01 New carboxamides with fungicidal activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES9501564A ES2107376B1 (en) 1995-08-02 1995-08-02 NEW DERIVATIVES OF PIRIMIDONA WITH ANTIFUNGAL ACTIVITY.
ESP9501564 1995-08-02
ES9502042A ES2112774B1 (en) 1995-10-20 1995-10-20 NEW AZOLIC DERIVATIVES WITH ANTIFUNGAL ACTIVITY.
ESP9502042 1996-10-20

Publications (1)

Publication Number Publication Date
WO1997005131A1 true WO1997005131A1 (en) 1997-02-13

Family

ID=26154905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003419 WO1997005131A1 (en) 1995-08-02 1996-08-02 New carboxamides with antifungal activity

Country Status (11)

Country Link
US (1) US5888941A (en)
EP (1) EP0783502A1 (en)
JP (1) JPH10507205A (en)
KR (1) KR970705560A (en)
AR (1) AR004180A1 (en)
AU (1) AU6788996A (en)
BR (1) BR9606546A (en)
CA (1) CA2201478A1 (en)
MX (1) MX9702380A (en)
NO (1) NO971471L (en)
WO (1) WO1997005131A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0884311A2 (en) * 1997-06-06 1998-12-16 Takeda Chemical Industries, Ltd. Triazole Derivatives and their production
US6599926B2 (en) 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
US6703509B2 (en) * 2000-02-07 2004-03-09 Merck Patent Gmbh Method for producing 5-aryl nicotinaldehydes
US6958339B2 (en) 1997-10-13 2005-10-25 Astellas Pharma Inc. Pyrazole derivative
US7138403B2 (en) 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
WO2007031440A3 (en) * 2005-09-13 2007-08-02 Janssen Pharmaceutica Nv 2-aniline-4-aryl substituted thiazole derivatives
US7446222B2 (en) 2002-11-01 2008-11-04 Glaxo Group Limited Phenyl compounds
US20100292236A1 (en) * 2007-07-19 2010-11-18 H. Lundbeck A/S 5-Membered Heterocyclic Amides And Related Compounds
US8008425B2 (en) 2005-08-18 2011-08-30 Nissan Chemical Industries, Ltd. Thiophene compound having sulfonyl group and process for producing the same
WO2012004588A2 (en) 2010-07-06 2012-01-12 Astrazeneca Ab Therapeutic agents 976
US8404851B2 (en) 2007-10-18 2013-03-26 Janssen Pharmaceutica Nv 1,3,5-trisubstituted triazole derivative
US8440701B2 (en) 2007-10-18 2013-05-14 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US8778974B2 (en) 2008-03-19 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US8779158B2 (en) 2008-05-09 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
US9241942B2 (en) 2007-06-08 2016-01-26 Mannkind Corporation IRE-1α inhibitors
US9758538B2 (en) 2015-07-15 2017-09-12 Pfizer Inc. Pyrimidine derivatives
US10653673B2 (en) 2013-08-16 2020-05-19 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US11767310B2 (en) 2021-08-10 2023-09-26 Abbvie Inc. Nicotinamide RIPK1 inhibitors

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5871000A (en) * 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
SK288015B6 (en) * 2001-06-11 2012-11-05 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
IN192526B (en) * 2001-09-25 2004-04-24 Ranbaxy Lab
AU2002364552A1 (en) 2001-12-13 2003-06-30 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US7028055B2 (en) * 2002-03-22 2006-04-11 Sun Microsystems, Inc. Method and apparatus for improving transaction specification by marking application states
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
CN100413861C (en) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 Compounds and methods for the treatment or prevention of flavivirus infections
AU2003300360A1 (en) * 2002-12-20 2004-07-22 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
US7273866B2 (en) * 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
AU2003300358A1 (en) * 2002-12-20 2004-07-22 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
KR20070097590A (en) 2005-01-25 2007-10-04 에픽스 델라웨어, 인코포레이티드 Substituted arylamine compounds and their use as 5-ht6 modulators
NZ576780A (en) 2006-11-15 2011-12-22 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
UY30892A1 (en) * 2007-02-07 2008-09-02 Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
KR20130043207A (en) 2010-07-22 2013-04-29 자프겐 인크. Tricyclic compounds and methods of making and using same
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA42488A (en) 2015-07-24 2018-05-30 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
JP6929276B2 (en) 2015-10-06 2021-09-01 プロテオステイシス セラピューティクス，インコーポレイテッド Compounds, pharmaceutically acceptable salts or stereoisomers thereof and pharmaceutical compositions
BR112018070747B1 (en) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc SILICONE ATOMS CONTAINING IVACAFTOR ANALOGS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES
ES2954658T3 (en) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compounds, compositions and methods for increasing CFTR activity
US11897850B1 (en) 2023-10-11 2024-02-13 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097469A2 (en) * 1982-06-18 1984-01-04 Pfizer Limited Triazole antifungal agents
EP0332387A1 (en) * 1988-03-04 1989-09-13 Sankyo Company Limited Triazole derivatives, their preparation and their use as fungicides
EP0617031A1 (en) * 1993-03-15 1994-09-28 J. URIACH & CIA. S.A. Orally active azole derivates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204494B (en) * 1986-03-28 1989-03-01 Roussel Maestretti Spa DERIVATIVES OF 1-STYRENE SULPHONYL 2-BONE 5-ALCOSS PYROLIDINE, THEIR PREPARATION PROCEDURE AND THEIR APPLICATION AS DRUGS
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
TW218017B (en) * 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097469A2 (en) * 1982-06-18 1984-01-04 Pfizer Limited Triazole antifungal agents
EP0332387A1 (en) * 1988-03-04 1989-09-13 Sankyo Company Limited Triazole derivatives, their preparation and their use as fungicides
EP0617031A1 (en) * 1993-03-15 1994-09-28 J. URIACH & CIA. S.A. Orally active azole derivates

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0884311A3 (en) * 1997-06-06 1999-01-27 Takeda Chemical Industries, Ltd. Triazole Derivatives and their production
EP0884311A2 (en) * 1997-06-06 1998-12-16 Takeda Chemical Industries, Ltd. Triazole Derivatives and their production
US7247635B2 (en) 1997-10-13 2007-07-24 Astellas Pharma Inc. Pyrazole derivative
US7285554B2 (en) 1997-10-13 2007-10-23 Astellas Pharma Inc. Pyrazole derivative
US6958339B2 (en) 1997-10-13 2005-10-25 Astellas Pharma Inc. Pyrazole derivative
US6703509B2 (en) * 2000-02-07 2004-03-09 Merck Patent Gmbh Method for producing 5-aryl nicotinaldehydes
USRE41008E1 (en) 2000-02-07 2009-11-24 Merck Patent Gmbh Method for producing 5-aryl nicotinaldehydes
US6599926B2 (en) 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
US7138403B2 (en) 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US7446222B2 (en) 2002-11-01 2008-11-04 Glaxo Group Limited Phenyl compounds
US8008425B2 (en) 2005-08-18 2011-08-30 Nissan Chemical Industries, Ltd. Thiophene compound having sulfonyl group and process for producing the same
WO2007031440A3 (en) * 2005-09-13 2007-08-02 Janssen Pharmaceutica Nv 2-aniline-4-aryl substituted thiazole derivatives
AU2006290814B2 (en) * 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
US9388175B2 (en) 2005-09-13 2016-07-12 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
EA015034B1 (en) * 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-aniline-4-aryl substituted thiazole derivatives
US9241942B2 (en) 2007-06-08 2016-01-26 Mannkind Corporation IRE-1α inhibitors
US9546149B2 (en) 2007-06-08 2017-01-17 Mannkind Corporation IRE-1α inhibitors
US9981901B2 (en) 2007-06-08 2018-05-29 Fosun Orinove Pharmatech, Inc. IRE-1α inhibitors
US9133204B2 (en) 2007-07-19 2015-09-15 H. Lundbeck A/S 5-membered heterocyclic amides and related compounds
US20100292236A1 (en) * 2007-07-19 2010-11-18 H. Lundbeck A/S 5-Membered Heterocyclic Amides And Related Compounds
US8404851B2 (en) 2007-10-18 2013-03-26 Janssen Pharmaceutica Nv 1,3,5-trisubstituted triazole derivative
US8440701B2 (en) 2007-10-18 2013-05-14 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US8778974B2 (en) 2008-03-19 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US8779158B2 (en) 2008-05-09 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
WO2012004588A2 (en) 2010-07-06 2012-01-12 Astrazeneca Ab Therapeutic agents 976
US10653673B2 (en) 2013-08-16 2020-05-19 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9758538B2 (en) 2015-07-15 2017-09-12 Pfizer Inc. Pyrimidine derivatives
US11767310B2 (en) 2021-08-10 2023-09-26 Abbvie Inc. Nicotinamide RIPK1 inhibitors

Also Published As

Publication number Publication date
JPH10507205A (en) 1998-07-14
AR004180A1 (en) 1998-11-04
KR970705560A (en) 1997-10-09
AU6788996A (en) 1997-02-26
NO971471L (en) 1997-05-30
EP0783502A1 (en) 1997-07-16
NO971471D0 (en) 1997-04-01
MX9702380A (en) 1998-02-28
CA2201478A1 (en) 1997-02-13
BR9606546A (en) 1998-07-14
US5888941A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
US5888941A (en) Carbozamides with antifungal activity
MXPA97002380A (en) New carboxamides with antifung activity
EP0783501B1 (en) pyrimidone derivatives with antifungal activity
AU655544B2 (en) Azole compounds, their production and use
MXPA97002382A (en) New pyrimidone derivatives with activityantifung
AU2006242824A1 (en) Antimicrobial agents
JPH0859665A (en) Heterocyclic bicyclic compound having antifungal activity
ES2202453T3 (en) ANTIFUNGIC AGENTS OF TRIAZOL.
Tsuruoka et al. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives
US5393769A (en) Anti-fungal triazole derivatives
US5478826A (en) Orally active azole derivatives
CA1293514C (en) Isoxazolylethanol derivatives
AU740324B2 (en) New triazoles as therapeutic agents for fungal infections
JP3056412B2 (en) Azole compounds and their uses
US6319933B1 (en) Azole derivatives
JP5092372B2 (en) Pyridazine compounds and fungicides containing the same
US6153616A (en) Triazoles as therapeutic agents for fungal infections
US5360813A (en) Sulfonamides as antifungal agents
CA2052921A1 (en) Sulfonamides as antifungal agents
Kumari et al. A REVIEW ON SYNTHESIS, CHARECTIRIZATION PHARMACOLOGICAL ACTIVITY OF 1, 2, 4 TRIAZOLE DERIVATIVES CONTAINING BENZOTHIAZOLE
JPS63146878A (en) Pyrazolesulfonamide derivative and herbicide
ZA200207604B (en) 1-(H-1,2,4-triazol-1-yl)butan-2-ol derivatives.
JPH07228574A (en) Optically active azole derivative, its production and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

WWE Wipo information: entry into national phase

Ref document number: 1019970701516

Country of ref document: KR

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 809815

Date of ref document: 19970321

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 08809815

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2201478

Country of ref document: CA

Ref country code: CA

Ref document number: 2201478

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/002380

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1996928404

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996928404

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970701516

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1996928404

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996928404

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970701516

Country of ref document: KR